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Abstract 
Our environment and diet contains a variety of man-made endocrine disrupting chemicals 
which may pose a significant health threat for wildlife and humans. In particular, there is 
increasing concern regarding the adverse effects caused by xenoestrogens which are believed 
to trigger many endocrine-related diseases. Since high systemic levels of oestrogens are 
cholestatic, it was investigated whether xenoestrogens are able to cause adverse hepatic 
effects in vivo in mouse models and whether these effects are mediated by interaction with the 
murine oestrogen receptors (ERs).  
The food dye tartrazine has previously been shown to activate the human ERα and 
intraperitoneal injection caused cholestasis in mice. In this study, tartrazine failed to activate 
murine ERα and two murine ERβ variants in vitro suggesting that cholestasis occurred 
independent of the ERs. Data indicate, however, that tartrazine, its major metabolites and a 
contaminant inhibited murine dopamine sulfotransferase. Considering the role of 
sulfotransferases in bile acid secretion, these findings suggest that impairment of bile acid 
sulfation and subsequent secretion may be a key event in tartrazine-mediated cholestasis. Oral 
exposure to tartrazine caused inflammation in the liver and gastrointestinal tract in vivo in 
mice without evidence of cholestatic effects.  
Several soil extracts prepared from soil samples collected from around an urban landfill site 
activated human and murine ERα and two murine ERβ variants in vitro. Pooled oestrogenic 
soil extracts had mild cholestatic effects in a mouse model. Given the cholestatic features of 
the liver disease primary biliary cholangitis (PBC), which is linked to exposure to xenobiotics 
associated with a toxic environment and proximities to waste sites, environmental 
xenoestrogens could be a component of a xenobiotic insult that triggers PBC. 
These findings indicate that if significant exposure to environmental xenoestrogens occurs, 
they can have adverse hepatic effects and may be part of a trigger process in cholestatic liver 
diseases. 
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Chapter 1. Introduction 
The development of novel medicines and materials for products has significantly contributed 
to the presence of synthetic chemicals within the environment. There is increasing concern 
regarding the adverse effects that these xenobiotics may cause in wildlife and humans. 
Extensive research has shown that many of these chemicals have the potential to disrupt the 
endocrine system which may lead to the development of endocrine-related diseases (e.g., 
reproductive disorders, metabolic disorders and cancer (Schug et al., 2011)). A large 
proportion of chemicals were found to have oestrogenic properties thus potentially targeting 
normal oestrogen signalling. Oestrogenic chemicals are contained in many consumer products 
and our diet. In order to reduce the health risk that oestrogenic chemicals may pose, it is 
critical to develop a better understanding of the effects of these chemicals. Given the hepatic 
toxic effects that high systemic levels of oestrogens can have, work in this thesis focuses on 
examining the effects of oestrogenic chemicals on the liver.   
1.1. The liver 
The liver is the largest internal organ as well as the largest gland in the human body. It is of 
brownish-red colour and located in the right upper portion of the abdominal cavity beneath 
the diaphragm and to the right above the stomach (Figure 1.1). Weighing between 1300-
1800 g depending on body size and gender, the liver contributes to approximately 2% of a 
healthy adult’s total body weight. A thin layer of fibrous tissue called the Glisson’s capsule, 
sheaths the liver and extends within to support inter- and intralobular vessels. The liver is 
further encased by the peritoneum, a serous membrane for protection and reduction of friction 
against other organs. A number of ligaments, namely the falciform, round, coronary and 
triangular ligaments hold the liver in place by anchoring it to the abdominal wall and 
diaphragm (Figure 1.2A) (Monga, 2011).  
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Figure 1.1 Location of the liver in the human body. Source: Herbal Health (2014).  
 
1.1.1. Anatomy 
The human liver is commonly described to consist of four primary lobes: the left, right, 
caudate and quadrate lobe. From an anterior view, the left lobe and the larger right lobe are 
separated by the falciform ligament (Figure 1.2A). The caudate and quadrate lobes are located 
at the posterior and inferior sides of the right lobe. A more precise way to characterise the 
liver’s functional anatomy, however, is described by the Couinaud classification. By looking 
at the vascular in and out flow, this classification allows for subdivision of the liver into eight 
segments. Each segment is supplied by a portal vein, hepatic artery and bile duct generally 
known as the portal triad (or portal tract), and drained by a hepatic vein located in the 
periphery of each segment (Figure 1.2B).  
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Figure 1.2 Anatomy of the human liver. A. Anterior view of the liver. The falciform ligament 
separates the left and right lobes of the liver. A number of other ligaments including the round and left 
triangular ligaments anchor the liver to the abdominal wall and diaphragm. Adapted from Brunicardi et 
al. (2010). B. Couinaud segmentation of the liver. According to Couinaud, the liver can be divided 
into 8 segments. Each segment is supplied with blood by a portal vein and drained by a hepatic vein in 
the periphery of each segment. Hepatic veins converge to form three major hepatic veins, the right, 
middle and left, which empty into the inferior vena cava. Adapted from Dancygier (2009). 
1.1.2. Intrahepatic vascular system 
1.1.2.a Blood flow 
The liver has a dual blood supply which means that it receives blood from two sources: the 
portal vein and the hepatic artery. Around 75% of the blood is delivered by the portal vein 
which carries partially oxygenated and nutrient- and toxin-rich blood collected from the 
intestinal system, spleen and pancreas. The hepatic artery delivers the remaining blood 
(~25 %) which is rich in oxygen but nutrient-poor. Mixing of the portal venous and arterial 
blood takes place mainly in the hepatic capillaries, termed liver sinusoids. Sinusoids possess a 
fenestrated endothelium which allows oxygen and nutrients to be delivered to hepatocytes, the 
main cell type of the liver. Liver sinusoids eventually intersect to create the central vein at the 
centre of the liver’s functional unit, the lobule, from where the blood is drained from the liver. 
Central veins combine to form three major hepatic veins and the blood is emptied into the 
inferior vena cava which carries de-oxygenated blood to the right atrium of the heart (Kuntz 
and Kuntz, 2009). 
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1.1.2.b Biliary system 
Bile produced by hepatocytes is transported to the duodenum through a complex network of 
bile ducts which increase in size the closer they are located to the duodenum. Bile canaliculi, 
formed by the apical membrane surfaces of 2-3 neighbouring hepatocytes are the smallest unit 
of the three-dimensional biliary system. Actin and myosin filaments in the ectoplasm of 
hepatocytes support the transport of canalicular bile towards an area called canals of Hering. 
This area is partly lined by hepatocytes and biliary epithelial cells and serves as the link 
between bile canaliculi and bile ductules of the biliary tree. From the canals of Hering, bile 
flows into pre-ductules which continue into cholangioles. Cholangioles converge to 
interlobular bile ducts running along the portal triad. Through a series of increasingly wider 
bile ducts, bile leaves the liver through the right and left hepatic ducts which eventually empty 
into the common bile duct (Dancygier, 2009; Kuntz and Kuntz, 2009). 
1.1.2.c Lymphatics 
Most of the lymph in the body is generated by the liver. Its primary site of production in the 
liver is the perisinusoidal space between hepatocytes and the liver sinusoids, referred to as the 
space of Disse. Through lymph capillaries, lymph is transported to the space of Mall, the 
periportal space between the connective tissue of the portal tract and adjacent hepatocytes.  
From here lymph flows through lymph vessels that increase in size and exit the liver though 
lymph nodes (Dancygier, 2009; Kuntz and Kuntz, 2009).  
1.1.3. Functional units of the liver 
The liver’s complex architecture is subject to a distinctive vascular pattern in which a system 
of blood vessels and bile ducts infiltrates the parenchymal tissue. Several models for the 
functional unit of the liver have been proposed, mirroring the organs functional diversity. 
Each model describes the hepatic functional unit from a different angle, considering different 
aspects such as morphology, structure, microcirculation and functionality. The two most 
commonly used models to describe the functional hepatic unit are the liver lobule and the 
liver acinus. 
1.1.3.a Liver lobule 
The liver lobule was first defined by Kieran in 1833 and this model mainly describes the 
functional unit of the liver from a structural and anatomical perspective. Cross-sectioned, the 
lobule features a hexagon which is defined by portal triads surrounding the central vein 
located at the centre (Figure 1.3A). Blood enters the liver lobule through the portal vein and 
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hepatic artery and flows towards the central vein with oxygen and substrate levels falling. 
Blood may also enter adjacent lobules. Bile flows in the opposite direction towards the bile 
duct in the portal triad. An adult liver contains around 1.0-1.5 million lobules (Kuntz and 
Kuntz, 2009).  
1.1.3.b Liver acinus 
The liver acinus was first described by Rapport and is the preferred model for 
histopathologists because it assists in the description of pathological lesions (Wallace et al., 
2008). In contrast to the liver lobule, this concept of the hepatic functional unit is descriptive 
of functional and structural correlations and concentrates on the secretory and metabolic 
functions of the liver. In this model, blood enters the acinus via the portal vein and hepatic 
artery and is drained radially towards central veins located to the left and right periphery of 
the acinus (Figure 1.3B). The centre of the acinus comprises the terminal branches of the 
hepatic artery and portal vein. According to their distance from the portal triad, hepatocytes 
are situated along a gradient of oxygen and substrates and are therefore allocated to one of 
three zones. Zone 1 is closest to the portal triad and receives blood high in oxygen and 
substrates which decrease along Zone 2. Zone 3 is situated closest to the central vein and 
contains blood low in oxygen and substrates. The bile flow occurs centripetally, opposite to 
the direction of the blood flow (Kuntz and Kuntz, 2009).  
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Figure 1.3 Schematic diagrams of the functional units of the liver. (A) Liver lobule. In the model 
of the liver lobule, blood enters the unit through the portal vein and hepatic artery which, together with 
the bile duct, form the portal triad. As the blood flows towards the central vein (CV), oxygen and 
nutrient levels decrease. Note that blood may also flow into adjacent lobules. (B) Liver acinus. In the 
liver acinus, blood delivered via the portal vein and hepatic artery is thought to remain within the 
acinar structure as it flows through Zone 1 to 3 towards the central veins in the periphery. A decrease 
in oxygen and substrate levels can be observed within the different zones with Zone 1 containing the 
highest and Zone 3 the lowest levels. Adapted from Wallace et al. (2008). 
  
Not only do the zones correspond with oxygen and substrate supply, hepatocytes can also be 
divided into zones depending on their enzymatic and metabolic capacity which is referred to 
as metabolic heterogeneity (Kuntz and Kuntz, 2009). Based on the model example of 
cytochrome P450 (CYP450) gene expression, hepatocytes in the periportal region (Zone 1) 
express low levels of CYP450 enzymes whereas centrilobular hepatocytes surrounding the 
central vein (Zone 3) express high levels of CYP450. Although periportal hepatocytes are 
exposed to higher levels of toxins, the damage is generally detected in the centrilobular region 
due to the presence of high levels of metabolising CYP450 enzymes (Dancygier, 2009). 
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1.1.4. Microarchitecture of the liver 
Within the lobular and acinar hepatic structures, hepatocytes are arranged in plates which 
radially extend towards the central vein. In mammals, each plate is one cell thick and 
comprises 15-25 hepatocytes. The plates of hepatocytes are surrounded by sinusoids which 
facilitate the blood flow from the portal vein and hepatic artery towards the central vein. 
Hepatic sinusoids are lined by fenestrated endothelial cells (see also Section 1.1.5) which 
direct the exchange of materials between the blood and the basolateral hepatocyte surface. 
The sinusoidal lumen known as the space of Disse contains extracellular matrix components 
which support the parenchyma and are fundamentally important for hepatocyte proliferation 
and regeneration. With their apical surface membranes, hepatocytes form bile canaliculi 
which direct the bile flow towards the bile duct (Figure 1.4) (Dancygier, 2009; Kuntz and 
Kuntz, 2009). 
 
Figure 1.4 Schematic diagram of the hepatic microarchitecture. Blood supplied by the portal vein 
and hepatic artery mixes in the liver sinusoid through which it flows towards the efferent central vein. 
Sinusoids are lined by sinusoidal endothelial cells and infiltrate the liver parenchyma. Hepatocytes are 
arranged in plates and secrete bile into the bile canaliculus. Bile flow occurs opposite to the direction 
of the blood towards the bile duct.  
1.1.5. Cells of the liver 
The liver comprises at least 7 different cell types which can broadly be divided into 
parenchymal (hepatocytes) and non-parenchymal cells (all other liver cells). Non-
parenchymal cells can further be subcategorised into a cell population called sinusoidal cells 
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which are cells associated with the liver sinusoids. These include sinusoidal endothelial cells, 
Kupffer cells, hepatic stellate cells and Pit cells. Biliary epithelial cells and oval cells 
complete the list of non-parenchymal cells. The following sections will describe the different 
cell types which are crucial to normal functioning of the liver (Kuntz and Kuntz, 2009; 
Monga, 2011). 
1.1.5.a Hepatocytes 
Hepatocytes are the main hepatic functional cells and account for approximately 80% of the 
total volume of the liver. They have many important roles including detoxification, 
metabolism and protein synthesis and are therefore responsible for the liver’s metabolic and 
synthetic functions. Hepatocytes are surrounded by sinusoids and are involved in the 
exchange of a variety of substances present in the blood. Given their location, hepatocytes are 
structurally polarised with three distinct surfaces: the sinusoidal (basolateral) side which faces 
the sinusoids; the canalicular (apical) surface forms the bile duct network; and the lateral sides. 
The sinusoidal membrane of the hepatocyte accounts for around 37% of the membrane 
surface and contains many microvilli which extend into the space of Disse as well as into the 
sinusoids facilitating the bi-directional exchange of substrates and proteins (Kuntz and Kuntz, 
2009). The canalicular surface makes up approximately 15% of the hepatocyte surface and 
faces the bile canaliculus which collects and transports bile generated by hepatocytes to the 
bile ducts. Neighbouring hepatocytes are linked by intercellular adhesion complexes on their 
lateral sides allowing for the separation of the perisinusoidal space from the bile canaliculi, 
therefore forming the blood-bile barrier. The expression of a large diversity of membrane-
associated transport proteins on the hepatocyte surface further contributes to their secretory 
and absorptive functions (Kuntz and Kuntz, 2009; Monga, 2011).   
1.1.5.b Sinusoidal endothelial cells   
Sinusoidal endothelial cells (SECs) line the network of liver sinusoids and constitute 
approximately 50% of the non-parenchymal cell type. Positioned on a layer of extracellular 
matrix, SECs are primarily involved in the regulation of transport and exchange of fluids and 
material between the blood and the subjacent hepatocytes. Unlike other mammalian 
endothelial cells, SECs have a distinctive phenotype in that they lack a basal membrane but 
possess pores and fenestrae which are essential to filtering solutes from the blood and allow 
for solutes to pass the endothelium. To further enhance the exchange of solutes and fluids 
from the blood, SECs possess a number of specific receptors on their surface for incorporation 
and transport of material to hepatocytes (Dancygier, 2009; Monga, 2011). 
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1.1.5.c Hepatic stellate cells 
Hepatic stellate cells (HSCs), also known as Ito cells or fat storing cells, represent around    
25% of the of the non-parenchymal liver cell population. They are situated in the space of 
Disse, between hepatocytes and SECs (see also Figure 1.4). In the normal liver, HSC are 
usually in a quiescent state in which their primary functions are the storage of retinoids 
(Vitamin A) as esters with fatty acids (retinylesters), as well as the secretion of non-fibril 
extracellular matrix components. In the injured liver, HSCs are predominantly found in an 
activated state, induced by various inflammatory signals including reactive oxygen species 
(ROS), cytokines and chemokines. When they become activated, HSCs transdifferentiate into 
a myofibroblast-like cell and lose their ability to store retinylesters. Activated HSCs further 
produce a number of cytokines and secrete fibrillary components of the extracellular matrix 
which makes them the key contributor to the development and progression of liver fibrosis. 
Their ability to contract and modulate the sinusoidal blood flow is thought to further enhance 
the progression of hepatic fibrosis (Dancygier, 2009; Monga, 2011). 
1.1.5.d Kupffer cells 
Kupffer cells are the residential macrophages of the liver and account for around 20% of non-
parenchymal liver cells. They migrate along the endothelium of the sinusoids and are more 
abundantly found in periportal regions (Kuntz and Kuntz, 2009) (see Figure 1.4). Kupffer 
cells make up the first line defence by responding to gut-derived bacterial and fungal 
components delivered via the portal vein (Monga, 2011). Once activated, Kupffer cells release 
a number of pro-inflammatory cytokines including tumour necrosis factor alpha (TNFα). The 
activation of Kupffer cells by the gut-derived bacterial component endotoxin, a 
lipopolysaccharide (LPS), has been extensively studied and will be further discussed in 
Section 1.5.3. 
1.1.5.e Pit cells 
Pit cells are natural killer (NK) cells specific to the liver. They are granular lymphocytes 
mainly found in the liver sinusoids and the space of Disse where they communicate with 
SECs and Kupffer cells. The primary function of Pit cells is to eliminate tumour, necrotic and 
foreign cells. It has also been proposed that they may destroy virally infected cells (Kuntz and 
Kuntz, 2009; Monga, 2011). 
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1.1.5.f Biliary epithelial cells 
Biliary epithelial cells (BECs) or cholangiocytes line the extra- and intrahepatic bile ducts of 
the biliary tree and constitute 3-5% of all liver cells. Depending on their location within the 
biliary network, BECs display morphological and functional heterogeneity explaining why 
many liver diseases that directly involve bile ducts (cholangiopathies) are restricted to certain 
regions of the biliary tree. BECs are primarily concerned with the production and transport of 
bile from the liver to the gall bladder. They are responsible for the generation of the final bile 
composition by alkalinisation and modification of the primary bile secreted by hepatocytes. 
Primary cilia on their apical plasma membrane extend into the bile duct and facilitate changes 
in bile composition and flow. In the healthy liver, BECs arrest in G0 phase of the cell cycle 
and are replicatively quiescent. Upon liver injury, however, they are able to proliferate and fill 
a role in the repair response which consequently may distort the structure of the bile duct 
network. Especially small BECs closest to the site of injury are thought to be capable of 
marked proliferation which incites a fibrotic response, mainly through interactions and cross-
talk with other hepatic cell types (Dancygier, 2009; Monga, 2011).  
1.1.5.g Oval cells 
Oval cells are bi-potential hepatic progenitor cells situated in the canals of Hering, the 
transition zone that delivers bile from bile canaliculi formed by hepatocytes to the bile ducts 
of the portal triads (Dancygier, 2009). In the presence of severe liver damage or if hepatocyte 
proliferation is impaired, oval cells are thought to be able to differentiate into both 
hepatocytes and BECs, playing a crucial role in liver regeneration (Oh et al., 2002; Newsome 
et al., 2004).  
1.1.6. Functions of the liver 
The liver performs a vast array of metabolic and regulatory processes which are essential for 
an organism’s health and wellbeing.   
1.1.6.a Xenobiotic metabolism 
One of the liver’s major metabolic functions is the detoxification and clearance of xenobiotics 
to which the human body is exposed daily in the form of pharmaceuticals, environmental 
contaminants, household chemicals and dietary supplements. The general principle of drug 
metabolism is the conversion of a lipophilic chemical into a more water-soluble metabolite to 
facilitate its urinary and biliary excretion. Drug metabolism processes are carried out by drug 
metabolising enzymes which are most abundantly expressed in hepatocytes, making the liver 
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cell the centre of the detoxification process. Generally, biotransformation processes can be 
divided into phase I and phase II reactions. Phase I reactions are also referred to as 
functionalization reactions and executed by CYP450 enzymes, flavin containing 
monooxygenases (FMO) and alcohol and aldehyde dehydrogenases (Klaassen, 2007). Phase I 
enzymes catalyse oxidation, reduction, hydrolysis and hydration reactions which transform a 
parent compound to a more water-soluble and active metabolite by inserting a polar functional 
group (e.g. –OH, –COOH, –SH, –NH2). Phase II reactions, also known as conjugation 
reactions, are executed by specific enzymes termed transferases. These enzymes conjugate 
active metabolites often formed in phase I with charged endogenous molecules such as 
activated glucuronic, sulfate, acetic or amino acids, glutathione or S-adenosyl methionine. 
The resulting conjugation product is more hydrophilic and more readily excreted in the urine 
or bile (Kuntz and Kuntz, 2009; Monga, 2011).  
1.1.6.b Bilirubin metabolism 
The liver is not only responsible for the elimination of xenobiotics; it also serves as a 
degradation and detoxification site for endogenously produced substances. An example for 
this is the elimination of bilirubin. Bilirubin is a breakdown product of haemoglobin and is 
primarily produced when ageing red blood cells are degraded in the spleen. It is a lipophilic 
substance and potentially toxic. Bound to serum albumin, bilirubin is transported to the liver 
for detoxification by hepatocytes. After separation from albumin at the sinusoidal hepatocyte 
membrane, free bilirubin is conjugated with glucuronic acid by specific transferases resulting 
in the formation of hydrophilic secondary bilirubin which is eliminated via the bile and urine 
(Kuntz and Kuntz, 2009). 
1.1.6.c Carbohydrate metabolism 
The liver plays a key role in the regulation and storage of carbohydrates and plays a 
significant role in the maintenance of blood glucose concentrations within a narrow range. In 
response to accumulation of glucose in the blood following the ingestion of carbohydrates, 
insulin is secreted from the pancreas promoting the uptake of glucose by hepatocytes which 
transform glucose molecules into glycogen for storage. During periods of fasting, blood 
glucose levels decrease and the liver catabolises glycogen to release glucose in response to 
signals such as the hormone glucagon to maintain optimal blood glucose concentrations 
(Kuntz and Kuntz, 2009; Monga, 2011). 
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1.1.6.d Protein synthesis and degradation 
The liver is involved in both the synthesis and turnover of proteins and is the main site for the 
degradation of essential amino acids in the body. The metabolism of amino acids can result in 
the release of toxic ammonia which is mainly detoxified by the liver-specific urea cycle. In 
the urea cycle, ammonia is transformed into the less toxic urea through an array of catalytic 
reactions. A smaller portion of ammonia is also rendered non-toxic by the enzyme glutamine 
synthase which catalyses the reaction of ammonia and glutamate to glutamine. This reaction, 
however, only temporarily detoxifies ammonia and serves as a nontoxic ammonia transport 
form (Kuntz and Kuntz, 2009). 
1.1.6.e Maintenance of hormonal homeostasis 
Contributing to the maintenance of hormonal homeostasis, the liver plays an important role in 
the inactivation of steroid hormones which include androgens, oestrogens, gestagens and 
glucocorticoids. Glucuronidation, sulfation or hydroxylation reactions increase the hormones 
polarity to facilitate their excretion via the urine, intestine or skin (Kuntz and Kuntz, 2009).  
1.1.6.f Lipid metabolism 
The liver’s functions in the metabolism of lipids include the synthesis and degradation of fatty 
acids as well as the maintenance of plasma lipid levels through its capacity to synthesise and 
secrete but also remove lipids in the form of lipoproteins from the circulation. Lipoproteins 
are macromolecules that consist of both lipids and proteins, essential for the transport of 
hydrophobic lipids in the blood. The liver also forms the majority of the body’s cholesterol 
which is the initial substrate in steroid and bile acid biosynthesis and an important substance 
to form and maintain cell membranes (Kuntz and Kuntz, 2009).  
1.1.6.g Bile acid metabolism 
Another important function of the liver is the metabolism of bile acids. Bile acids are derived 
from cholesterol and are a major component of bile which facilitates the digestion and 
absorption of lipids in the duodenum. The synthesis of bile acid takes place exclusively in the 
liver and is primarily localised to centrilobular hepatocytes (Staels and Fonseca, 2009; Monga, 
2011). Through a series of enzymatic reactions involving the CYP450 family of enzymes, 
lipophilic cholesterol is transformed into the more water soluble, primary bile acids cholic 
acid and chenodeoxycholic acid. To further improve their water-solubility, primary bile acids 
are conjugated with taurine or glycine and/or are sulfated by sulfotransferases before secretion 
into the bile canaliculi. Bile acids are stored in the gallbladder and are released into the 
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duodenum following ingestion of a meal. Enterohepatic circulation allows for 95% of bile 
acids to be reabsorbed from the small intestine and transported back to the liver which 
simultaneously serves as a feedback mechanism for bile acid synthesis (Staels and Fonseca, 
2009; Monga, 2011). Alterations in bile acid homeostasis, such as through inhibition of bile 
acid transporters or bile acid detoxification enzymes by xenobiotics can lead to an impaired 
excretion and thus interruption of the bile flow through the liver, a condition known as 
cholestasis (Rodrigues et al., 2014). 
1.2. Cholestasis 
Cholestasis is commonly known as a condition in which the normal bile flow through the 
liver is interrupted or impaired. Although a large number of possible causes exist, cholestatic 
conditions can generally be categorised into one of two types: an obstructive type where the 
bile flow is impaired by physical blockages such as gallstones or tumours; or a metabolic type, 
where cholestasis occurs as a result of functional defects in bile formation and secretion 
caused by drugs, hormones or genetic defects (Monga, 2011). As a result of an impaired bile 
flow, bile acids accumulate in the liver where they have toxic effects causing liver cell 
necrosis and apoptosis and therefore liver injury (Woolbright and Jaeschke, 2012; Woolbright 
et al., 2015). Cholestasis also results in a build-up of bile acids in the serum which causes the 
common clinical symptoms typically associated with cholestatic disorders including pruritus 
(itchy skin) and fatigue (Kuntz and Kuntz, 2009).   
There is rapidly growing interest in the role that bile acid transporters play in the development 
and progression of cholestasis. Hepatocytes possess a large number of sinusoidal and 
canalicular transport proteins involved in the uptake and excretion of bile acids. Canalicular 
excretion of bile salts is mediated by a range of ATP-binding cassette (ABC) transporters 
which are the rate-limiting step of bile formation (Trauner and Boyer, 2003; Oude Elferink et 
al., 2006). Many cholestatic disorders have been linked to genetic defects of hepatobiliary 
ABC transporters such as the bile salt export pump (BSEP) or the multidrug resistance protein 
3 (MDR3) (Trauner and Boyer, 2003). These hereditary mutations result in inherited 
progressive cholestatic liver disorders including progressive familial intrahepatic cholestasis 
(PFIC) (Deleuze et al., 1996; Strautnieks et al., 1998). Not only can cholestasis result from 
hereditary genetic transport protein defects, there are many other factors including drugs and 
hormones, such as oestrogens, that can cause acquired cholestatic disorders by directly 
inhibiting transport protein function or by reducing transporter protein expression (Wagner et 
al., 2009).   
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1.3. Oestrogen 
Oestrogens are commonly defined as the primary female sex hormones and belong to the 
family of steroid hormones. They are predominantly implicated in the development and 
regulation of the sexual reproductive system but also exert a variety of other biological 
functions in the immune, cardiovascular, musculoskeletal, and central nervous system
 
(Gustafsson, 2003; Heldring et al., 2007). The most potent endogenous oestrogen is 17β-
oestradiol (E2) which is the major oestrogen present in pre-menopausal women. Oestrone  
(E1) and oestriol (E3), playing larger roles in the post-menopausal stage and during 
pregnancy, respectively, are metabolites of E2 and much less potent (Heldring et al., 2007). 
Ethinyl oestradiol (EE) is a synthetic derivate of E2 and commonly used in oral contraceptive 
pills. The chemical structure of these oestrogens and relevant information is summarised in 
Table 1.1. 
Name    Structure Description 
Oestrone (E1) 
 
Least abundant of the three naturally 
occurring oestrogens. Major 
oestrogen found in menopausal 
women.  
17β-oestradiol 
(E2) 
 
Most potent endogenous oestrogen. 
Most abundantly present in women 
but also found in men as a metabolite 
of testosterone. 
Oestriol (E3) 
 
Mainly produced during pregnancy 
by the placenta. If not pregnant, 
levels in women and men are similar.  
Ethinyl oestradiol 
(EE) 
 
Synthetic orally bioactive derivate of 
E2. Present in most modern oral 
contraceptives.  
Table 1.1 Oestrogens – chemical structure and relevant information. 
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1.3.1. Oestrogen synthesis and metabolism 
Oestrogens are primarily synthesised in the ovaries or testes by metabolic conversion of the 
precursors androstenedione and testosterone (both derived from cholesterol) to E1 and E2, 
respectively, although extragonadal tissues such as the brain and adipose tissue produce low 
but significant levels of oestrogens (Mauvais-Jarvis et al., 2013; Gao et al., 2015). The 
conversion reaction is catalysed by a group of enzymes termed aromatases which belong to 
the cytochrome P450 superfamily (Nelson and Bulun, 2001). Oestrogen levels are tightly 
regulated by mechanisms which include the conversion of the most potent oestrogen E2 to the 
less potent E1 or E3 or by sulfation of E2 by sulfotransferases which renders E2 inactive by 
inhibiting its interaction with the oestrogen receptor (Cui et al., 2013). 
1.3.2. Oestrogen receptor  
Cellular signalling of oestrogens is mediated by the oestrogen receptors (ERs), members of 
the nuclear receptor family of transcription factors. Two subtypes of the ER exist: the ERα 
(NR3A1) and the ERβ (NR3A2). For many years, the ERα was believed to be the only ER 
responsible for the regulation of oestrogen signalling, however, the discovery of the ERβ in 
1996 altered the way in which ER signalling was understood (Green et al., 1986; Greene et al., 
1986; Kuiper et al., 1996; Mosselman et al., 1996; Moore et al., 1998).  
ERα and ERβ are derived from distinct genes located on different chromosomes but share a 
high degree of sequence homology (Menasce et al., 1993; Enmark et al., 1997; Klinge, 2000; 
Heldring et al., 2007; Kumar et al., 2011). Both ERs consist of six functional domains, 
labelled A to F (see Figure 1.5). Domains A and B encode the activation function-1 (AF-1) 
which modulates oestrogenic transcriptional activity independent of a ligand. The central C 
domain contains the DNA recognition and binding region (DBD) and with 96% homology 
between ERα and ERβ is the most conserved domain. The hinge region can be found in the D 
domain and contains sequences for nuclear translocation and receptor dimerisation. The 
ligand-binding domain (LBD, within the E domain) encodes activation function-2 (AF-2) 
which regulates transcriptional activity in a ligand-dependent manner. The function of the C-
terminally located F-domain was found to be involved in transcriptional activity and receptor 
dimerisation (Nilsson and Gustafsson, 2000; Koide et al., 2007; Yang et al., 2008).  
The full length human ERα (hERα), regarded as the wild type form, is 595 amino acids long 
with an approximate size of 66 kDa (also referred to as hERα66) whereas an ERβ variant of 
530 amino acids and 59 kDa is regarded as the wild type hERβ (Etienne et al., 1998). 
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Figure 1.5 Domain organisation of the ER subtypes ERα and ERβ. Source: Kumar et al. (2011). 
1.3.2.a ERs: tissue distribution and roles 
ERα and ERβ exhibit both overlapping and distinctive physiological roles that are highly 
dependent on the tissue and cell type (Shanle and Xu, 2011). Mammalian tissues reported to 
contain detectable levels of ERα include the cardiovascular system, central nervous system 
and bones with peak levels in the male and female reproductive tracts (uterus, ovaries, vas 
deference), mammary glands as well as the pituitary (Couse et al., 1997; Gustafsson, 2003) 
(see also (NURSA, 2016a)). The primary role of ERα is the regulation of sexual reproduction, 
as exemplified in ERα knock out mice - females are infertile and males have decreased 
fertility (Lubahn et al., 1993). Further, ERα activation is thought to mainly exhibit 
proliferative effects on target tissues and cells (Helguero et al., 2005).  
The ERβ is commonly found in ovaries, prostate, certain brain regions, pancreas, lung and 
adipose tissue (Nilsson et al., 2001; Mollerup et al., 2002; Naaz et al., 2002; Nomura et al., 
2002; Morales et al., 2003) (see also (NURSA, 2016b)). ERβ knockout mice develop 
relatively normally and have normal fertility (Krege et al., 1998). As opposed to ERα, ERβ 
signalling is commonly associated with anti-proliferative effects (Paruthiyil et al., 2004; 
Helguero et al., 2005; Warner and Gustafsson, 2010; Mancuso et al., 2011). 
Co-expression of the two ER subtypes has been reported for the mammary gland, bone, liver 
and certain regions of the brain although they may not be expressed in the same cell type 
(Matthews and Gustafsson, 2003). If co-expression in the same cell type occurs, ERβ has 
been reported to be able to antagonise ERα transcriptional activity, presumably by altering the 
recruitment of co-regulatory proteins or by enhancing the proteolytic degradation of ERα 
(Matthews and Gustafsson, 2003; Matthews et al., 2006). 
In the classical oestrogen signalling pathway, both ERα and ERβ are ligand-activated by 
oestrogenic compounds such as E2 and mediate changes in gene expression by interacting 
with specific DNA sequences. The mechanisms of this pathway as well as alternative 
oestrogen signalling pathways are described in more detail in Section 1.3.3. 
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1.3.3. Oestrogen signalling pathways 
Several distinct oestrogen signalling pathways exist by which oestrogens and ERs regulate 
biological processes (Figure 1.6).  
In the classical signalling pathway, ligand-dependent activation of the ER results in the 
formation of ER homo- or heterodimers which, dependent on the dimerisation partner, may 
have independent and distinct functions (Kumar and Chambon, 1988; Cowley et al., 1997). 
ER dimers translocate and interact with specific DNA sequences termed oestrogen response 
elements (EREs) which are located in the regulatory regions of oestrogen-responsive genes 
(Tsai and O'Malley, 1994; Klinge, 2001). The ERE consensus sequence, GGTCA-nnn-
TGACC, is a 5-bp palindrome which is separated by a tri-nucleotide spacer (nnn) (Klein-
Hitpass et al., 1986; Shu et al., 2010). Following binding of the ER-ligand complex to DNA a 
variety of co-activators and -regulators are recruited which initiate transcriptional responses to 
oestrogens (Cowley et al., 1997; Shibata et al., 1997; Klinge, 2000).  
Another oestrogen signalling pathway which results in the modulation of gene expression is 
the crosstalk of ERs with other transcription factors. ERs have been shown to interact with 
nuclear factor-κB (NF-κB), specificity protein-1 (SP-1), activator protein-1 (AP-1) and ERK-
1 and may therefore regulate transcription of genes independent of  EREs (Kushner et al., 
2000; Saville et al., 2000; Shou et al., 2004; DeNardo et al., 2005).  
Oestrogens may also act through a non-genomic pathway which is also referred to as rapid 
signalling. This form of signal transduction occurs within minutes following oestrogen 
exposure. Membrane bound ERs such as GP30 and other membrane localised proteins 
including MAP kinase can be activated by oestrogen or extranuclear ER variants leading to 
the initiation of signalling cascades (Levin, 2002; Bjornstrom and Sjoberg, 2005; Thomas and 
Dong, 2006; Stephen and Ellis, 2007).  
ER-mediated induction of gene expression in the absence of a ligand is a fourth possible 
signalling mechanism. Phosphorylation of the ER induced by growth factors and as a result of 
downstream signalling of oestrogen independent pathways can lead to ER activation (Font de 
Mora and Brown, 2000; Roman-Blas et al., 2009). 
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Figure 1.6 Oestrogen signalling pathways. (1) In the classical signalling pathway, ligand-dependent 
dimerisation of the ER leads to nuclear translocation and binding of the ER to the oestrogen response 
element (ERE) in the regulatory regions of oestrogen responsive genes. The recruitment of co-factors 
leads to the initiation of transcription of target genes. (2) Activated ER can regulate gene transcription 
by interacting with other transcription factors such as AP-1 and NF-κB. (3) ERs can act through a non-
genomic pathway where membrane-bound or cytosolic ERs initiate rapid responses by activating the 
phosphatidylinositol-3/Akt (PI3K/Akt) and/or PKC/MAPK signal transduction pathways. (4) In the 
ligand-independent pathway, ERs can be activated as part of growth factor (e.g. IGF-1 and TGF-β) -
mediated signalling by direct interaction or by MAP and PI3/Akt kinase-dependent  phosphorylation. 
ER, oestrogen receptor; GF, growth factor; GFR, growth factor receptor;  TF, transcription factor. 
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1.3.4. ER splice variants 
Several different splice variants for both the ERα and the ERβ have been described in humans. 
Over 20 different hERα splice variants have been found in breast cancers, other tumours and 
cell lines, however, only 3 were reported to have functional activity (Poola et al., 2000; 
Sotoca et al., 2012). The two most referenced hERα splice variants are hERα36 and hERα46. 
hERα36 is a truncated form of wild type hERα which lacks AF-1 and AF-2 and thus has no 
transcriptional activity (Wang et al., 2005). This variant was reported to inhibit full length 
hERα and hERβ transcriptional activity, however, and is capable of activating non-genomic 
ER pathways (Wang et al., 2006). hERα36 was cloned from a human uterus cDNA library 
suggesting that it is a naturally occurring isoform. hERα46 was first identified in the human 
breast cancer cell line MCF-7 (Flouriot et al., 2000) but was later found to also be expressed 
in primary human osteoblasts (Denger et al., 2001) and endothelial cells (Figtree et al., 2003; 
Li et al., 2003). This truncated variant lacks AF-1 and has been shown to play a role in cell 
cycle control (Penot et al., 2005). hERα46 is a functional ligand-dependent transcription 
factor with AF-2 and has been reported to inhibit hERα transcriptional activity (Figtree et al., 
2003; Sotoca et al., 2012). 
 
Figure 1.7 Schematic diagram of full length hERα and its splice variants hERα46 and hERα36. 
AF, activation function; DBD, DNA binding domain; LBD, ligand binding domain; aa, amino acid.  
 
Although some of the hERα variants have only been found in tumours and cell lines and have 
not been reported to have functional activity (Flouriot et al., 2000), many variants of the 
hERβ are expressed as functional proteins in tissues and are implicated in the modulation of 
oestrogen signalling, impacting the regulation of target genes (Matthews and Gustafsson, 
2003; Ramsey et al., 2004; Poola et al., 2005; Leung et al., 2006). At least 5 hERβ isoforms 
exist, named hERβ1-hERβ5 with hERβ1 (hERβ) referred to as the full-length wild type 
receptor. Most hERβ splice variants are truncated C-terminally and have been shown to form 
heterodimers with full length hERβ and hERα thus playing an important role in the regulation 
of ER transcriptional activity (Ogawa et al., 1998; Inoue et al., 2000; Leung et al., 2006).   
A/B C D E/FhERα
hERα46
hERα36
595 aa
411 aa
273 aa
AF-1 DBD LBD and AF-2
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Figure 1.8 Schematic diagram of full length hERβ (hERβ1) and its splice variants hERβ2-5. AF, 
activation function; DBD, DNA binding domain; LBD, ligand binding domain; aa, amino acid. 
 
Similar to ERs in humans, many different isoforms of the mouse ER (mER) α and mERβ have 
been identified (Couse et al., 1997; Tremblay et al., 1997; Lu et al., 1998; Lu et al., 2000; 
Nielsen et al., 2000). Full length mERα comprises 599 amino acids (White et al., 1987) 
whereas the full-length mERβ isoform consists of 549 amino acids (Tremblay et al., 1997). 
1.3.5. Other oestrogen receptors 
Several other receptors through which oestrogens can mediate their effects have been 
identified expanding the possible mechanism by which oestrogens may affect target 
cells/tissues. These include other nuclear receptors such as the oestrogen related receptors 
(ERRs) which are insensitive to E2 but interact with some isoflavones, and the constitutive 
androstane receptor (CAR) in both mouse (Kawamoto et al., 2000) and humans (Koh et al., 
2012). Membrane-bound oestrogen binding proteins such as GPER1 (also known as GP30) 
have been reported to mediate non-genomic oestrogen signalling by activation of kinases and 
modulation of intracellular calcium levels (Rainville et al., 2015). 
1.3.6. Modulators of oestrogen signalling 
For many decades, oestrogen signalling has been a therapeutic target for the treatment of a 
variety of medical conditions. A large number of drugs have been developed to modulate 
oestrogen signalling pathways or alter levels of oestrogen signalling by modulating oestrogen 
metabolism or by displaying ER agonistic or antagonistic effects. ER agonists are commonly 
used for contraceptive purposes or in hormonal replacement therapy in post-menopausal 
women whereas drugs with ER antagonistic properties find, among others, use in the 
treatment of breast cancer (Burkman, 2003; Vogel, 2003; Ng et al., 2014). For a long time, 
A/B C D E/FhERβ1 530 aa
495 aa
513 aa
AF-1 DBD LBD and AF-2
hERβ2
hERβ3
hERβ4
hERβ5
581 aa
472 aa
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drugs were designed to exclusively target the ERα, however, the discovery of the ERβ lead to 
the design of ERα and ERβ specific drugs. The distinct tissue distribution pattern of ERα and 
ERβ further contributes to the interest in novel oestrogenic agents for therapy and has led to 
the awareness of new sites for pharmacological intervention in a variety of diseases 
(Gustafsson, 2003).  
1.3.6.a Selective oestrogen receptor modulators 
Selective oestrogen receptor modulators (SERMs) are nonsteroidal compounds that bind to 
the ERs. SERMs can have both agonistic and antagonistic activities depending on the type of 
target tissue and the ER subtype they interact with. Although drugs with SERM-properties 
have been used for a long time, their tissue-specificity in humans has only recently been 
recognised which makes them a major therapeutic advance for clinical application (Riggs and 
Hartmann, 2003). Examples of SERMs are the drugs tamoxifen and raloxifene which are 
widely used as treatment for breast cancer. Tamoxifen and raloxifene are capable of binding 
to both the ERα and ERβ but depending on the ER they interact with, display either agonistic 
or antagonistic properties (Riggs and Hartmann, 2003). Their agonist-antagonist activity 
further depends on the tissue type in which they operate. In the mammary gland, both drugs 
exhibit ER antagonistic effects where they prevent oestrogen-stimulated breast cancer growth 
(Jordan, 2003; Barrett-Connor et al., 2006). In endometrial cells, however, tamoxifen is an 
ER agonist and promotes endometrial cancer whereas raloxifene has neither agonistic nor 
antagonistic activities and is therefore considered neutral (Gottardis et al., 1988; Shang and 
Brown, 2002; DeMichele et al., 2008). The chemical structure of tamoxifen and raloxifene is 
shown in Table 1.2.  
Although only partially understood, the mechanism of selective agonist-antagonist and tissue-
specific SERM action can mostly be explained by three interactive mechanisms: 1) SERM 
action depends on the type of ER present in a particular target tissue, 2) the ER can have 
differential conformational changes on ligand binding which determines SERM function and 
3) SERM action depends on the type of co-regulatory proteins expressed in the target tissue 
which determine ER functional activity (Riggs and Hartmann, 2003; McDonnell and Wardell, 
2010). Shang and Brown (2002) have shown that in breast tissue, tamoxifen and raloxifene 
recruit regulatory co-repressor proteins to ER target promotors thus inhibiting ER target gene 
expression (Shang and Brown, 2002). In endometrial cells, however, tamoxifen leads to the 
recruitment of co-activators making it an ER agonist whereas raloxifene does not recruit co-
activators and therefore has no effects. The interest of SERMs for use as therapeutic agents 
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has heightened because of their potential to display beneficial oestrogenic effects while 
avoiding most of its negative effects (Riggs and Hartmann, 2003). 
1.3.6.b Selective oestrogen receptor degraders  
Selective oestrogen receptor degraders (SERDs) represent a new class of drugs used to 
antagonise oestrogen signalling. As the name suggests, SERDs interact with the oestrogen 
receptor and facilitate ER degradation in target cells. The drug ICI182,780 (ICI; also known 
as Fulvestrant or Faslodex) is a SERD used for treatment of ER-positive breast cancers. ICI is 
capable of interacting with both the ERα and ERβ, however, similar to SERMs, has 
differential effects on the stability of the ER subtypes as it only induces turnover of the ERα 
(Peekhaus et al., 2004).  The chemical structure of ICI182,780  is shown in Table 1.2.  
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Name Structure Description 
17β-oestradiol 
(E2) 
 
Most potent endogenous 
oestrogen.  
Tamoxifen 
 
Has agonistic and antagonistic 
effects on ERα but mainly 
antagonises ERβ (Barkhem et 
al., 1998) (Paige et al., 1999). 
ER antagonistic effects in 
breast but agonist in uterus 
and bone (Paige et al., 1999). 
Raloxifene 
 
ER antagonist in breast, 
agonist in bone but not uterus 
(Black et al., 1994) (Paige et 
al., 1999). 
ICI182,780 
 
Antagonistic effects on both 
ERα and ERβ (Wakeling et 
al., 1991; Paige et al., 1999).  
Table 1.2 Chemical structure of selected SERMs and SERDs compared to E2. 
 
Not only can oestrogen signalling be modulated by the deliberate use of pharmaceuticals such 
as SERMs and SERDs, there are a large number of chemicals present in the environment, diet 
and consumer products that can inadvertently interfere with and alter oestrogen signalling 
(Diamanti-Kandarakis et al., 2009). Chemicals that are capable of modifying the hormone 
system are referred to as endocrine disrupting chemicals (EDCs) and are elaborated upon in 
Section 1.3.7. 
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1.3.7. Endocrine disrupting chemicals 
EDCs have long been recognised to pose a potential health threat due to their ability to 
interfere with normal hormone signalling, synthesis and metabolism which can result in 
disruption of the endocrine system (Diamanti-Kandarakis et al., 2009). Adverse effects of 
exposure to EDC was first reported by Sumpter and co-workers (1994) who showed that male 
fish exposed to sewage waste water were subject to feminisation (Purdom et al., 1994; 
Sumpter, 1995). Ever since, many studies have been conducted showing that EDCs adversely 
affect the male and female reproductive system, can lead to the development of cancer and 
have disruptive effects on the metabolic, neuroendocrine and cardiovascular systems (Bay et 
al., 2006; Soto and Sonnenschein, 2010; Alonso-Magdalena et al., 2011; Mattison et al., 
2014). The group of molecules identified as EDCs is heterogeneous and includes both 
synthetic and natural compounds. Synthetic chemicals with endocrine disrupting activity 
include industrial solvents/lubricants and their by-products such as polychlorinated biphenyls 
(PCBs) and dioxins, flame retardants (polybrominated biphenyls (PBB)), plastics and 
plasticisers (Bisphenol A (BPA) and phthalates), pesticides (methoxychlor, 
dichlorodiphenyltrichloroethane (DTT) and chlorpyrifos) as well as pharmaceutical agents 
(Legler and Brouwer, 2003; Diamanti-Kandarakis et al., 2009). Natural compounds present in 
the diet include genistein and coumestrol (Pierre M et al., 1978; Diamanti-Kandarakis et al., 
2009). EDCs may disrupt the endocrine system via several mechanisms involving different 
pathways including the oestrogenic pathway.   
1.3.8. Xenooestrogens 
Xenoestrogens are EDCs which are able to mimic the effects of natural oestrogens thus 
interfering with normal oestrogen signalling. Similar to natural oestrogens, xenoestrogens can 
modulate both genomic and non-genomic ER signalling pathways through direct interaction 
with the ERs, indirectly through other transcription factors or by interfering with normal 
oestrogen biosynthesis, sequestration, metabolism or excretion (Shanle and Xu, 2011).  
Xenoestrogens can be found in many everyday products including foodstuffs, personal care 
items, food and beverage containers and household chemicals. Commonly known 
xenoestrogens include the natural phytoestrogen genistein and the synthetic chemical BPA 
which is commonly found in plastics and food containers (Kuiper et al., 1998; Laws et al., 
2000). Although a xenoestrogen may have little oestrogenic activity or the exposure to a 
particular xenoestrogenic compound may be low, recent research has shown that mixtures of 
xenoestrogens expected to be found in the environment can have dramatic disrupting effects 
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on hormonal mechanisms (Vinas and Watson, 2013). In order to reduce the risks posed by 
compounds with oestrogenic activity, a variety of in vitro and in vivo screening assays exist 
designed to identify new xenoestrogens.   
1.3.9.  Measurement of oestrogenic activity 
A number of in vitro and in vivo assays exist that are used to determine if a chemical has 
oestrogenic activity. In vitro reporter gene assays are frequently used to assess if a compound 
is capable of activating the ER via the classical oestrogen signalling pathway (Huang et al., 
2014). In reporter gene assays, activation of the ER will result in consequent expression of a 
reporter gene from a reporter construct that has been transfected into the test cell line. The 
level of reporter gene expression can consequently be measured and indicates the level of ER 
activation. A commonly used cell line is the human breast cancer cell line MCF-7 which 
expresses the ERα and is oestrogen responsive (Wiseman et al., 1993). Some ER negative cell 
lines may also be employed which allow testing for differential activation of the ERα and 
ERβ through transfection of ER-expression vectors. Other in vitro assays able to determine if 
a compound has the potential to modulate ER signalling and has oestrogenic activity include 
cell-free receptor binding assays and cell-based translocation and proliferation assays (Huang 
et al., 2014). 
Although in vitro assays typically allow cost- and time-effective high-throughput analysis, 
there are limitations including metabolism and clearance of the test compound and tissue-
specific effects that require the use of in vivo assays. The classical in vivo method by which 
oestrogenic (ERα) activity of a compound is measured, and often defined, is the mouse 
uterine bioassay. In this assay, the growth of the uterus in response to treatment with a test 
compound is assessed since the treatment with oestrogens results in growth of the uterus and 
causes uterotropic changes including an increase of depth of the uterine epithelium. Typically, 
prepubertal female mice, 19 days of age, are given the test compounds or the vehicle as 
control by intraperitoneal injection for up to 5 days followed by euthanisation and 
measurement of uterine relative wet weight and uterotropic changes (Rubin et al., 1951; 
Galey et al., 1993).  
1.4. Oestrogens and the liver 
Previous investigations have suggested that the ERα is the only ER subtype expressed in 
hepatocytes making the liver a hormonal target via the ERα (Ahlbory-Dieker et al., 2009). In 
the liver, oestrogens regulate a variety of metabolic processes including the synthesis of sex 
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hormone binding globulin (Hammond, 2011), stimulation of anti-lipogenic metabolism and 
prevention of insulin resistance (Mauvais-Jarvis et al., 2013). 
The liver further plays a key role in controlling circulating oestrogen levels by metabolic 
conversion of oestrogens to inactive products (Tsuchiya et al., 2005; Bondesson et al., 2015; 
Ziegler et al., 2015). Its significance is demonstrated in men with chronic liver disease who 
may be subject to feminisation as a result of compromised hepatic metabolism and clearance 
of oestrogens (Burra, 2013). Oestrogens are also known to have toxic hepatic effects and can 
cause alterations in bile constituents and a disruption of the bile flow and thus cholestasis.  
1.4.1. Oestrogen-mediated cholestasis     
Oestrogens are known to have the ability to induce intrahepatic cholestasis. This can be seen 
in susceptible women during pregnancy when circulating oestrogen levels are high, as a result 
of oral contraceptive intake and during postmenopausal replacement therapy (Vore, 1987; 
Lammert et al., 2000). The prevalence of oestrogen-induced cholestasis varies geographically 
and with ethnicity. Intrahepatic cholestasis of pregnancy is the most prevalent form of 
oestrogen-mediated cholestasis and is most common in Chile (Reyes, 2008). In susceptible 
individuals, the elevations in circulating oestrogens can be sufficient to lead to hepatic failure 
and death in the absence of liver transplantation (Ozkan et al., 2015).  
Several mechanisms as to how natural/endogenous oestrogens cause cholestasis have been 
proposed and often involve the inhibition or repression of bile salt transport proteins. In a rat 
model for oestrogen-induced cholestasis, Stieger et al. (2000) reported that the oestrogen 
metabolite oestradiol-17beta-glucuronide inhibited the activity of the bile acid and drug 
transporter BSEP thus identifying an important target involved in initiating cholestasis 
(Stieger et al., 2000). Several years later, Yamamoto et al. (2006) showed that ethinyl 
oestradiol (EE2) exposure resulted in the repression of a number of bile acid and cholesterol 
transporters including BSEP and Na(+)/taurocholate co-transporting polypeptide (NTCP) in 
mice. This effect was lost in ERα null mice resistant to EE2-induced cholestasis suggesting 
that oestrogen-mediated adverse hepatic effects in the liver are induced by interactions with 
the ERα (Yamamoto et al., 2006). In addition, a number of studies have reported that a 
microtubule-independent endocytic internalisation of both Bsep and Mrp2 in response to 
oestradiol 17β-D-glucuronide was observed (Mottino et al., 2002; Crocenzi et al., 2003; 
Mottino et al., 2005) and mediated by ERα (Barosso et al., 2012) proposing another 
mechanism by which oestrogen exposure may cause cholestasis. 
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1.4.2. Xenoestrogens and cholestasis 
Given the ability of oestrogens to cause cholestasis, exposure to xenoestrogens may have 
similar adverse hepatic effects. Recently, experimental data has shown that the food colourant 
tartrazine is an activator of the human ERα in vitro (Datta and Lundin-Schiller, 2008; Axon et 
al., 2012) and intraperitoneal injection of tartrazine into mice resulted in a mild cholestatic 
liver injury (Axon, Thesis 2012). A similar cholestatic injury in mice has been observed after 
the exposure to E2 (Axon et al., 2010).  
Not only can xenoestrogens mediate their effects through interaction with the oestrogen 
receptors, but they may target the oestrogen pathway by altering synthesis, transport and 
metabolism of endogenous oestrogens. For example, research has shown that metabolites of 
PCBs, environmental pollutants known for their xenoestrogenic properties, are potent 
inhibitors of oestrogen sulfotransferases (Kester et al., 2000). The sulfation of oestrogens 
prevents their interaction with the ERs thus rendering them inactive. Impaired oestrogen 
inactivation due to sulfotransferase inhibition increases their bioavailability in target tissues, 
such as the liver, which may explain their  hepatotoxic effects (Guzelian, 1983). 
Xenoestrogen exposure may also play a role in the development of the chronic cholestatic 
liver disease primary biliary cholangitis (PBC) which has been proposed to be triggered in 
part by exposure to xenobiotics (Prince et al., 2001; Ala et al., 2006; Jones, 2007).  
1.4.3. Primary biliary cholangitis 
Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is a chronic 
cholestatic liver disease which primarily affects peri- and post-menopausal women over the 
age of 40. Histologically, PBC is characterised by inflammation of the portal tracts and 
disappearance of the intrahepatic bile ducts which eventually leads to a decreased bile flow 
and build-up of toxic substances in the liver, causing hepatocyte damage, cirrhosis and 
ultimately liver failure (Kaplan and Gershwin, 2005).  
It has been established that genetic predisposition plays an important role in disease 
development. Relatives of affected individuals are more likely to develop PBC and it was 
reported that around 6% of cases occur within first-degree relatives (Gershwin et al., 2005). In 
2004, a twin study was conducted which has shown that in monozygotic twins, the 
concordance rate for PBC is 63% consolidating that genetics are involved in disease 
pathogenesis (Selmi et al., 2004).  
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Although of unknown aetiology, PBC exhibits several hallmarks indicative of an autoimmune 
disorder. These include the observation that, similar to other autoimmune diseases, PBC 
predominantly affects women with a female-to-male ratio of 9:1 (Talwalkar and Lindor, 
2003). In addition, anti-mitochondrial antibodies (AMAs) are present in the serum of the 
majority of patients. AMAs target 2-oxoacid dehydrogenase complexes (2-OADC), a family 
of enzymes located in the inner mitochondrial membrane and play a critical role in oxidative 
energy metabolism. 2-OACDs consist of three main subunits, namely branched chain 
ketoacid dehydrogenase (BCKD), ketoglutarate dehydrogenase (KGD) and pyruvate 
dehydrogenase complex (PDC). The majority of patients are found to produce AMAs directed 
at PDC, in particular the PDC subunit E2 (PDC-E2). Serum AMA of 50% of PBC patients 
with PCD-E2 specific antibodies have also been reported to be able to cross-react with 
epitopes of the E2 subunit of BCKD and KGD.   
Whilst PBC is often considered as an autoimmune disease, several observations have been 
made which will question its mere autoimmune background. First, all nucleated cells contain 
2-OADC, however, AMA, which are distributed throughout the body, predominantly target 
the liver (Kaplan and Gershwin, 2005; Selmi et al., 2007). Second, AMAs are only found in 
90-95% of all PBC patients indicating that they may not be solely responsible for the 
development of the disease (Mayo, 2008). Third, compared to other autoimmune disorders, 
the treatment with immunosuppressant is relatively ineffective and does not significantly 
improve symptoms (Mauss et al., 2014). Fourth, development of PBC in individuals under the 
age of 25 is rare and PBC is absent in children (Gershwin et al., 2000; Kaplan and Gershwin, 
2005). 
Although genetic predispositions seems to be a major determinant in disease development, 
more recent studies have implicated a role for environmental factors as potential triggers of 
PBC. These triggers are thought to be either of infectious (bacteria and viruses) or chemical 
(xenobiotics) nature. In regard to infectious agents, previous research has documented that 
microbes, in particular bacteria, are capable of inducing an autoimmune response by 
presenting peptides with similar homology to self-proteins which may lead to the production 
of antibodies that will react with the bacterial peptide and simultaneously targeting self-
epitopes thus causing the destruction of self-tissue (Van de Water et al., 2001). A number of 
infectious agents have been proposed to be able to trigger PBC including Escherichia coli 
(Shelley et al., 1990), Salmonella minnesota (Stemerowicz et al., 1988), Staphylococcus 
aureus (O'Farrelly and Doherty, 2007) and Novosphingobium aromaticivorans, the latter 
increasingly gaining interest as it has been shown to cause a specific antibody reaction and 
 29 
 
faecal samples of PBC patients have been reported to contain 16s rRNA sequences specific to 
this bacterium (Selmi et al., 2003; Kaplan, 2004). 
More recently, research findings suggest that a link between the exposure to environmental 
xenobiotics and the development of PBC exist. In theory, xenobiotics may bind to and 
therefore alter self-proteins which will result in conformational changes of native protein 
forming an unrecognised structure capable of inducing an immune response. An autoimmune 
response may then in turn lead to cross-reactivity with the self-epitope sustaining the immune 
response and thus causing chronic autoimmunity (O'Farrelly and Doherty, 2007). In terms of 
PBC, it has been proposed that a xenobiotic may conjugate to the PDC subunit E2 which 
consequently leads to protein alterations and creation of unrecognised structures. This in turn 
may induce the production of antibodies against the unrecognised protein as well as the native 
form resulting in loss of self-tolerance to PDC-E2. In fact, research has shown that serum 
AMAs from PBC patients target synthetically produced xenobiotic-conjugated PDC-E2 with 
higher affinity than to the native form of the protein (Long et al., 2001). Many of the 
conjugated xenobiotics were halogenated hydrocarbons which are commonly found in 
pesticides and detergents (Long et al., 2001; Kaplan and Gershwin, 2005).   
A likely role for xenobiotics as a causative agent in PBC is further supported by the 
demonstration that disease ‘hot spots’ exist. A cluster analysis of data from the UK found that 
PBC occurs more frequently in former industrial and coal mining areas such as in the north-
east of England (Prince et al., 2001). Moreover, the analysis also revealed that the risk of 
developing PBC was higher in urban areas than in surrounding rural areas (Prince et al., 
2001). Incidences of PBC have further been linked to living in close proximity to waste tip 
sites (Ala et al., 2006) indicating that exposure to environmental xenobiotics may increase the 
susceptibility of genetically predisposed individuals to developing PBC. Although 
associations between the use of nail polish and hair dyes and PBC exist (Gershwin et al., 2005) 
they should be interpreted with caution. PBC primarily occurs in women and therefore 
associations made between PBC and products predominantly used by women do not 
necessarily mean causation.  
1.5. Gut-liver axis 
The term gut-liver axis describes the close interplay that exists between the gut and the liver 
which together play a critical role in absorption and metabolism of nutrients and xenobiotics. 
Approximately 70% of the liver’s blood supply, delivered via the portal vein, is derived from 
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the intestine which makes the liver one of the first and major organs to be exposed to gut-
derived toxins, including bacteria and bacterial components (Szabo and Bala, 2010). The gut 
is home to billions of microorganisms and the gut epithelial barrier keeps microbiota from 
entering the portal circulation (Lieber, 2004). Trace amounts of bacterial components, such as 
the lipopolysaccharide (LPS) present in the cell wall of Gram-negative bacteria, may escape 
the gut and translocate to the liver where they are readily cleared by Kupffer cells and 
hepatocytes to maintain immune homeostasis (Szabo and Bala, 2010). Uptake and 
detoxification of endotoxin is critical for prevention of systemic inflammatory responses to 
blood-borne LPS.  
An increase in endotoxin translocation from the gut may outweigh the liver’s clearance 
capacity thus leading to the induction of transcription of a number of pro-inflammatory genes 
and release of cytokines. An acute inflammatory response in the liver will lead to the 
recruitment of immune cells such as neutrophils which, through their activity, further 
contribute to the development of liver damage. Elevated endotoxin translocation from the gut 
to the liver has been linked to a variety of liver disorders, including alcohol-induced liver 
disease (Han, 2002). 
1.5.1. Alcohol, endotoxin and liver disease 
Long term alcohol abuse is linked to the development of a variety of medical disorders 
including liver injury, brain injury and heart disease. Endotoxin seems to be a key factor in 
inducing alcohol-mediated tissue/organ damage and plays a convincing role in initiating a 
spectrum of liver diseases; fatty liver, alcoholic hepatitis and cirrhosis are the most prevalent 
types of alcohol-associated liver injury (Menon et al., 2001; Mann et al., 2003; Adachi and 
Brenner, 2006). The involvement of endotoxin in alcohol-induced liver damage became 
conspicuous when patients with alcoholic liver disease (ALD) showed elevated plasma 
endotoxin levels (endotoxemia) (Bode et al., 1987; Fukui et al., 1991). Since then, several 
studies provided the evidence that increased plasma endotoxin levels in humans is linked with 
ALD (Hanck et al., 1998; Fujimoto et al., 2000; Parlesak et al., 2000).  
A number of studies employing a rat model of alcoholic liver injury have highlighted the 
connection between alcohol, endotoxin and liver damage in a number ways. First, 
administering LPS on a background of ethanol feeding was found to induce fatty and necrotic 
changes in the liver and increased the bioactivity of a number of pro-inflammatory cytokines 
in the plasma (Pennington et al., 1997). Second, ethanol feeding and simultaneous treatment 
of rats with antibiotics to eliminate bacteria residing in the gut prevented alcohol induced liver 
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injury by reducing plasma endotoxin levels (Adachi et al., 1995). Third, animals fed with 
ethanol and Lactobacilli, which suppress the growth of gram negative bacteria in the gut, 
showed reduced endotoxin plasma levels and the absence of liver injury (Nanji et al., 1994). 
More recent studies have also found a connection between ethanol-induced liver damage in 
rats and increased plasma endotoxin levels (Mathurin et al., 2000; Nanji et al., 2001). These 
findings indicate that endotoxin plays a key role in the initiation of alcohol-induced liver 
disease.    
1.5.2. Oral ingestion of alcohol affects intestinal barrier function 
The mechanisms leading to elevated plasma endotoxin levels have received significant 
attention. Three explanations have been proposed to account for the processes involved in 
alcohol-mediated endotoxemia: 1) Kupffer cells, the residential macrophages of the liver 
responsible for the clearance of toxins and pathogens, are dysfunctional with a decreased 
ability to eliminate endotoxin; 2) overgrowth of bacteria in the gut causes excessive 
production of endotoxins; and 3) an increased intestinal permeability due to alcohol-induced 
disruption of intestinal barrier function results in increased uptake of endotoxins and bacteria 
by the gut (Rao et al., 2004).  
The third explanation has received particular attention and clinical and experimental data have 
shown that alcohol intake results in augmented gut permeability to macromolecules. Using 
51
CrEDTA as an indicator for gut permeability, alcoholics showed an increased intestinal 
permeability to this molecule (Bjarnason et al., 1984). Further, assessing gastrointestinal 
permeability by the excretion of polyethylene glycol (PEG) 400, an increase in intestinal 
permeability was measured in healthy subjects after oral administration of alcohol (Robinson 
et al., 1981). The administration of PEG with different molecular weights (Mr 400-10000) to 
subjects chronically abusing alcohol and healthy controls shows that especially larger 
molecules were increasingly excreted in the urine of alcoholics compared to healthy subjects. 
This suggests that alcohol increases intestinal permeability to macromolecules by impairing 
the intestinal barrier function. 
Chronic alcohol administration to rats by gavage led to an increase of permeability of the 
intestinal mucosa to macromolecules such as haemoglobin (Bungert, 1973) and horseradish 
peroxidase (Worthington et al., 1978). Furthermore, the assessment of gut permeability by the 
lactulose/mannitol (L/M) ratio showed that intragastric infusion of ethanol in rats increased 
the L/M ratio significantly (Mathurin et al., 2000).  
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In vitro studies using a cell culture model of the intestinal epithelium (Caco-2 cell line) 
revealed that ethanol and especially its metabolic product acetaldehyde effectively reduced 
the transepithelial electrical resistance which was used as a measure of paracellular 
permeability. These results along with measuring the unidirectional flux of extracellular 
markers such as inulin and mannitol, which could increasingly pass the cell monolayer, 
indicate an increase in paracellular permeability (Rao, 1998; Atkinson and Rao, 2001). 
The cumulative results of these studies suggest that alcohol consumption can lead to an 
increase in gut permeability to macromolecules including endotoxin. The effect that alcohol 
has on the gastrointestinal mucosa and intestinal barrier function is likely to be the first site of 
injury which initiates a complex cascade of cellular responses causing liver inflammation and 
damage. 
1.5.2.a The role of acetaldehyde in disruption of intestinal epithelial tight junctions 
Acetaldehyde, a metabolic product of ethanol, may be associated with the development of 
alcohol-related diseases (Salaspuro, 1996). In the gastrointestinal tract, ethanol is oxidised to 
acetaldehyde by alcohol dehydrogenases in the mucosa and especially by alcohol 
dehydrogenases of bacteria residing in the gut. Acetaldehyde is then further oxidised to 
acetate by mucosal or bacterial aldehyde dehydrogenases (Figure 1.9). Enzymatic activities of 
aldehyde dehydrogenases in the colon are generally lower compared to other tissues so that 
acetaldehyde is likely to accumulate in the colon (Salaspuro, 1996).  
It has been reported that acetaldehyde impairs the epithelial barrier function by disrupting 
tight junctions (Atkinson and Rao, 2001; Basuroy et al., 2005). Tight junctions are junctions 
between the apical membrane of neighbouring cells forming a barrier to the paracellular flux 
of water and solutes in epithelia
 
(Fanning et al., 1998). A study investigating intracolonic 
acetaldehyde levels in rats reported concentrations of up to 3 mM of the alcohol metabolite in 
the colon (Salaspuro, 1996). In Caco-2 cells, acetaldehyde concentrations of 0.1-0.6 mM were 
able to disrupt tight junctions and subsequently increase paracellular permeability in Caco-2 
cells (Rao, 1998; Atkinson and Rao, 2001). In comparison, it seems likely that intracolonic 
acetaldehyde in alcoholics is able to cause endotoxemia by disrupting tight junctions.  
The mechanism by which acetaldehyde loosens tight junctions and impairs epithelial barrier 
function is by redistribution of tight junction proteins from the intercellular junctions (Rao et 
al., 2004). As has been shown in Caco-2 cells, this is mediated by the effects of acetaldehyde 
on  tyrosine kinases by inhibiting protein tyrosine phosphatase activity (Atkinson and Rao, 
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2001). A subsequent increase in tyrosine phosphorylation of a number of proteins such as ZO-
1 and beta-catenin (a protein involved in tight junctions/adherens junctions respectively) may 
be a key mechanism of acetaldehyde-initiated tight junction destabilisation and inhibition of 
protein tyrosine phosphatase activities (Atkinson and Rao, 2001). By altering intracellular 
signal-disruption pathways, acetaldehyde has the ability to disrupt protein complexes 
involved in tight junction regulation causing an increase in intestinal permeability to 
endotoxin. Acetaldehyde production and accumulation in the intestinal lumen may therefore 
result in augmented endotoxin uptake and liver damage by triggering a cascade of cellular 
responses.  
 
Figure 1.9 Ethanol metabolism. Ethanol is oxidised to acetaldehyde by the alcohol dehydrogenases 
(ADH). Acetaldehyde is then further oxidised to acetate by aldehyde dehydrogenases (ALDH). 
 
1.5.3. Endotoxin-mediated activation of Kupffer cells 
Alcohol-induced liver damage is mediated by ethanol metabolites, gut-derived endotoxin, 
ROS and inflammatory cytokines such as TNF-α and Interleukin (IL)-1/IL-6 (Ajakaiye et al., 
2011). In alcohol-mediated liver damage, ROS and pro-inflammatory cytokines are 
predominantly released by the liver’s residential macrophages, the Kupffer cells (Figure 1.10). 
The phagocytotic activity of Kupffer cells plays an important role in removing antigens and 
other foreign substances such as intestine-derived endotoxin from the general and specifically 
portal circulation which is critical to prevention of hepatic injury (Toth and Thomas, 1992). 
Despite their disease preventing function, Kupffer cells can also contribute to the 
development of liver damage by releasing pro-inflammatory mediators as seen in alcohol- and 
endotoxin-associated injury. Their ability to induce hepatic damage has been shown by 
Adachi et al. (1994) who were able to prevent alcohol-induced liver damage by treating 
ethanol-exposed (by intragastric feeding) rats with gadolinium chloride (GdCl3) (Adachi et al., 
1994). GdCl3 is selectively toxic to Kupffer cells inhibiting their activity and preventing them 
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-
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from functioning normally. These results provide an insight in the important and paradoxical 
role of Kupffer cells in the onset of early liver injury.   
Other studies also support the hypothesis that Kupffer cell activation is involved in alcohol- 
and endotoxin-mediated liver disease in various ways. First, Kupffer cell function including 
phagocytosis, bactericidal activity and cytokine production is affected by ethanol (Yamada et 
al., 1991). Second, patients chronically abusing alcohol showed elevated levels of TNF-α 
which is generated by monocyte-derived macrophages only; Kupffer cells represent this 
lineage’s largest population. Third, intracellular calcium levels in Kupffer cells isolated 24 
hours after intragastric administration of ethanol to rats rose significantly in response to low-
dose LPS treatment (Enomoto et al., 1998). Temporary Ca
2+
 influx is necessary for LPS-
induced production of TNF-α (Watanabe et al., 1996).  
Kupffer cells once activated are responsible for the secretion of TNF-α, Interleukin (IL)-1 and 
IL-12 as well as ROS and RNS (Ajakaiye et al., 2011). In Kupffer cells, ROS generation is 
catalysed by the enzyme nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. 
The release of TNF-α and Kupffer cell mediated infiltration of neutrophils further contribute 
to continuous oxidative stress through the production of ROS leading to liver damage 
(Ajakaiye et al., 2011). 
 35 
 
 
Figure 1.10 Alcohol-mediated translocation of endotoxin and subsequent Kupffer cell activation 
results in pro-inflammatory cytokine and ROS production causing liver injury. Chronic alcohol 
consumption can impair the epithelial barrier function causing gut derived endotoxin of intestinal 
Gram-negative bacteria to translocate to the liver via the portal vein. Endotoxin then activates Kupffer 
cells which subsequently release ROS and pro-inflammatory cytokines including TNF-α resulting in 
liver damage.  
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1.6. Study objectives 
The main hypothesis underpinning this thesis was that exposure to xenoestrogens causes 
adverse hepatic effects. This hypothesis was formulated in light of the ability of oestrogens to 
cause cholestasis. To test this hypothesis, the three main aims of the study were: 
1. Develop an in vitro mouse-based reporter gene assay in order to be able to examine a 
variety of xenobiotics for their potential to interact with the mouse ERs and to 
determine their suitability for use in an in vivo mouse model 
2. Examine the potential hepatic adverse effects that xenoestrogens may have in vivo by 
employing a mouse model.  
3. Determine if alcohol co-administration results in increased uptake of orally 
administered xenoestrogens and thus cholestatic injury.   
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Chapter 2. Materials and Methods 
2.1. Materials 
Unless otherwise stated, all materials, chemicals and reagents were purchased from Sigma-
Aldrich (Poole, UK) and were of molecular or analytical grade. 
2.2. Animal work 
All experiments were conducted in accordance with the UK Animal (Scientific procedures) 
Act of 1986, with UK Home Office Guidance on the implementation of the Act and with all 
the applicable Codes of Practice for the care and housing of laboratory animals. Animal 
welfare and Ethical Review Body (Newcastle University) and UK Home Office approval 
were granted for all animal procedures. 
2.2.1. Husbandry 
All animals were housed in the Comparative Biology Centre at Newcastle University and kept 
in an air conditioned environment of 23°C ± 1°C with a controlled relative humidity of 47% 
and a 12-hour light/dark cycle. Mice were kept in saw-dust filled and filter top individually 
ventilated cages in groups of up to six mice per cage. The bedding was changed twice weekly 
and animals had access to water and food ad libitum. 
2.2.2. C57Bl/6 wild type mice  
C57Bl/6 wild type (wt) mice were sourced from Charles River (Kent, UK) and housed as 
described in Section 2.2.1. Mice were bred in house. Mice were at least 10 weeks old and 
between 25-34 g body weight at the beginning of all experiments.  
2.2.3. Transgenic C57Bl/6-NF-κB-luciferase mice 
Transgenic (tg) C57Bl/6-NF-κB-luciferase (NF-κB-luc) mice (bearing a transgene composed 
of three NF-κB sites from the Ig κlight chain promoter coupled to the gene encoding Firefly 
luciferase) were originally obtained from Dr Harald Carlsen (Oslo University, Norway). 
Mouse colonies were expanded in house. Animals were housed as described in Section 2.2.1. 
and were at least 10 weeks old and between 21-35 g body weight at the beginning of all 
experiments. 
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2.2.4. Genotyping  
Mice were genotyped at an age not younger than 6 weeks using the In Vivo Imaging System 
(IVIS) as described in Section 2.2.6.  Tg NF-κB-luc mice show a basal level of NF-κB-driven 
luciferase activity as can be seen in Figure 2.1.  
 
Figure 2.1 Phenotyping of mice using IVIS. Tg NF-κB-luc mice exhibit basal levels of luciferase 
activity following intraperitoneal (i.p.) injection of D-Luciferin. Wt, wild type; tg, transgenic. 
2.2.5. In vivo studies 
2.2.5.a Ethanol-mediated gut permeability pilot study 
Oral alcohol exposure is believed to increase gut permeability and/or alter the gut microbiota 
(Kirpich et al., 2012b; Szabo, 2015). A pilot study was carried out to determine the time of 
ethanol dosing required to see an increase in gut permeability. One male adult mouse per 
group was assigned to 1 of 4 groups and dosed twice daily by oral gavage for 14 days (except 
alpha-naphthyl isothiocyanate (ANIT)), dosed orally once at beginning of study) as outlined 
in Table 2.1. Dextrose treatment served as a control to account for the energy content of 
ethanol. ANIT is known to cause liver injury (Goldfarb et al., 1962) and was therefore 
included as a positive control. An oral dose of 50 mg/kg bw ANIT has previously been shown 
to cause detectable liver injury in tg NF- κB-luc mice (Probert, Thesis 2014).  
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Group Animals Dose Vehicle 
1 1x C57BL/6 wt Dextrose (6.32 g/kg bw) H2O 
2 1x NF-κB-luc  Dextrose (6.32 g/kg bw) H2O 
3 1x NF-κB-luc Ethanol (3 g/kg bw) H2O 
4 1x NF-κB-luc ANIT (50 mg/kg bw) Olive oil 
Table 2.1 Pilot study dosing regimen. Dosing solutions were prepared as follows: Dextrose was 
dosed from a 0.33 g/ml solution in H2O at 19 ml/kg bw. Ethanol was dosed from a 20% (v/v) ethanol 
solution in H2O at 19 ml/kg bw. 100 mg of ANIT was dissolved in 8 ml of olive oil, mixed on a roller 
and dosed at 4 ml/kg bw. wt, wild type; bw, body weight. 
 
On day 1, mice were imaged before and at 1 and 6 hours after the initial dose and from then 
on mice were imaged once on day 3, 6, 9, 12 and 14 using the IVIS as described in Section 
2.2.6.  On day 14 post imaging, tail vein blood was collected for serum enzyme analysis (see 
Section 2.2.7). 
2.2.5.b Oral tartrazine study  
To study the hepatic and gastrointestinal effects of oral tartrazine exposure, female adult tg 
NF-κB-luc mice and male C57Bl/6 wt mice were randomly assigned to 4 groups. In order to 
increase gut permeability, mice were pre-dosed with 3 g/kg body weight (bw) ethanol (control 
mice were dosed with 6.32 g/kg bw dextrose to account for the energy content of ethanol) for 
2 weeks followed by dosing with 50 mg/kg bw tartrazine (+/- 3 g/kg bw ethanol) for 10 
consecutive weeks. A dose of 50 mg/kg bw tartrazine was used because at this dose, tartrazine 
has previously been shown to induce mild cholestasis in mice following i.p. injection (Axon, 
Thesis 2012). Tartrazine (Sigma, cat# T0388) used in all studies had a purity of 85% or 
greater (which meets the EC specifications for its use as a food additive). Control mice were 
dosed with dextrose or ethanol alone. All dosing was carried out by oral gavage, twice daily 
with at least 7 hours between doses. The dosing regimen of all groups is specified in Table 2.2.  
 40 
 
Group Animals Pre-dose (2 weeks) Dose (10 weeks) 
1 
3x wt 
3x tg 
Dextrose (6.32 g/kg bw) Dextrose (6.32 g/kg bw) 
2 
6x wt 
3x tg 
Dextrose (6.32 g/kg bw) Tartrazine (50 mg/kg bw) 
3 
6x wt 
4x tg 
Ethanol (3 g/kg bw) Ethanol (3 g/kg bw) 
4 
7x wt 
4x tg 
Ethanol (3 g/kg bw) 
Tartrazine (50 mg/kg bw) + 
Ethanol (3 g/kg bw) 
Table 2.2 Dosing regimen to assess in vivo effects of oral tartrazine exposure. Dosing solutions 
were prepared and dosed as follows: Dextrose was dosed from a 0.33 g/ml solution in H2O at 19 ml/kg 
bw. Ethanol was dosed from a 20% (v/v) ethanol solution in H2O at 19 ml/kg bw. For tartrazine 
treatments with or without ethanol, 50 mg of tartrazine was dissolved in 19 ml of ethanol or dextrose 
solution respectively. Tg, transgenic NF-κB-luc mice; wt, C57Bl/6 wt mice; bw, body weight. 
 
Tg NF-κB-luc mice were imaged for inflammation before and after the pre-treatment period 
and then at 4, 8 and 10 weeks from the beginning of tartrazine dosing by IVIS as outlined in 
Section 2.2.6. After 12 weeks, tg mice were imaged and then terminated by cervical 
dislocation and their liver, spleen, kidney and intestinal tract removed immediately and 
imaged for inflammation ex vivo.  
Wt mice were terminated on the last day of the study and their livers harvested and fixed in  
10% (w/v) formalin in 1x phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 
2 mM KH2PO4, 8 mM Na2HPO4, pH 7.4) or snap frozen in liquid nitrogen and stored at -80°C. 
Blood was collected for serum enzyme analysis as described in Section 2.2.7. Body weights 
were measured once a week for the purposes of health monitoring and dosage adjustments. 
2.2.5.c Hepatic effects of xenoestrogens 
To investigate the hepatic effects of xenoestrogen exposure, male adult tg NF-κB-luc mice 
were randomly assigned to 4 groups and were dosed at 0, 24 and 48 hours by intraperitoneal 
(i.p.) injection (except ANIT, dosed once at beginning of study by oral gavage) as described 
in Table 2.3. EE was dosed at 0.5 mg/kg which has previously been shown to result in hepatic 
adverse effects in mice (Axon et al., 2010).  
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Group Animals Dose Vehicle 
1 3x NF-κB-luc Control vehicle 10% ethanol/90% olive oil (v/v) 
2 3x NF-κB-luc  EE (0.5 mg/kg bw) 10% ethanol/90% olive oil (v/v) 
3 3x NF-κB-luc 
Butyl paraben  
(50 mg/kg bw) 
10% ethanol/90% olive oil (v/v) 
4 1x NF-κB-luc ANIT (50 mg/kg bw) Olive oil 
Table 2.3 Dosing regimen to investigate in vivo hepatic effects of xenoestrogens. Dosing solutions 
were prepared and dosed as follows: Vehicle was dosed at 5 ml/kg bw. Ethinyl oestradiol (EE) 
treatment was prepared by diluting 0.1 mg/ml in 10% ethanol/90% olive oil (v/v) and dosed at 5 ml/kg 
bw. Butyl paraben was dosed from a 10 mg/ml solution in 10% ethanol/90% olive oil (v/v) at 5 ml/kg 
bw. 100 mg of ANIT was dissolved in 8 ml of olive oil, mixed on a roller and dosed at 4 ml/kg bw.  
 
After 72 hours, mice were imaged for inflammation by IVIS as detailed in Section 2.2.6. Mice 
were then terminated by cervical dislocation and their livers harvested and fixed in 10% (w/v) 
formalin in 1x PBS or snap frozen in liquid nitrogen and stored at -80°C. Blood was collected 
to measure serum enzyme activities as described in Section 2.2.7. 
2.2.5.d Hepatic effects of soil sample extracts 
To examine the effects that ethanol extracts prepared from soil samples collected from around 
a landfill site and from 3 control sites (extract preparation is described in Section 2.17) have 
on the liver, male tg NF-κB-luc mice were randomly assigned to 4 groups and were dosed 
once by i.p. injection as outlined in Table 2.4.  
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Group Animals Dose Vehicle 
1 3x NF-κB-luc Control vehicle 10% ethanol/90% olive oil (v/v) 
2 3x NF-κB-luc  EE (0.5 mg/kg bw) 10% ethanol/90% olive oil (v/v) 
3 3x NF-κB-luc 
Combined oestrogen- 
positive soil ethanol 
extracts* from landfill 
site (20 ml/kg bw) 
10% ethanol/90% olive oil (v/v) 
4 3x NF-κB-luc 
Combined oestrogen-
negative soil ethanol 
extracts* from landfill 
site (20 ml/kg bw) 
10% ethanol/90% olive oil (v/v) 
Table 2.4 Dosing regimen to examine the in vivo hepatic effects of soil sample extracts. Dosing 
solutions were prepared and dosed as follows: Vehicle was dosed at 20 ml/kg bw. EE treatment was 
prepared by diluting 0.025 mg/ml in 10% ethanol/90% olive oil (v/v) and dosed at 20 ml/kg bw. For 
preparation of soil sample extracts, 3.5 ml of ethanol soil extracts were dried down to 175 µl with 
nitrogen, diluted 1:9 (v/v) with olive oil and dosed at 20 ml/kg bw. *As determined by dual-glo 
luciferase reporter gene assay. 
 
Mice were imaged for inflammation at 0, 1, 6 and 24 hours post i.p. injection using the IVIS 
as detailed in Section 2.2.6. Mice were then terminated by cervical dislocation and their livers 
harvested and fixed in 10% (w/v) formalin in 1x PBS or snap frozen in liquid nitrogen and 
stored at -80°C. Blood was collected to measure serum enzyme activities as described in 
Section 2.2.7. 
2.2.6. In vivo luminescent imaging 
Tg NF-κB-luc mice were imaged using the IVIS Xenogen 200 Spectrum imaging system and 
luminescence was quantified and analysed using the Living Image 4.0 software (Caliper Life 
Sciences, Hoplinton, USA).  
To genotype mice, animals were anaesthetised with isoflurane prior to imaging and injected 
i.p. with 100 μl of 15 mg/ml D-luciferin (Synchem, Altenburg, Germany) in 1x PBS, sterile 
filtered. Ten minutes after injection, mice were imaged, marked with ear punches for 
identification and returned to their cages. For luminescent imaging as part of in vivo studies, 
mice were anaesthetised with isoflurane and their abdominal fur removed by shaving using 
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clippers. Mice were then injected i.p. with 200 μl of 15 mg/ml D-Luciferin in 1x PBS 
followed by imaging at 1, 5 and 10 minutes post injection. Following imaging, animals were 
returned to their cages. For imaging of organs ex vivo, mice were injected with 200 μl D-
luciferin and euthanised 10 minutes post injection. Organs were dissected rapidly and images 
taken.  
In order to quantify the luminescent signal from captured images, regions of interest were 
manually circled using the Living Image software and total flux values (photons/second) were 
calculated.   
2.2.7. Serum enzyme assays 
Serum samples were collected by tail vein bleed or by terminal bleed after autopsy. Blood 
was left to clot before centrifugation at 16,000 xg for 5 minutes. The serum was aspirated and 
transferred to a clean microcentrifuge tube. Serum samples were stored at -80°C until analysis 
for liver serum enzyme activities of alkaline phosphatase (ALP, biomarker for cholangiocyte 
injury (Scharschmidt et al., 1983) and alanine aminotransferase (ALT, biomarker for 
hepatocyte injury (Sherman, 1991)). ALP serum levels were determined using a fluorimetric 
alkaline phosphatase assay kit (Abcam, cat# ab83371) following the manufacturer’s 
instructions. ALP cleaves the phosphate group of the non-fluorescent 4-methylumbelliferyl 
phosphate disodium salt substrate which results in a fluorescent signal (Ex/Em = 360 nm / 
440 nm) being emitted by the reaction product 4-methylumbelliferone (Figure 2.2). The 
fluorescent signal was measured using a microplate reader (Synergy HT, BioTek, Swindon, 
UK). Serum ALT activities were measured by the Royal Victoria Infirmary Clinical 
Biochemistry Department in Newcastle Upon Tyne, UK. 
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Figure 2.2 Alkaline phosphatase reaction. 
2.3. Cell culture 
2.3.1. Materials and reagents 
Dulbecco’s Modified Eagle’s Medium (DMEM, cat# D5546), Minimum Essential Medium 
Eagle (MEME, cat# D2279), Ham’s F12 medium (cat# 51651C), Foetal Bovine Serum (FBS, 
cat# F9665), glutamine, penicillin-streptomycin solution, adenine, triiodothyronine, 
epinephrine, ITS solution, hydrocortisone and trypsin-ethylenediaminetetraacetic acid 
(Trypsin-EDTA) were purchased from Sigma. Non-essential amino acids and sodium 
pyruvate were sourced from Gibco (Life technologies). 1x PBS was prepared from tablets 
(Sigma) dissolved in ultrapure laboratory grade (MilliQ) water and sterilised by autoclaving. 
All routine culture plastic ware was obtained from Greiner Bio-one Ltd (Stonehouse, UK).  
2.3.2. Culture of adherent cell lines 
Adherent cell lines were sourced and routinely cultured in 75 cm
2
 cell culture flasks in 
appropriate complete culture medium as specified in Table 2.5. Cells were maintained at 37°C 
in a 5% CO2, humidified atmosphere. Cell culture medium was changed every 2-3 days. 
 
 
4-Methylumbelliferyl phosphate 4-Methylumbelliferone
H2O
Alkaline 
phosphatase
+ H2PO4
Ex: 360 nm
Em: 440 nm
  
4
5
 
Cell line Source Species/Morphology Culture medium 
603B 
Gift from Dr Yedidya Saiman (Mount 
Sinai School of Medicine, New York) 
murine biliary epithelial  
DMEM (low glucose), 10% (v/v) FBS, 2 mM glutamine, 
100 U/ml penicillin, 100 μg/ml streptomycin 
MCF-7 
Gift from Dr Katherine Rennie 
(Newcastle University, UK) 
human breast cancer  
HEK293  
ECACC (catalogue 85120602, Porton 
Down, UK) 
human embryonic kidney  
SH-SY5Y 
Gift from Dr Peter Hanson (Newcastle 
University, UK)  
human neuroblastoma  
AR42J-B13 
Gift from Dr Karen Wallace 
(Aberdeen University, UK) 
rat pancreatic acinar  
LTPA 
ATCC (catalogue CRL-2389, 
Manassas, Virginia) 
murine pancreatic epithelial   
MEME, 10% (v/v) FBS, 2 mM glutamine, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 1% (v/v) NEAA, 
1 mM sodium pyruvate  
H69 
Gift from Dr Andrew Axon, 
Newcastle University 
human biliary epithelial  
DMEM:Ham’s F12 (2:1), 10% (v/v) FBS, 2 mM 
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 
240 ng/ml adenine, 27 ng/ml triiodothyronine, 10 μg/ml 
epinephrine, 1x ITS solution, 1 μM hydrocortisone 
Table 2.5 Adherent cell lines, source and cell culture media. ECACC, European Collection of Cell Cultures; DMEM, Dulbecco’s Modified Eagle’s Medium; FBS, 
Foetal bovine serum; MEME, Minimum Essential Medium Eagle; NEAA, Non-Essential Amino Acids; ITS, Insulin-Transferrin-Selenium. 
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2.3.3. Cell passage 
To maintain cell lines in an exponential growth phase, cells were passaged 2-3 times a week 
or upon reaching 80-100% confluency. Cells were washed with 10 ml of sterile 1x PBS 
before incubation with 2-3 ml (for a 75 cm
2
 flask) of 1x Trypsin-EDTA diluted in 1x PBS to 
detach cells (typically no more than 10 minutes). Careful impact to the cell culture vessel was 
used to encourage detachment. The trypsin was inactivated by adding complete culture 
medium to the cell suspension. Cells were collected in 50 ml tubes and centrifuged at 200 xg 
for 5 minutes. The supernatant was discarded and cells were re-suspended in fresh complete 
culture medium. Cells were then seeded into 75 cm
2
 flasks or multi-well plates for 
maintenance or subsequent experiments. 
2.3.4. Long term cell storage 
Cell stocks for all cell lines used were periodically frozen and stored in liquid nitrogen. After 
trypsinisation, cells of one confluent 75 cm
2
 flask were pelleted and re-suspended in 2 ml 
freezing medium containing 90% (v/v) FBS and 10% (v/v) dimethyl sulfoxide (DMSO). 
One ml of cell suspension was added per sterile cryogenic storage vial and frozen at a 
controlled rate in a freezing container filled with isopropyl alcohol. Frozen cell stocks were 
then transferred to liquid nitrogen for long-term storage. 
2.3.5. Revival of cell stocks 
Cell stocks cryogenically stored in liquid nitrogen were thawed in a 37°C water bath. The cell 
suspension was carefully re-suspended and transferred to 10x its volume of pre-warmed 
(37°C) complete medium in a 50 ml tube. Cells were pelleted by centrifugation at 200 xg for 
5 minutes, the supernatant was discarded and the cell pellet was re-suspended in fresh 
complete culture medium. The cell suspension was added to a 25 cm
2
 tissue culture flask and 
viable cells were allowed to attach for 24 hours before the culture medium was replaced. 
Upon reaching confluency, cells were trypsinised, transferred to 75 cm
2
 culture flasks and 
cultured as previously described. 
2.3.6. Assessment of cell viability and number 
Cell viability was measured by trypan blue exclusion assay (Strober, 2001), a dye that is able 
to pass the membrane of dead cells thus staining them blue. Cells that stain blue are 
considered as non-viable whereas cells with a clear cytoplasm are considered viable. Cell 
suspensions were diluted 1:1 with 0.2 % (w/v) trypan blue solution and loaded onto a 
disposable haemocytometer (C-Chip, Neubauer improved, Digital Bio). Total cell number and 
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cell viability in a known volume were determined by counting both trypan blue excluding 
(viable) and non-excluding (non-viable) cells.  
2.3.7. Charcoal/dextran-treated FBS 
FBS contains a number of steroid hormones which can affect nuclear receptor activities. It is 
therefore often required to deplete or ‘strip’ FBS of endogenous hormones for experiments 
investigating steroid hormone signalling. Pre-treatment of FBS with activated charcoal and 
dextran can be carried out to remove steroid hormones and other low molecular weight 
compounds from the serum (Aakvaag et al., 1990). 
3% (w/v) of activated charcoal and 0.03% dextran T70 were added to 24 ml MilliQ H2O 
which was subsequently vortexed and incubated for 15 minutes at room temperature. The 
charcoal/H2O mixture was then centrifuged at 9000 xg for 10 minutes and the supernatant 
discarded. The wash step in H2O was repeated once more. The charcoal pellet was then re-
suspended in 25 ml FBS and incubated at 4°C for 30 minutes on a rotator followed by 
incubation at 45°C for 30 minutes in a water bath, vigorously shaking. The charcoal/FBS was 
centrifuged at 3200 xg at 4°C for 10 minutes. The supernatant was removed to a clean tube 
and centrifuged again at 3200 xg at 4°C for 15 minutes followed by removal and transferal of 
the supernatant to a clean tube and a final spin at 25,000 xg at 4°C for 20 minutes. The FBS 
supernatant was aliquoted and stored at -20°C. Following addition of stripped FBS to media, 
the media was sterilised by filtering through a 0.22 μm filter unit. 
2.4. Isolation of primary human biliary epithelial cells from human liver  
Primary human biliary epithelial cells (hBECs) were isolated from surgical liver resections 
from the margins of tissue from patients with both benign and malignant tumours. Tissue was 
obtained with informed donor consent and ethical approval from the Newcastle & North 
Tyneside 2 Research Ethics Committee.  
2.4.1. Digestion 
The liver tissue was perfused with Hank’s Balanced Salt Solution (HBSS) without calcium 
and magnesium (HBSS
-
)  (10x stock (1.38 M NaCl, 53.3 mM KCl, 56 mM glucose, 4.4 mM 
KH2PO4, 3 mM Na2HPO4 and 0.3 mM phenol red) made up with sterile water to 1x and 
further supplemented with 6 mM sterile (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
(HEPES) and 4 mM NaHCO3) to remove the remaining blood from the resected tissue. To 
facilitate digestion, the resected liver tissue was then perfused with HBSS
+
 (HBSS
-
 with the 
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addition of 1 mM CaCl2) containing 1 mg/ml Collagenase A and 80 μg/ml DNAse I to reduce 
clumping. Following perfusion, the fibrous Glisson’s capsule was removed and the liver was 
divided into pieces (around 30-40 g) which were minced (1-2 mm
2 
pieces) in a sterile petri 
dish using a sterile scalpel. The liver tissue was then transferred to a sterilin. All following 
steps apply to 30-40 g of tissue. Five ml of 10 mg/ml collagenase type A and 2 ml of 2 mg/ml 
DNase I was added to the minced tissue and diluted with 43 ml of 1x PBS. The liver was 
incubated at 37°C for 30-45 minutes. After incubation, the liver tissue and collagenase 
mixture was sieved through a 125 μm Nybolt mesh attached to a beaker (sterile) using a 
plunger from a 10 ml syringe. 1x PBS was added frequently to facilitate cell passage. The 
tissue was mashed for 10-15 minutes until only connective tissue remained. The mesh was 
carefully removed from the beaker and squeezed to encourage further cell extraction. Five ml 
of 2 mg/ml DNase I was added to the resulting cell suspension which was made up to 400 ml 
with 1x PBS and then divided between 8 x 50 ml tubes. The tubes were centrifuged for 5 
minutes at 600 xg at room temperature. The supernatant was discarded and each pellet was re-
suspended in 20 ml 1x PBS. Two pellets were pooled in one 50 ml tube, made up to 50 ml 
with 1x PBS and centrifuged again for 5 minutes at 600 xg. This step was repeated until all 
pellets were pooled in one 50 ml tube, re-suspended in 24 ml 1x PBS. 
2.4.2. Semi-purification of hBECs using density gradient 
Following digestion, hBECs were semi-purified using non-toxic low viscosity and low 
osmolarity density gradients made from Percoll which consists of colloidal silica particles of 
15-30 nm diameter (23% w/w in water) coated with polyvinylpyrrolidone (PVP) (GE 
Healthcare, Amersham, UK). To prepare a percoll stock solution, percoll was diluted 9:1 (v/v) 
with 10x PBS. The percoll stock solution was then used to generate a 33% (v/v) and a 77% 
(v/v) percoll solution by dilution with 1x PBS. Gradients were prepared in 15 ml centrifuge 
tubes by underlying 3 ml of 33% percoll with 3 ml of 77% percoll. Next, 3 ml of the liver cell 
suspension were carefully layered onto each Percoll gradient. The tubes were centrifuged at 
670 xg for 30 minutes at 80% acceleration and 0% deceleration at room temperature. 
Centrifugation results in the appearance of 2 rings, the top ring containing hepatic stellate 
cells (HSCs) and the bottom ring comprises the hBECs (Figure 2.3).  
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The bottom ring and the overlying aqueous layer containing primarily hBECs were carefully 
extracted using a Pasteur pipette and transferred to 50 ml tubes. To wash the extracted hBECs, 
three volumes of 1x PBS were added and cells were centrifuged at 600 xg for 5 minutes. The 
supernatant was discarded and the pellet re-suspended in 9 ml of cold 0.1% (w/v) bovine 
serum albumin (BSA) in 1x PBS. The mixture was transferred to a 15 ml centrifuge tube.  
2.4.3. Anti-HEA-125 immuno-magnetic affinity purification of hBECs 
After semi-purification by density gradient, hBECs were purified by immuno-magnetic cell 
separation using HEA-125 Dynabeads (Thermofisher, UK). These Dynabeads are 
superparamagnetic polymer beads coated with the monoclonal antibody HEA-125 specific for 
the epithelial cell surface antigen epithelial cell adhesion molecule (EpCAM) (Shan, 2011) 
which allow for hBECs to be separated using a magnet (Figure 2.4).  
 
Figure 2.3 Semi-purification of hBECs by percoll density gradient centrifugation. HSC, hepatic 
stellate cells; BEC, biliary epithelial cells. 
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Figure 2.4 Immuno-magnetic separation of hBECs.  
 
Following adequate mixing on a roller, 50-100 µl of Dynabeads were transferred to a 1.5 ml 
microcentrifuge tube and 1 ml of cold 0.1% BSA in 1x PBS was added. The tube was placed 
on the magnet (Dynamag, Life technologies) for 1 minute. The supernatant was carefully 
removed with a pipette and 1 ml of 0.1% BSA in 1x PBS was added. The tube was removed 
from the magnet and Dynabeads were resuspended and added to the semi-purified hBEC 
suspension. The suspension was incubated on a roller at 4°C for 30 minutes. The tube was 
then placed on the magnet for 5 minutes before carefully removing the supernatant with a 
Pasteur pipette. Ten ml of 0.1% BSA in 1x PBS was added to the tube, the tube was removed 
from the magnet and hBECs bound to Dynabeads were resuspended. The tube was placed 
back on the magnet for 2 minutes following careful removal of the supernatant. The last wash 
step was repeated once more to ensure removal of non-binding cells. Human BECs bound to 
Dynabeads were resuspended in 10 ml of pre-warmed BEC medium (see Section 2.4.4) and 
transferred to a 25 cm
2
 tissue culture flask.  
2.4.4. Culture of hBECs 
Isolated primary hBECs were grown in 1:1 DMEM:Hams F12 medium supplemented with 
10 % (v/v) FBS, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 10 ng/ml 
epidermal growth factor (EGF), 0.248 IU/ml Insulin, 2 µg/ml hydrocortisone, 10 ng/ml 
cholera toxin, 2 nM tri-iodo-L-thyronine and 5 ng/ml hepatocyte growth factor (HGF). Cells 
were grown in 25 cm
2
 culture flasks or 6-well plates in conditions described in 2.3.2. Cell 
culture medium was changed every 1-2 days. 
 51 
 
2.5. Isolation of primary mouse biliary epithelial cells from mouse livers 
Primary mouse biliary epithelial cells (mBECs) were isolated from livers of female and male 
C57Bl/6 wt mice and tg NF-κB-luc mice. Mice were terminated by cervical dislocation and 
their livers dissected.  
2.5.1. Digestion 
Livers were cut into small pieces in a sterile petri dish and up to six livers were pooled in a 
50 ml tube containing 25 ml HBSS
+
 supplemented with 1 mg/ml collagenase type A (made up 
as a stock of 10 mg/ml) and 80 μg/ml DNAse I (from a 2 mg/ml stock). The livers were 
incubated at 37°C for 30-45 minutes until digested. After incubation, the liver tissue and 
collagenase mixture was poured onto a Nybolt mesh attached to a beaker (sterile) and sieved 
into the beaker using a plunger from a 2 ml syringe. HBSS
+
 was added frequently to facilitate 
cell passage. The mash was carefully removed from the beaker and 0.5 ml of 2 mg/ml 
DNase I was added to the resulting cell suspension which was made up to 100 ml with HBSS
+
 
and then divided between 2 x 50 ml tubes. The tubes were centrifuged for 5 minutes at 600 xg 
at room temperature. The supernatant was discarded and each pellet was re-suspended in 20 
ml HBSS
+
. The pellets were pooled in a 50 ml tube, filled up to 50 ml with HBSS
+
 and 
centrifuged again for 5 minutes at 600 xg. The pellet was washed one more time with HBSS
+
. 
The final pellet was resuspended in 12 ml HBSS
+
. 
2.5.2. Semi-purification and culture  
Next, mBECs were semi-purified by Percoll density gradient as described in Section 2.4.2 
with the following changes: after the wash step with PBS, the supernatant was discarded and 
the pellet re-suspended in BECs growth medium as specified in Section 2.4.4. Anti-HEA125 
affinity purification was not carried out since the antibody did not crossreact with its mouse 
orthologue and did not improve the yield or purity. 
Mouse BECs were seeded into a 25 cm
2
 tissue culture flask, 6-well plates or 4-chamber 
microscope slides (BD Falcon) as required and maintained as described in Section 2.3.2. 
2.6. Cell transfections 
2.6.1. Transfection using Effectene reagent 
Effectene transfection reagent (Qiagen, Manchester, UK) was used to routinely transfect 603B 
and LTPA cells according to the manufacturer’s instructions. On the day before transfection, 
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cells were seeded into 24-well tissue culture plates in 0.5 ml of growth medium and allowed 
to reach 60-70% confluency. Typically for one well of a 24-well plate, 250 ng of total plasmid 
DNA was mixed with 20 μl EC buffer before the addition of 1.5 μl enhancer. Following 5 
minutes incubation at room temperature, 1.6 μl effectene reagent was added to the 
transfection mix, vortexed and incubated at room temperature for 15 minutes. The 
transfection mix was made up to 150 μl with complete culture medium and added to the cells 
in a drop-wise manner. Cells were incubated for 24 hours under normal culture conditions. 
For transfection of cells seeded into smaller/larger multi-well plates, volumes of transfection 
reagents and DNA amounts were scaled down/up according to the surface area of the well.  
2.6.2. Transfections using polyethyleneimine  
MCF-7 and HEK293 cells were routinely transfected using polyethyleneimine (PEI). A 
1 mg/ml PEI working solution was prepared by dissolving PEI in MilliQ H2O. The solution 
was neutralised to pH7 with NaOH, filter sterilised (0.22 μm) and aliquoted for longer term 
storage at -20°C. Once thawed, the working stock was stored at 4°C for up to 6 months. To 
transfect cells, a transfection mix was prepared by adding 7 μg of total plasmid DNA and 
21 μl PEI working solution to 1 ml of serum-free DMEM. The mix was vortexed and 
incubated at room temperature for 20 minutes before drop-wise addition to ~70% confluent 
cells. Typically for one well of a 24-well plate, 30 μl of the transfection mix was added. Cells 
were incubated for 24 hours under standard culture conditions before the experimental 
procedure continued. The volume of transfection mix to add to the cells was scaled up/down 
according to the surface area of the wells that cells were grown in.   
2.6.3. Transfections using Lipofectamine 2000 reagent 
B-13 cells were transfected using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. Cells were seeded into 24-well tissue culture plates in 0.5 ml of 
medium 24 hours before transfection to grow to around 70% confluence. Typically for 
transfection in one well of a 24-well plate, 500 ng of total plasmid DNA and 1.1 µl of 
Lipofectamine 2000 reagent were used. The appropriate amount of plasmid DNA and 
Lipofectamine 2000 were added to serum free medium in separate vials and incubated for 
5 minutes at room temperature. Vials were then combined, gently mixed by tapping and 
incubated at room temperature for 20 minutes before 50 µl of transfection mix were added 
drop-wise to each well of a 24-well plate. Transfected cells were incubated for 24 hours under 
standard conditions before the culture medium was changed and the experimental procedure 
continued. 
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2.6.4. Assessment of transfection efficiency 
For the assessment of transfection efficiency, a green fluorescent protein (GFP) control 
plasmid (peGFP-N1, Clonetech) was included for all transfection methods as described above. 
GFP expression was visualised 24-48 hours after transfection by fluorescent microscopy (see 
Figure 2.5). GFP-positive cells were counted and expressed as a percentage of the total cell 
number of cells per field of view, the average transfection efficiency of 3 fields per view was 
calculated.   
 
Figure 2.5 peGFP-N1 transfected AR42J-B13 cells. Merged bright field and FITC image of AR42J-
B13 cells transfected with the peGFP-N1 plasmid.  
2.7. Dual-glo luciferase reporter gene assay 
A dual luciferase reporter system was used to assess ER transcriptional activity. This system 
is designed to decrease experimental variability between replicates which can occur due to 
unequal cell numbers and transfection rates. Cells were co-transfected with two different 
plasmids resulting in the expression of two different reporter enzymes, Firefly (Photinus 
phyralis) and Renilla (Renilla reniformis, sea pansy) luciferase, within a single system. In 
these experiments, Firefly luciferase is normally regulated by response elements in conjuction 
with a minimal promotor whereas the Renilla luciferase is under the control of a constitutively 
active promoter. The dual-glo assay system (Promega, Southampton, UK) measures both 
Firefly and Renilla luciferase activities in the same sample. The addition of luciferin, the 
substrate for Firefly luciferase, permits the measurement of Firefly luciferase activity. The 
reaction is then quenched by the addition of the Stop and Glo solution which inhibits Firefly 
luciferase and at the same time provides the substrate for and initiates Renilla luciferase 
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activity (Figure 2.6). Both reactions produce a luminescent signal as readout for luciferase 
activity which can be read using a luminometer.  
 
Figure 2.6 Bioluminescent Firefly and Renilla luciferase reactions.   
 
Cells in 24-well plates were transfected with a reporter construct (either the (ERE)3-
pGL3promotor construct or the 3XERE TATA luc construct, for vector maps see Sections 
2.8.1 and 2.8.2) and the control construct RL-TK as outlined in Section 2.6 at a ratio of not 
less than 6:1 followed by incubation for 24 hours and treatments as indicated for another 
24 hours. On the day of the dual-glo luciferase assay, the culture medium was removed and 
cells were washed with sterile 1x PBS. Cells were then lysed with 150 μl of NETN buffer 
(100 mM NaCl, 20 mM Tris-Cl (pH 8.0), 0.5 mM EDTA, 0.5 % (v/v) Nonidet P-40 (NP-40)) 
per well of a 24-well plate for 15 minutes at room temperature on an orbital shaker before 
50 μl of the lysate was transferred to a well of a white 96-well microplate. An equal volume 
of luciferase buffer (prepared following the manufacturer’s instructions) was added to the cell 
lysate which was then incubated for 10 minutes at room temperature before the measurement 
of the luminescent signal produced by Firefly luciferase using a microplate reader (Synergy 
HT, BioTek, Swindon, UK). The luciferase activity was subsequently inhibited by adding 
50 µl of pre-diluted Stop and Glo reagent per well and the luminescent signal produced by 
active Renilla luciferase was measured. After subtraction of background luminescence (from 
non-transfected cells), expression of Firefly luciferase was normalised to the expression of 
Renilla luciferase by dividing the Firefly value by the Renilla measurement. All 
measurements were further normalised to the control group (vehicle control) or to a group as 
indicated and values constituted as a fold change in normalised luciferase activity in response 
to different treatments. 
Luciferin
+ ATP O2+
Oxyluciferin
+ AMP CO2++ PPi +
Firefly Luciferase
Coelenterazine
O2+
Coelenteramide CO2+ +
Renilla Luciferase
Mg2+ light
light
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2.8. Plasmid DNA constructs and cloning 
2.8.1. (ERE)3-pGL3promotor construct  
The (ERE)3-pGL3promotor plasmid is a luciferase reporter construct that allows to 
quantitatively measure the regulation of oestrogen-dependent gene expression in vitro (Axon 
et al., 2012). It consists of three repeats of the consensus oestrogen response element (ERE) 
with a three base pair (ATT) spacer (GGTCA ATT TGACC) located upstream of the reporter 
gene coding for Firefly luciferase. Activation of the ER and consequent binding to the ERE 
will result in the expression of the Firelfy luciferase reporter gene which can subsequently be 
measured by dual-glo reporter gene assay (see Section 2.7).  
 
Figure 2.7 (ERE)3-pGL3promotor vector map. Adapted from Promega (2016a). 
 
2.8.2. 3XERE TATA luc construct 
The 3XERE TATA luc plasmid (5757 bp) was a gift from Dr. Donald McDonnell (Addgene 
plasmid #11354 (Hall and McDonnell, 1999)) and similar to the (ERE)3-pGL3promotor 
construct, it provides a basis to measure the regulation of oestrogen-dependent gene 
expression in vitro. The 3XERE TATA luc plasmid differs from the (ERE)3-pGL3promotor 
construct in that it has a different vector backbone (pGL2-TATA-Inr) and it comprises three 
copies of the vitellogenin ERE (GGTCA CAG TGACC) situated upstream of the Firefly 
luciferase reporter gene. 
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Figure 2.8 3XERE TATA luc vector map. Addgene (plasmid #11354). 
 
2.8.3. RL-TK construct 
The RL-TK construct (Promega, cat# E2241) was used as an internal control reporter and was 
co-transfected into cells along with the experimental ERE luciferase reporter constructs 
described in Sections 2.8.1 and 2.8.2. The RL-TK plasmid encodes the Renilla luciferase (RL) 
gene which is under the control of a constitutively active minimal promotor from the 
housekeeping gene thymidine kinase (TK). Constitutive expression of Renilla luciferase (i.e. 
independent of nuclear receptor regulation) allows for experimental data to be normalised, a 
process which is required to account for experimental variations such as cell number and 
transfection efficiency between treatment groups.  
 57 
 
 
Figure 2.9 RL-TK vector map. Catalogue #E2241. Source: Promega (2016b). 
 
2.8.4. pcDNA3.1 vector 
The pcDNA3.1 vector (5428 bp) is designed for high level constitutive protein expression in a 
range of mammalian cell lines. It contains a CMV promotor and a multiple cloning site 
containing a large number of common restriction sites which allow a gene of interest to be 
inserted.  
 
Figure 2.10 pcDNA3.1 vector map. Source: Xenbase (2016). 
  
 58 
 
2.8.5. Ligation of a gene of interest into a pCR-Blunt or pcDNA3.1 vector 
After amplification of a gene of interest by Polymerase Chain Reaction (PCR, see Section 
2.10), gel extracted (see Section 2.8.11) blunt-end PCR products were ligated into the pCR-
Blunt vector using the Zero Blunt PCR Cloning Kit (Life technologies) according to the 
manufacturer’s instructions. The ligation reaction was typically set up as specified in Table 
2.6. The ligation reaction was incubated at 16°C for 4 hours before transformation into E.coli 
cells (Section 2.8.6). 
Reagent Volume 
pCR-Blunt vector 1 μl (25 ng) 
PCR product (blunt-end) 5 μl 
5X T4 DNA ligase buffer 2 μl 
Sterile H2O 1 μl 
T4 DNA ligase 1 μl 
Table 2.6 Set up of ligation reaction using the Zero Blunt PCR Cloning Kit. 
 
For ligation of a specific gene into the destination vector pcDNA3.1, the linearised vector was 
first treated with Antarctic Phosphatase (New England Biolabs, Hitchin, UK) which removes 
5’ phosphates to prevent recircularization. Generally, 3.3 μl of 10x reaction buffer and 1 μl of 
phosphatase were added to 30 μl of vector DNA. The reaction was incubated at 37°C for 15 
minutes followed by heat-inactivation of the enzyme at 70°C for 5 minutes. 
Two ligation reactions were then set up with molar vector:insert ratios of 1:3 and 1:6. The 
following equation was used to calculate the amount of insert needed for 100 ng of pcDNA3.1 
destination vector: 
 
𝑖𝑛𝑠𝑒𝑟𝑡 [𝑛𝑔] =
100 𝑛𝑔 𝑣𝑒𝑐𝑡𝑜𝑟 𝑥 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 (𝑘𝑏)
𝑠𝑖𝑧𝑒 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 (𝑘𝑏)
 𝑥 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 𝑜𝑓 
𝑖𝑛𝑠𝑒𝑟𝑡
𝑣𝑒𝑐𝑡𝑜𝑟
 
 
The appropriate amounts of phosphatase-treated vector and insert were then set up in a 
ligation reaction as outlined in Table 2.7. Before addition of T4 DNA ligase (Promega), the 
ligation mix was incubated at 65°C for 5 minutes and then cooled down on ice. T4 DNA 
ligase was added and the ligation mixture was incubated at room temperature for 3 hours or at 
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16°C overnight before transformation of the ligation product into E.coli bacterial cells (see 
Section 2.8.6).  
Reagent Amount/Volume 
pcDNA3.1 plasmid 100 ng 
Insert (gene of interest) to be calculated 
10X T4 DNA ligase buffer 1 μl 
Sterile H2O Make up to 9 μl 
T4 DNA ligase 1 μl 
Table 2.7 Set up of ligation reaction to clone a gene of interest into the mammalian expression 
vector pcDNA3.1.  
2.8.6. Transformation of competent E. coli cells 
To propagate plasmid DNA, chemically competent TOP10 E. coli cells (Life technologies) 
were transformed with the plasmid or ligation product of interest. The bacterial cells were 
stored at -80°C and thawed on ice before use. In order to transform cells, 50-100 ng of 
plasmid DNA was added to one vial of E. coli cells which were gently mixed by tapping and 
incubated on ice for 30 minutes. To facilitate cellular uptake of DNA, E. coli cells were heat-
shocked in a 42°C water bath for 30 seconds followed by incubation on ice for at least 2 
minutes. Two hundred and fifty microlitres of pre-warmed S.O.C. medium (2% (w/v) 
tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, and 20 mM glucose) was added to each vial of bacterial cells which were then 
incubated for 1 hour at 37°C in an orbital rotating incubator set to 225 rpm. The cells were 
spread on LB agar plates (Luria Broth: 10 g NaCl, 10 g tryptone, 5 g yeast extract + 15 g agar 
in 1L MilliQ H2O) containing the appropriate selective antibiotic (Ampicillin: 100 μg/ml, 
Kanamycin: 50 μg/ml) in order to select clones. The plates were incubated upside-down at 
37°C overnight. On the next day, several colonies were picked and each colony was grown in 
mini cultures (5 ml of LB (10 g NaCl, 10 g Tryptone, 5 g yeast extract in 1L MilliQ H2O) 
containing the appropriate selective antibiotic marker) at 37°C overnight, shaking at 225 rpm, 
for the purpose of making glycerol stocks for storage or to purify plasmid DNA by miniprep.  
2.8.7. Storage of transformed bacterial cultures 
To safely store transformed bacterial clones long-term, glycerol stocks were prepared. 
Bacterial overnight mini cultures were mixed with sterile glycerol at a ratio of 1:1 before 
storage at -80°C. Whenever required, glycerol stocks were used to produce more plasmid 
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DNA by streaking out 10 μl of the stock onto a LB agar plate containing the appropriate 
selective antibiotic followed by incubation at 37°C overnight. A mini culture was then 
prepared from a single colony as previously described and plasmid DNA was purified by 
mini- or maxiprep.  
2.8.8. Plasmid DNA miniprep 
For low-scale plasmid DNA purification from transformed E. coli cells, minipreps were 
performed according to the manufacturer’s instructions (Qiagen). Generally, 5 ml of overnight 
mini culture were pelleted at 3200 xg for 15 minutes at 4°C. Following plasmid extraction 
according to the manufacturer’s protocol, plasmid DNA was re-suspended in 50 μl nuclease-
free H2O (Qiagen) and stored at -20°C. 
2.8.9. Plasmid DNA maxiprep 
Maxipreps (Qiagen) were performed when large amounts of plasmid DNA were required. 
Typically, 1 ml of overnight mini culture was added to 200 ml of LB containing the 
appropriate selective marker on the day before plasmid extraction and grown overnight at 
37°C, shaking at 225 rpm. Bacterial cells were then pelleted at 3200 xg for 30 minutes at 4°C. 
Plasmid DNA from transformed E. coli cells was extracted as per protocol supplied by the 
manufacturer. The resulting plasmid DNA pellet was re-suspended in 500-750 μl nuclease-
free H2O and stored at -20°C. DNA concentration was determined as described in Section 
2.9.3.  
2.8.10. Restriction digest 
Following isolation by mini- or maxiprep, plasmid DNA was analysed for correct assembly 
by digest with restriction endonucleases, enzymes which cut DNA at a particular place 
dependent on the sequence. Restriction digests were essentially carried out as per the 
manufacturer’s protocol (New England Biolabs). Typically, restriction digests were prepared 
to contain 2 μl of 10x reaction buffer (depending on type of enzyme used), 2 μl of plasmid 
DNA as obtained after mini- or maxiprep, 1 μl of restriction enzyme and made up to 20 μl 
with nuclease-free H2O. Reactions were incubated at 37°C for 3-4 hours. Following 
incubation, DNA loading buffer was added to the samples and DNA fragments were 
separated by agarose gel electrophoresis as described in Section 2.10.4.  
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2.8.11. Purification of DNA from agarose gel 
Following restriction digest and agarose gel separation (see Section 2.10.4) DNA fragments 
and vector backbones were isolated from agarose gels using the QIAquick gel extraction kit 
(Qiagen) according to the manufacturer’s instructions. In brief, DNA was visualised with UV 
light in a gel documentation system (G:BOX, Syngene) and the desired fragment was excised 
using a sterile scalpel. The gel containing the DNA fragment was weighed and transferred to a 
microcentrifuge tube followed by extraction of DNA as per supplied protocol. DNA was 
essentially eluted with 30 μl of nuclease-free H2O and quantified as outlined in Section 2.9.3.  
2.8.12. DNA sequencing 
When required, plasmid DNA was sequenced by DNAseq (Dundee, UK) with sequence 
specific primers. DNA sequencer chromatogram data was analysed using the publically 
available software Finch TV (Geospiza, Inc.).  
2.9. Isolation and quantification of RNA 
2.9.1. RNA purification using Trizol 
Trizol (Invitrogen, Paisley, UK) was used to isolate RNA from cultured cells or whole tissue. 
For isolation of RNA from adherent cells, growth medium was removed, cells were washed 
twice with sterile 1x PBS and 1 ml of Trizol was added to 1 well of a 6-well plate. Cells were 
incubated in Trizol for 3 minutes at room temperature before mixing by pipetting and transfer 
to a 1.5 ml microcentrifuge tube. For isolation of RNA from tissue, 1 ml of Trizol was added 
to tissue not exceeding 10% of the volume of Trizol. Tissue samples were manually 
homogenised and debris were spun down at 1500 xg for 4 minutes using a table-top 
centrifuge. The supernatant was then transferred to a clean 1.5 ml tube. The following steps 
apply to both cell and tissue samples. 0.2 ml of chloroform was added to the cells/tissue in 
Trizol and tubes were mixed for 15 seconds by vigorously shaking and incubated at room 
temperature for 5 minutes. Tubes were then centrifuged at 16,000 xg for 15 minutes at 4°C. 
The upper aqueous layer which contains the RNA was transferred to a clean 1.5 ml tube. 0.5 
ml ice-cold isopropanol were added, the tube was inverted once and incubated on ice for 10 
minutes. The tube was then centrifuged at 16,000 xg for 10 minutes at 4°C. The supernatant 
was discarded and 0.5 ml of ice-cold 70% ethanol was added to wash the pelleted RNA. The 
tube was again centrifuged at 16,000 xg for 10 minutes at 4°C. The supernatant was removed 
and the pellet was air-dried for 5-10 minutes before it was re-suspended in 10-20 µl RNase 
free H2O (Qiagen). RNA samples were stored at -20°C or -80°C for long term storage. 
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2.9.2. DNAse treatment 
To remove any potentially contaminating genomic DNA from RNA samples, isolated RNA 
was treated with RQ1 RNase-free DNase (Promega). To an RNA sample of 10 µl, 1 µl (0.1 x 
the volume of the RNA sample) of both RQ1 RNase-free DNase and 10x DNase buffer were 
added and incubated at 37°C for 30 minutes. The DNase was then inhibited by adding 0.1 x 
the volume of RNA sample of DNase stop solution followed by incubation at 65°C for 10 
minutes. 
2.9.3. Quantification of RNA and DNA concentration and integrity 
RNA and DNA concentration and purity within a sample were determined by measuring their 
absorbance at 260 nm and 280 nm using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific, Loughborough, UK). Nuclease-free H2O was used as a blank. An A260/A280 
(Absorbance at 260nm and 280nm) ratio between 1.8 and 2.0 generally suggests a pure 
nucleic acid sample whereas deviant values indicate sample contamination such as with 
proteins or phenol. RNA samples were then diluted to 200 ng/µl with nuclease-free H2O and 
stored at -20°C.  
2.10. Reverse Transcription Polymerase Chain Reaction (RT PCR) 
2.10.1. cDNA synthesis by reverse transcription 
Moloney murine leukaemia virus (MMLV) reverse transcriptase is a RNA dependent 
polymerase used for first strand cDNA synthesis. Four microlitres of a to 200 ng/µl diluted 
RNA sample (800 ng RNA) were mixed with 1 µl of random primers (50 ng/µl, Promega) and 
incubated at 90°C for 3 minutes. Samples were then placed on ice. A reverse transcription 
master mix containing (per reaction) 4 µl of 5x RT buffer, 8 µl H2O, 2 µl of 10 mM dNTP’s 
and 1 µl of MMLV was prepared on ice and added to each RNA sample (total volume of 
20 µl). The reaction mix was incubated at 42°C for 50 minutes to generate cDNA and samples 
were stored at -20°C. 
2.10.2. Primer design 
Forward and reverse primer pairs to amplify specific DNA sequences by PCR were designed 
using Primer BLAST, a publically available tool on the National Center for Biotechnology 
Information (NCBI) website (www.ncbi.nlm.nih.gov). Primers were designed to have a length 
of around 20 nucleotides with a GC content of approximately 60% and melting temperatures 
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(Tm) close to 60°C. The annealing temperature for each primer set was optimised by starting 
at 5°C below the calculated Tm. All primers were custom synthesised from Sigma.  
2.10.3. Polymerase Chain Reaction (PCR) 
PCR is a technique that allows accurate and rapid amplification of specific DNA sequences 
by using thermostable DNA polymerases in a thermal cycling process. As demonstrated in 
Figure 2.11, double stranded DNA is initially denatured at high temperatures (>90°C) before 
annealing of short 5'-3' DNA oligonucleotides (primers) to complementary DNA sequences 
upstream and downstream of a target region that is to be amplified (amplicon). DNA 
polymerases then elongate single stranded DNA molecules from 5'-3'. Over several cycles, the 
target sequence will in principle be amplified exponentially creating large amounts of the 
amplicon which can be separated and visualised by agarose gel electrophoresis (see Section 
2.10.4). 
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Figure 2.11 The PCR cycle. dsDNA = double stranded DNA, ssDNA = single stranded DNA.  
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Taq polymerase, derived from the thermophile bacterium Thermus aquaticus, is generally 
used in PCR for amplification of short DNA fragments. The Taq polymerase, however, has a 
comparatively high error rate as it lacks 3’-5’ exonuclease proofreading activity (Lundberg et 
al., 1991). For applications that require a greater accuracy (e.g. cloning) Phusion High 
Fidelity polymerase which possesses exonuclease activity was used. 
Routine semi-quantitative PCR was carried out using 2x Go-Taq green master mix (contains 
Taq DNA polymerase, 1.6 mM dNTPs, 3mM MgCl2 and reaction buffer, Promega). The 2x 
Phusion High-Fidelity PCR Master Mix with HF Buffer (40 units/ml Phusion polymerase, 1.6 
mM dNTPs, 4 mM MgCl2, HF reaction buffer, New England Biolabs) was used for cloning 
work. PCR reactions with the above mentioned DNA polymerases were set up as outlined in 
Table 2.8. 
Taq polymerase  Phusion polymerase 
Reagents Volume  Reagents Volume 
2x Master Mix 10 μl  2x Master Mix 25 μl 
Fwd primer (10 μM)  1.5 μl   Fwd primer (10 μM) 3.75 μl  
Rev primer (10 μM) 1.5 μl   Rev primer (10 μM ) 3.75 μl 
cDNA 1 μl  cDNA 4 μl 
Nuclease-free H2O to 20 μl  Nuclease-free H2O to 50 μl 
Table 2.8 PCR reactions using Taq or Phusion polymerase. Fwd, forward; Rev, reverse. 
 
A bench top thermocycler (Px2, Thermo Scientific) was used to perform the PCR reactions 
with optimised cycle parameters and annealing temperatures for each set of primers (detailed 
in Table 2.10). A typical program for both Taq and Phusion polymerases is shown in Table 
2.9. 
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Step 
Taq Polymerase Phusion Polymerase 
Cycles 
Temp (°C) Time Temp (°C) Time 
Denaturation 90 2 min 98 30 s 1 
Denaturation 90 50 s 98 10 s 
30 Annealing x 1 min x 30 s 
Elongation 72 1 min/kb 72 30 s/kb 
Final Elongation 72 10 min 72 10 min 1 
Hold 4 ∞ 4 ∞ 1 
Table 2.9 Typical PCR protocol for Taq and Phusion polymerases. 
2.10.4. Agarose gel electrophoresis 
PCR amplified DNA was separated for identification using agarose gel electrophoresis. This 
method allows nucleic acids to be identified by their length since a DNA fragment migrates 
inversely proportional towards the positive pole of an electrical field across a polymerised 
agarose gel. A DNA ladder was run alongside for comparison of the DNA fragments with 
fragments of known size. DNA is visualised by the addition of ethidium bromide to the 
agarose gel. Ethidium bromide forms a fluorescent complex with nucleic acids which can be 
visualised under UV light (Lepecq and Paoletti, 1967). 
Depending on the size of the target DNA fragment, the percentage of agarose in the gel was 
chosen to be between 1-2%. Agarose gels were made by adding the required mass of agarose 
powder (w/v) to 1x tris-acetate-EDTA (TAE) buffer (40 mM tris, 20 mM acetic acid, 1 mM 
EDTA). The solution was heated to 180°C on a hot-plate and left to boil until the agarose was 
completely melted and degassed. Once the mixture cooled down to approximately 60°C, 1 µl 
ethidium bromide per 100 ml melted agarose was added and gently swirled to mix. The gel 
was cast and a comb was used to form sample wells. The gel was left to set for 1 hour and 
then placed into an electrophoresis chamber were it was covered with 1x TAE. The PCR 
samples were mixed with 5x loading dye where appropriate and loaded onto the gel alongside 
a 2-log DNA ladder (0.1-10 kb, New England Biolabs). Gels were run at 80V until desired 
migration was reached and PCR products were then visualised under UV light (G:BOX, 
Syngene).  
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Oligo ID 5’-3’ sequence Annealing [°C] Comments 
hERαUS 
hERαDS 
CAGTCTATGGGTTGGGGCTC 
CTGGAACCCATGACCGGAAA 
57 
Will amplify all 4 human ERα transcript variants 
(NM_000125; NM_001122740; NM_001122741; 
NM_001122742) cDNA sequences of 423 bp 
hERβUS 
hERβDS 
GGAGTCTGGTCGTGTGAAGG 
TGTACCAACTCCTTGTCGGC 
57 
Will amplify 6  human ERβ transcript variants (NM_001437; 
NM_001040275; NM_001214902; NM_001214903; 
NM_001271876; NM_001271877) cDNA sequence of 440 bp 
humanCK19 F 
humanCK19 R 
GCCACTACTACACGACCATCC 
CAAACTTGGTTCGGAAGTCAT 
57 
Will amplify human cytokeratin 19 (NM_002276.4) cDNA 
sequence of 126 bp 
hCYP2E1US 
hCYP2E1DS 
GTTCTTTGCGGGGACAGAGA 
GAGGGTGATGAACCGCTGAA 
59 
Will amplify human cytochrome P450, family 2, subfamily E, 
polypeptide 1 (NM_000773.3) cDNA sequence of 202 bp 
rmhGAPDHUS 
rmhGAPDHDS 
TGACATCAAGAAGGTGGTGAAG 
TCTTACTCCTTGGAGGCCATGT 
55 
Will amplify rat (NM_017008), human (NM_002046) or 
mouse (NM_008084) glyceraldehyde 3 phosphate 
dehydrogenase cDNA sequence of 243 bp 
mERαUS 
mERαDS 
AAGGGCAGTCACAATGAACC 
GCCAGGTCATTCTCCACATT 
59 
Will amplify mouse ERα (NM_007956) cDNA sequence of 
155 bp 
mERβUS 
mERβDS 
GGGTGAAGGAGCTACTGCTG 
GTGTCAGCTTCCGGCTACTC 
59 
Will amplify mouse ERβ transcript variants 1 and 2 
(NM_207707 and NM_010157) cDNA sequence of  576 bp 
and 522 bp respectively 
mCK19US 
mCK19DS 
GTACGCATTGGGTCAGGGGGT 
TAGGGCGCGCACCTTGTCCAA 
55 
Will amplify mouse cytokeratin 19 (NM_008471.2) cDNA 
sequence of 246 bp 
mERβUScloning 
mERβDScloning 
TCCGCCTTAAGCCTGGCCGTCACTG 
TCCGCCTTAAGCCTGGCCGTCACTG 
65 
Will amplify mouse ERβ transcript variants 1 and 2 
(NM_207707 and NM_010157) cDNA sequence of 1744 bp 
and 1690  bp respectively 
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Oligo ID 5’-3’ sequence Annealing [°C] Comments 
mERaCloningDSHindIII_1 
mERaCloningUSEcoRI 
CCTGGAAGCTTTCAGATCGTGTTGGGG 
CGCCGAATTCCACTTACCATGACCATG 
72 
Will amplify mouse ERα transcript variants  1, 2 and 3 
(NM_007956.5, NM_001302531.1, NM_001302532.1) cDNA 
sequence of 1829 bp (2-step PCR) 
mVimentinUS 
mVimentinDS 
GTGGCTCCGGCACATCGAGC 
GCGTCGGCCAGCGAGAAGTC 
56 
Will amplify mouse vimentin (NM_011701.4) cDNA sequence 
of 226 bp 
mCYP2E1US 
mCYP2E1DS 
GTGTTCCGAGGATATGTCATC 
AAAGCAGAAACAGTTCCATGC 
56 
Will amplify mouse CYP2E1 (NM_021282.2) cDNA sequence 
of 223 bp 
Table 2.10 DNA oligonucleotide sequences used in RT-PCR.  
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2.11. Isolation and quantification of protein 
2.11.1. Protein isolation from cell lines 
The culture medium was aspirated and cells were washed twice with sterile 1x PBS. Whole 
cell protein extracts were obtained by scraping cells directly into 1x LDS sample buffer 
(lithium dodecyl sulfate, diluted from 4x stock, Invitrogen) containing 5% 2-mercaptoethanol. 
Samples were boiled at 95°C for 5 minutes and the protein concentration was determined 
using the Bradford assay (Section 2.11.3).  
2.11.2. Protein isolation from tissue 
Tissue samples (snap frozen in liquid nitrogen and stored at -80°C) were manually 
homogenized in ice-cold RIPA buffer (150 mM NaCl, 1% (w/v) NP-40, 0.5% (w/v) sodium 
deoxycholate, 0.1% (w/v) SDS, 50 mM Tris, pH 8.0) on ice in a 1.5 ml centrifuge tube 
(~300 µl RIPA buffer per 15 mg tissue). The samples were incubated by inverting for 2 hours 
at 4°C.  Tissue debris were then spun down at 13,500 xg for 20 minutes at 4°C. The 
supernatant was transferred to a clean tube and the protein concentration was determined by 
Bradford assay (Section 2.11.3).   
2.11.3. Determination of protein concentration by Bradford assay 
Total protein concentration was determined by Bradford assay (Bradford, 1976). Bovine 
serum albumin (BSA, Thermo Scientific) was used to make standards of known protein 
concentration, ranging from 0 µg/ml to 2000 µg/ml diluted in MilliQ H2O (final volume: 
20 µl). Unknown protein samples were diluted 1:20 with MilliQ H2O prior to analysis. Five µl 
of each standard and diluted unknown sample were pipetted into wells of a flat-bottom 96-
well plate in triplicates. Two hundred and fifty microlitres of coomassie protein assay reagent 
(Thermo Scientific) was added to each well which was then incubated at room temperature 
for 10 minutes. The absorbance of each sample at 595 nm was measured using a microplate 
reader (BioTek Synergy). A standard curve was produced from the absorbance of the BSA 
standard concentration samples and the equation for the line of best fit was rearranged to 
quantify the protein concentration of the unknown samples (Figure 2.12). 
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Figure 2.12 BSA protein standard curve as part of the Bradford assay.  
2.12. SDS-PAGE and Western Blotting 
2.12.1. SDS-PAGE 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a commonly used 
method to separate proteins according to their molecular weight. As required, complete 
denaturisation and lineralisation of proteins is achieved by heating the samples in the presence 
of SDS (or LDS) and a reducing agent such as 2-mercaptoethanol. The negatively charged 
SDS binds to proteins and when loaded onto a polyacrylamide gel, allows proteins to migrate 
towards the positive electrode within an electric field resulting in their size-dependent 
separation. Pre-cast 4-12% Bis-Tris polyacrylamide gels (Novex by Life Technologies) were 
secured in an electrophoresis tank and submerged with 1x running buffer (20x stock from 
NuPAGE, Novex by Life Technologies, made up to 1x with MilliQ H2O) before protein 
samples were loaded onto the gel.  
2.12.2. Preparation of protein samples for SDS-PAGE 
Protein samples were diluted to 2 mg/ml with 4x LDS sample buffer (Life technologies). 2-
mercaptoethanol (Sigma) was used as reducing agent and was added to a final concentration 
of 5% (v/v). DNA was sheared by sonication of protein samples for 15-20 seconds. Where 
necessary, DNA was further eliminated by incubation of protein samples with Benzonase 
endonuclease (Millipore, Consett, UK).  Before loading on a gel, proteins were denatured by 
heating to 95°C for 5 minutes. Twenty micrograms of protein were then added to each sample 
well and the gel was run at 160V until the sample front reached the end of the gel. Following 
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this, the gel was removed from its cassette and proteins were transferred to a nitrocellulose 
membrane for immunodetection.  
2.12.3. Western blotting 
The transfer of proteins from a polyacrylamide gel to a nitrocellulose membrane is known as 
Western Blot. The iBlot device (Invitrogen) was used to perform a semi-dry electrotransfer. 
Proteins on the membrane were then stained with Ponceau S (Sigma) to check if the transfer 
was successful. At this point, membranes were appropriately cut and labelled before they 
were de-stained in 2 x 10 minute washes with TBST (Tris buffered saline (50 mM Tris-Cl, 
pH7.6; 150 mM NaCl) including 0.02% (v/v) Tween-20). 
2.12.4. Immunodetection 
After the transfer, nitrocellulose membranes were blocked in blocking buffer (5% dried 
skimmed milk (w/v) in TBST) for 1 hour at room temperature. Membranes were then 
incubated with specific primary antibodies (Table 2.11) diluted in blocking buffer overnight at 
room temperature. Excess antibody was removed by washing the membranes with TBST 
twice for 10 minutes. Membranes were then incubated with the appropriate HRP-conjugated 
secondary antibody in blocking buffer for 45 minutes at room temperature followed by 
several washes with TBST for at least 1 hour. The protein of interest was visualised by 
chemiluminescent detection. ECL prime reagent (GE healthcare) was applied to the 
membranes, incubated for 30 seconds and signals from the secondary antibody (Table 2.11) 
were then detected in a gel documentation system (G:BOX, Syngene; software: GeneSnap 
from Syngene).  
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Antigen Mwt (kDa) Dilution Comments and Source 
Primary antibodies    
ERα 68 
1/500 WB 
1/250 ICC 
Rabbit polyclonal to oestrogen receptor alpha (Santa Cruz, sc-7207) 
ERα 68 
1/100 ICC 
1/250 WB 
Mouse monoclonal [33] to Estrogen Receptor alpha - ChIP Grade (Abcam, ab2746) 
ERβ 59 1/1000 WB Rabbit polyclonal to oestrogen receptor beta (ab3576) 
ERβ 59 1/250 ICC Rabbit polyclonal to Estrogen Receptor beta (Santa Cruz, sc8974) 
ERβ 59 1/100 ICC Mouse monoclonal [14C8] to Estrogen Receptor beta (Ab288) 
GAPDH 37 1/5000 WB Rabbit monoclonal to  GAPDH (Cell Signaling, 2118S) – loading control 
CK19 44 1/500 ICC Rabbit polyclonal to Cytokeratin 19 (Abcam, ab84632) 
Vimentin 54 1/100 ICC Rabbit monoclonal [EPR3776] to Vimentin – (Abcam, ab92547) – cytoskeleton marker 
CYP2E1 54 1/1000 WB Rabbit polyclonal to Cytochrome P450 2E1 (Abcam, ab28146) 
Seconday antibodies    
Anti-rabbit-Alexa 
Fluor 647 (2°) 
n/a 1/500 ICC Goat anti-rabbit, Alexa Fluor 647 conjugated (Cell Signaling, 4414S) 
Anti-rabbit-Alexa 
Fluor 488 (2°) 
n/a 1/500 ICC Goat anti-rabbit, Alexa Fluor 488 conjugated (Cell Signaling, 4412S) 
Anti-rabbit-FITC 
(2°) 
n/a 1/80 ICC Goat anti-Rabbit, FITC conjugated (Sigma, F0382) 
    
  
7
3
 
Antigen Mwt (kDa) Dilution Comments and Source 
Anti-mouse-Alexa 
Fluor 488 (2°) 
n/a 1/500 ICC Goat anti-mouse, Alexa Fluor 488 conjugated (Cell Signaling, 4408S) 
Anti-mouse-HRP (2°) n/a 1/2000 - 1/5000 WB Anti-mouse IgG, horseradish peroxidase-linked (Cell Signaling, 7076S)  
Anti-rabbit-HRP (2°) n/a 1/2000 - 1/5000 WB Anti-rabbit IgG, horseradish peroxidase-linked (Cell Signaling, 7074S) 
Table 2.11 Specifications and source of primary and secondary antibodies. ICC, Immunocytochemistry; WB, Western Blot.  
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2.13. Histology 
2.13.1. Tissue preparation  
2.13.1.a Paraffin sections 
Tissue samples were fixed in 10% formalin in 1x PBS for 24-48 hours depending on tissue 
type and thickness and then transferred to 70% ethanol until processing. Following a standard 
protocol as used by the histology laboratory (Newcastle University), fixed tissue samples 
were processed and embedded in paraffin wax before being sectioned (typically 4 μm) and 
mounted onto super frost microscope slides. Tissue sections were then de-waxed in xylene for 
10 minutes and rehydrated by sequential 3-minute-washes in ethanol of decreasing 
concentration (100%  95%  90%  70%) and then placed into tap water.  
2.13.1.b Frozen sections 
Tissue samples were snap-frozen in liquid nitrogen and stored at -80°C until processing. For 
cutting, frozen tissue samples were mounted in OCT (Optimal cutting temperature) medium 
(Thermo Scientific) and then sectioned (typically 10 μm) in a microtome-cryostat. Frozen 
sections were air-dried onto microscope slides for 2 hours at room temperature before being 
stored at -20°C until further processing.  
2.13.2. Haematoxylin and eosin (H&E) staining 
H&E staining is a common staining technique used for routine examinations of tissue 
histology. This staining procedure results in nuclei to appear blue (haematoxylin staining) and 
the cytoplasm stains pink (eosin staining). Tissue sections were de-waxed in xylene and 
rehydrated through a serious of ethanol washes as described in Section 2.13.1.a. Tissue 
sections were then stained with haematoxylin for 1 minute, washed with running tap water for 
2 minutes and then placed in bluing solution (Scott’s tap water (20 g NaHCO3 and 3.5 g 
MgSO4 in 1L dH2O) for 30 seconds. For eosin counterstaining, tissue sections were immersed 
in eosin for 30 seconds and then thoroughly washed with running tap water before being 
dehydrated through a series of ethanol washes of different concentration (50%  70%     
90%  95%  100%). Slides were then placed in Xylene for 10 minutes and mounted in 
DepexTM mountant (Sigma).  
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2.13.3. Oil Red O staining  
Oil Red O staining is used for the detection of fat and neutral lipids in frozen tissue sections 
(Mehlem et al., 2013).  The histological mechanism behind this staining method is that the 
dye Oil Red O is more soluble in the lipid than in the dye solvents resulting in bright red 
staining of lipids.  
Frozen sections cut at 10 µm were fixed in 10% formalin in 1x PBS for 15 minutes followed 
by rinsing with running tap water for 5 minutes. Sections were transferred to 60% isopropanol 
for 5 minutes and then stained with freshly prepared Oil Red O working solution (for the Oil 
Red O working solution, 0.5% (w/v) Oil Red O stock stain in isopropanol was diluted 3:2 
with distilled H2O, allowed to stand for 10 minutes and filtered into an airtight container) for 
15 minutes at room temperature. Sections were then washed with 60% isopropanol for 5 
minutes before being counterstained with Mayer’s haematoxylin for 1 minute and incubation 
in Scott’s tap water for 10 seconds. Sections were rinsed with distilled H2O for 5 minutes and 
then mounted in aqueous mountant and left to dry for 24 hours. The end result is that lipids in 
frozen tissue sections appear red and nuclei appear blue.  
2.14. Immunocytochemistry 
Adherent cells were washed with 1x PBS and then fixed with 4% formaldehyde in 1x PBS for 
10 minutes at room temperature. Following fixation, the fixative solution was removed and 
cells were washed with 1x PBS three times for 10 minutes and then permeabilised with 0.2% 
Triton in 1x PBS for 15 minutes at room temperature. Non-specific protein binding was 
blocked by incubation with the blocking buffer (PBS-T (1x PBS + 0.02% Tween 20) 
containing 5% of the species serum in which the secondary antibody was raised (if available)) 
for 20 minutes at room temperature. Cells were then incubated with the primary antibody 
diluted in blocking buffer at 4°C overnight. If cells were stained with two primary antibodies 
against two different antigens at the same time (double staining), primary antibodies that were 
raised in different species (e.g., rabbit and mouse) were used.  The next day cells were washed 
three times with PBS-T for 10 minutes each and then incubated with the appropriate 
secondary antibody(s) diluted in blocking buffer for 45 minutes in the dark at room 
temperature. Following three washes with PBS-T for 10 minutes cell nuclei were stained with 
DAPI (6 μg/ml in 1x PBS), a fluorescent dye that binds to AT rich regions of double stranded 
DNA and, when bound, has an emission maximum of 461 nm (blue). Cells were then 
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thoroughly washed with 1x PBS and mounted with a glass coverslip using a water-based 
mounting medium before being left to dry at 4°C overnight.  
2.15. Preparation of S9 fractions  
S9 fractions prepared from an organ, most commonly the liver, contain microsomes, which 
contain the CYP450 enzymes, as well as the cytosolic fraction which contains several other 
enzymes including the majority of transferases. S9 fractions as a result are often used to study 
the metabolism of xenobiotics and drugs.  
S9 fractions were prepared from mouse liver tissue. C57Bl/6 mice were terminated by 
cervical dislocation and their liver’s dissected. To reduce blood contamination, livers were 
roughly chopped in a petri dish containing ice-cold 1x PBS using a scalpel. Chopped liver 
tissue was then transferred to approximately five volumes of ice-cold TKMS buffer (50 mM 
Tris; 25 mM KCl, 5 mM MgCl2, 250 mM sucrose – pH 7.5). Mouse liver tissue was then 
disrupted in TKMS buffer using a potter homogeniser with tissue kept on ice throughout 
disruption. The homogenate was filtered through a tea strainer into centrifuge tubes and 
centrifuged at 12,000 xg for 20 minutes at 4°C to pellet the nuclear and 
mitochondrial/lysosomal fraction. The fatty top layer was removed from the supernatant 
(supernatant is the S9 fraction) and the S9 fraction was transferred to clean centrifuge tubes 
and centrifuged again at 12,000 xg for 20 minutes at 4°C. The supernatant was carefully 
transferred to a clean tube and then aliquoted, snap frozen in liquid nitrogen and stored 
at -80°C. The protein concentration of the S9 fraction was determined by Bradford assay (see 
Section 2.11.3).  
2.16. Sulfotransferase [35S]-PAPS radiometric activity assay 
Sulfotransferases (SULTs) are cytosolic phase II metabolizing enzymes that play a major role 
in the clearance of endogenous and exogenous compounds including hormones, drugs and 
xenobiotics (Paul et al., 2012). SULTs catalyse the transfer of a sulfo group from a donor 
molecule, often 3′-phosphoadenosine 5′-phosphosulfate (PAPS), to the compound to be 
metabolised to inactivate it or making it more water soluble and therefore less biologically 
active. SULT activity can be assessed by measuring the transfer of radiolabelled sulfo group 
[
35
S] from [
35
S]-PAPS to a particular substrate (Figure 2.13). S9 fractions isolated from 
mouse liver were used as the source of cytosolic SULTs (for preparation of S9 fraction see 
Section 2.15). 
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Figure 2.13 Transfer of a radiolabelled sulfo group from [
35
S]-PAPS to a substrate catalysed by 
SULT enzymes.  
 
S9 fraction (1 mg/ml), substrates (from 100x concentrated stocks) and, where applicable, 
SULT inhibitors (from 100 x concentrated stocks) where combined in a 0.6 ml tube on ice 
and made up to 100 μl with sample buffer (5 mM KH2PO4 (pH 6.5), 10 mM dithiothreitol 
(DTT), made fresh on day of assay). Fifty microlitre of reaction cocktail (25 μl 50 mM 
KH2PO4 (pH 6.5) + 25 μl of 5 mM MgCl2 containing 24 mM DTT and 1.28 μM [
35
S]-PAPS 
(PerkinElmer, Seer Green, UK) were then added to each tube followed by incubation for 30 
minutes at 37 C. To stop the reaction, 100 μl of stop mixture (1:1 (v/v) of 0.1 M barium 
hydroxide and 0.1 M barium acetate) was added to each tube. Unreacted [
35
S]-PAPS was 
precipitated by adding 50 μl of 0.1M ZnSO4, the tubes were then vortexed and centrifuged at 
16,000 xg for 3 minutes at room temperature. Following centrifugation, 50 μl of 0.1 M barium 
hydroxide was added to each tube, tubes were vortexed, and 50 μl of 0.1 M ZnSO4 were 
added to each tube. The precipitate was spun down by centrifugation at 16,000 xg for 10 
minutes at room temperature. Twenty microlitres of the supernatant was transferred to a 
microplate and 200 μl scintillation cocktail (Optiphase HiSafe 3, PerkinElmer) was then 
added. [
35
S] product radioactivity was determined in a scintillation counter (MicroBeta® 
TriLux, PerkinElmer). 
2.17. Generation of aqueous, alcohol and organic extracts from soil 
Surface soil samples (0-5 cm in depth) from around the boundary of a functioning waste site 
situated within a sub- or peri-urban area as well as three soil samples from rural, suburban and 
urban control sites were collected and aqueous, alcohol and organic extracts were generated 
by Dr Martin Cooke (School of Civil Engineering and Geosciences, Newcastle University). 
To produce aqueous and alcohol extracts, 250 g of soil (freed from stones, roots and vegetable 
matter) were mixed with 300 ml of methanol followed by sonication for 10 minutes. A further 
100 ml of methanol were then added and sonicated again for 10 minutes. The methanol mix 
was filtered (25 μm), divided into 3 vials and evaporated using nitrogen. Following 
substrate substrate
SULT
PAP35S
PAP
35S
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evaporation, the remnants were re-dissolved in 10 ml phosphate buffer (aqueos extract) or 
ethanol (alcohol extract). Organic extracts were generated following the same extraction 
protocol but instead of methanol, chloroform was used. The remnants after nitrogen 
evaporation were dissolved in 10 ml chloroform. For application in cell-culture based assays, 
200 μl of the chloroform extract were left to evaporat overnight in a fume cabinet and re-
dissolved in the same volume of DMSO.   
2.18. Statistical Analysis 
Statistical analysis was performed using SPSS21 (IBM) or Excel and statistical significance 
was considered when p<0.05. To test for statistical significance of more than one treatment 
group versus a control group, such as in dose-response experiments, a one-way ANOVA with 
Dunnett’s post-hoc test was performed. For multiple comparisons of 3 or more samples, a 
one-way ANOVA was used and Bonferroni post-hoc tests were performed to control for Type 
I error rate. In cases where multiple t-tests (two-tailed) were performed, such as when the 
effects of antagonist versus a certain treatment were examined, p-values were corrected for 
Type I errors using Holm-Bonferroni post-hoc tests. 
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Chapter 3. Development of a mouse-based in vitro screening system to 
assess transcriptional oestrogenic activity  
Many everyday products contain chemicals that are able to disrupt normal hormone signalling 
potentially causing serious health conditions (Diamanti-Kandarakis et al., 2009). Of particular 
concern are unwanted interactions of endocrine disrupting chemicals (EDCs) with the 
oestrogen receptors (ERs) which, due to the receptors involvement in a vast range of 
biological processes, may account for a spectrum of adverse effects in wildlife and humans 
including reproductive, neuroendocrinological and metabolic disorders as well as cancer 
(Ascenzi et al., 2006; Soto and Sonnenschein, 2010; Yoon et al., 2014).  
Although a number of different oestrogen-signalling pathways exist, many EDCs may affect 
ER signalling by directly targeting the ERs. Such direct-acting chemicals include food and 
cosmetic additives, plasticisers, pharmaceuticals and pesticides (Rogers et al., 2013). In vitro 
screening assays are often employed to identify potential EDCs that bind to the ERs. In 
particular, cell-based trans-activation reporter gene assays which can distinguish between 
agonistic and antagonistic effects are commonly used (Huang et al., 2014).  
In order to examine the potential adverse effects that ER-targeting EDCs may have in vivo in 
mice, a mouse-based in vitro screening assay was required to test a range of chemicals for 
activation of the mouse ERs (mERs). This chapter describes the development of a reliable 
mouse-based trans-activation reporter gene assay that will allow for xenobiotics to be tested 
for oestrogenic activity in mice. Since the primary focus of this thesis is to examine the effects 
that oestrogenic chemicals may have in the liver, and given that oestrogens may target the 
liver via the ERα which is primarily expressed in hepatocytes (Ahlbory-Dieker et al., 2009; 
Uebi et al., 2015), this cell type would have been the preferred option for screening the 
oestrogenicity of chemicals. Since hepatocytes are non-proliferative in vitro, however, 
transfection efficiencies are low. To develop an in vitro assay that will generate high signal to 
noise readouts and allow for semi-high throughput screening of a relatively large set of 
samples, the use of hepatocytes was not a realistic option. Therefore, cells with a ductal 
hepatopancreatobiliary phenotype were employed. Biliary epithelial cells (BECs) have been 
reported to not express the ER in healthy liver, however, expression of both ER subtypes ERα 
and ERβ was observed in BECs of patients with PBC (Alvaro et al., 2004). Since oestrogens, 
and therefore potentially xenoestrogens are known to be cholestatic, ER expression and 
signalling in cholangiocytes may play an important role in the development and/or 
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progression of cholestatic liver conditions. The use of hepatopancreatobiliary cells was as a 
result considered to be an appropriate alternative to hepatocytes. 
3.1. Analysis for mER expression in the mouse ductal cell lines 603B and LTPA 
On account of limitations of the number of primary BECs that could be isolated from mouse 
liver, the mouse BEC cell line 603B as well as the mouse ductal pancreatic cell line LTPA 
were employed. Although LTPA cells are not derived from the liver, biliary and pancreatic 
ducts have the same developmental origin and are physiologically linked (Probert et al., 2015). 
603B and LTPA cells were examined for expression of the two mER isoforms α and β by RT-
PCR, Western Blot and immunocytochemical staining. Figure 3.1A shows that mERα mRNA 
was detected in 603B (see lane 2) but not in LTPA cells (lane 3) and that neither cell line 
expressed mERβ mRNA. Murine uterus, liver and ovary tissues were included as positive 
controls for the mERα (uterus, liver and ovary) and the mERβ (ovary). Western Blot analysis 
showed that mERα and mERβ proteins were not detectable in either cell line (Figure 3.1B) 
which was confirmed by immunocytochemical staining (Figure 3.2). HEK293 cells which are 
widely used as an expression tool for recombinant proteins due to their high transfection rate 
and protein production (Thomas and Smart, 2005), are ER negative (see Figure 3.8) and were 
transiently transfected with a pcDNA3.1 expression vector coding for the mERα (pcDNA3.1-
mERα) or mERβ transcript variant 1 (pcDNA3.1-mERβv1) for use as a positive control for 
the mERs as part of the immunostaining. Figure 3.2 shows nuclear localisation of the 
recombinant mER proteins in HEK293 cells. 
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Figure 3.1 Analysis for the expression of mERs in 603B and LTPA cells by RT-PCR and 
Western Blot. (A) RT-PCR analysis for mERα and mERβ mRNA expression in 603B and LTPA cells 
and the indicated murine tissues. RNA was isolated from 603B and LTPA cells as well as murine 
tissue followed by RT-PCR (30 PCR cycles) using primers specific for the mERα and mERβ. GAPDH 
was used as a loading control. PCR products were separated by agarose electrophoresis and visualised 
by UV transillumination. (B) Western Blot analysis for mERα and mERβ protein expression in 603B 
and LTPA cells. Total protein was isolated from 603B, LTPA cells and murine tissue following 
separation by gel electrophoresis and visualisation (20 μg total protein/lane). Data are typical of three 
independent experiments. 
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Figure 3.2 Analysis for the expression of mERs in 603B and LTPA cells by 
immunocytochemistry. Immunocytochemical staining for mERα and mERβ expression in 603B and 
LTPA cells. HEK293 cells transfected with an expression vector coding for either the mERα or 
mERβv1 were included as a positive control. Scale bars: 50 μm. Data are typical of two independent 
experiments. 
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3.2. Construction of the mERα and mERβ transcript variant 1 and variant 2 
expression constructs 
Since the mER proteins were undetectable in 603B and LTPA cells, their expression, however, 
required to develop an in vitro screening system to test for mouse ER activation, mERα and 
mERβ cDNA sequences were cloned from murine tissue and ligated into an mammalian 
expression vector in order to ectopically express the mouse ERs in the mouse ductal 603B and 
LTPA cell lines.  
3.2.1. Cloning of the mERα and two mERβ transcript variants from murine tissue 
The mERα cDNA sequence was amplified from RNA isolated from mouse uterine tissue with 
specific cloning primers designed to yield EcoRI and HindIII restriction sites upstream and 
downstream of the mERα open reading frame for subsequent ligation into an expression 
vector (for primer sequences see Table 2.10). Separation of the PCR reaction by agarose gel 
electrophoresis following amplification of mERα cDNA resulted in a single band of the 
approximate size predicted to be 1829 bp (Figure 3.3A).  
Two mERβ cDNA sequences were amplified from RNA extracted from mouse ovaries with 
specific primers containing EcoRI and AflII restriction sites. PCR amplification using these 
primers was predicted to result in PCR products of 1744 bp (full length mERβ transcript 
variant 1 (mERβv1), NM_207707.1) and 1690 bp (mERβ transcript variant 2 (mERβv2), 
NM_010157.3, lacking an in-frame exon in the coding region, creating a protein lacking 
amino acids 383 – 400 present in variant 1). Amplification by PCR resulted in a single 
detectable band of PCR products migrating at a size of around 1.7 kb, likely containing the 
PCR amplification products of both mERβ variants due to their similar size (Figure 3.3B). 
PCR bands from both mERα and mERβ amplification reactions were purified from the gel for 
subsequent ligation. 
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Figure 3.3 Amplification of mERα and mERβ cDNA sequences by RT-PCR. (A) Amplification of 
the mERα cDNA from RNA isolated from mouse uterine tissue (30 cycles) using cloning specific 
primers followed by agarose gel electrophoresis and visualisation by transillumination. (B) 
Amplification of the mERβv1 and mERβv2 cDNAs from RNA isolated from mouse ovaries (35 
cycles) using cloning specific primers followed by agarose gel electrophoresis and visualisation by 
transillumination. 
3.2.2. Ligation of the mERα, mERβv1 and mERβv2 cDNAs into a pCR-Blunt vector 
Gel purified mERα and mERβ cDNAs were first ligated into a pCR-Blunt vector using the 
Zero Blunt PCR cloning kit which offers an easy method for high-efficiency (>80%) cloning 
of blunt-end PCR products. Recombinant pCR-mER constructs were transformed into E.coli 
bacterial cells and numerous clones were screened by restriction digest with the appropriate 
restriction enzymes for recombinant vectors containing the correct insert. To check for 
insertion of the mERα cDNA, recombinant plasmids were digested with EcoRI and HindIII 
restriction enzymes. Figure 3.4A shows that clones 1-6 contained an insert with the 
approximate predicted size of 1829 bp, the size of the mERα insert.  
To check for insertion of the mERβv1 and mERβv2 cDNAs, recombinant plasmids were 
digested with EcoRI. Figure 3.4B shows that clones 1 and 4 contained an insert with the size 
of the mERβv1 (1744 bp, see lane 2 and 5) whereas clones 2, 5, 6 and 8 contained an insert 
with the size of the mERβv2 (1690 bp, lane 3, 6, 7 and 9), the latter migrating slightly further 
due to its smaller size compared to the mERβv1 insert.  
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Figure 3.4 Restriction digest of recombinant pCR-Blunt constructs to test for presence of the 
cloned mER inserts. (A) EcoRI and HindIII double restriction digest to screen for correctly 
assembled recombinant pCR-Blunt vectors with the mERα insert. (B) EcoRI restriction digest to 
screen for correctly assembled recombinant pCR-Blunt vectors containing the mERβv1 or mERβv2 
insert. Digested plasmid DNA was separated by agarose gel electrophoresis and visualised by 
transillumination. 
 
All clones with an insert of the correct size were analysed by DNA sequencing to verify that 
the inserts were the expected mER cDNA sequences and to ensure that the sequences did not 
contain any mutations following PCR amplification. DNA sequencing results verified that all 
clones analysed contained either the mERα (NM_007956.5), mERβv1 (NM_207707.1) or 
mERβv2 (NM_010157.3) cDNAs with no mutations. A a result, clone 1 and 2 for the mERα, 
clone 1 and 4 for the mERβv1 and clone 2 and 5 for the mERβv2 were chosen to be used for 
the next cloning step. 
3.2.3. Preparation of the mER inserts and the pcDNA3.1 destination vector for ligation 
Following verification that the recombinant pCR-vectors contained the cDNAs for the mERα, 
mERβv1 or mERβv2, the mouse ER cDNA inserts were excised on a large scale from the 
respective pCR-Blunt vector from clones as indicated with EcoRI and HindIII restriction 
enzymes for the mERα (see Figure 3.5A) and EcoRI and AflII restriction enzymes for the 
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mERβv1 and mERβv2 (Figure 3.5B). The pcDNA3.1 vector (for vector map see Figure 2.10 
in Chapter 2) used as the destination vector originally contained a c/EBPβ cDNA sequence 
which was excised with the same combination of restriction enzymes (EcoRI + HindIII or 
EcoRI + AflII) obtaining linearisation of the destination vector with ‘sticky ends’ for ligation 
of the mER inserts. The restricted mER inserts as well as the linearised pcDNA3.1 vector 
were gel purified for ligation.  
 
 
Figure 3.5 Excision of the mER inserts from recombinant pCR-Blunt vectors and linearisation 
of the destination vector by restriction digest. (A) Large scale EcoRI and HindIII restriction digest 
of the recombinant pCR-Blunt construct containing the mERα insert (pCR-mERα) from clone 1 and 2 
and linearisation of the destination vector pcDNA3.1. (B) Large scale EcoRI and AflII restriction 
digest of the recombinant pCR-Blunt construct containing the mERβv1 (pCR-mERβv1, clone 1 and 
4), or mERβv2 insert (pCR-mERβv2, clone 2 and 5) and linearisation of the destination vector 
pcDNA3.1. Digested plasmid DNA was separated by agarose gel electrophoresis and visualised by 
transillumination. 
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3.2.4. Sub-cloning of the mERα, mERβv1 and mERβv2 cDNAs into the destination 
vector pcDNA3.1 
Gel purified mER inserts and the linearised destination vector pcDNA3.1 were combined in a 
ligation reaction followed by transformation into E.coli bacterial cells. Several clones were 
screened for correctly constructed recombinant plasmids by restriction digest with the 
appropriate restriction enzymes. Figure 3.6A shows that all clones screened contained an 
insert of the size of the mERα (1829 bp). Clones 3-8 in Figure 3.6B contained an insert the 
size of the mERβv1 (1744 bp) and clones 1-4 in Figure 3.6C contained and insert the size of 
the mERβv2 (1690 bp).  
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Figure 3.6 Restriction digests of recombinant mER-pcDNA3.1 plasmids to test for presence of 
the mER inserts. (A) EcoRI and HindIII double restriction digest to screen for correctly assembled 
recombinant pcDNA3.1 construct with mERα insert. (B) EcoRI and AflII double restriction digest to 
screen for correctly assembled recombinant pcDNA3.1 construct with mERβv1 insert. (C) EcoRI and 
AflII double restriction digest to screen for correctly assembled recombinant pcDNA3.1 constructs 
with mERβv2 insert. Digested plasmid DNA was separated by agarose gel electrophoresis and 
visualised by transillumination. 
 
To verify that the excised inserts were the expected mER cDNA sequences, recombinant 
pcDNA3.1-mER plasmids were analysed by DNA sequencing. Sequencing results confirmed 
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that all analysed clones contained the cDNA sequences for the mERα, mERβv1 or mERβv2 
and were correctly assembled (see Appendix A-C). Accordingly, clone 4 and 6 containing the 
mERα cDNA, clone 5 containing the mERβv1 cDNA and clone 1 containing the mERβv2 
cDNA were chosen to be tested for their functionality. 
3.3. Testing for correct functioning of the newly generated pcDNA3.1-mER expression 
constructs  
3.3.1. Determining transfection efficiency in the mouse ductal cell lines using a variety 
of transfection methods 
Following cloning, the newly generated pcDNA3.1-mER expression constructs were tested 
for correct functioning. In order to decide on the cell line to do the testing in, the transfection 
efficiency in 603B and LTPA cells was determined using a number of transfection reagents 
and a plasmid encoding the green fluorescent protein (GFP, peGFP-N1). 603B and LTPA 
cells transfected with the GFP-plasmid using polyethylenimine (PEI) show low levels of 
transfection after 24 and 48 hours, regardless of the amount of PEI added to the cells (Figure 
3.7A). In LTPA cells, changes in cell morphology after 48 hours were observed indicating 
that PEI exhibits cytotoxic effects in these cells. The average transfection efficiency using PEI 
calculated from 3 fields per view was found to be less than 0.7% for 603B and less than 1.4% 
for LTPA cells.  
Cells transfected using Effectene (Qiagen) show higher transfection rates after 48 hours 
compared to PEI with calculated transfection efficiencies of 8.67% for 603B transfected with 
a DNA:Effectene ratio of 1:10 and 3.3 % for LTPA cells using a ratio of 1:50 (Figure 3.7B). 
Transfection of 603B and LTPA cells with the peGFP-N1 using the calcium phosphate 
transfection method resulted in an average transfection efficiency of less than 1% for both cell 
lines (Figure 3.7C).  
Since 603B showed the highest transfection efficiency when the transfection reagent 
Effectene with a DNA:Effectene ratio of 1:10 was used, this cell line was employed to test the 
cloned mouse ER-pcDNA3.1 constructs for correct functioning.  
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Figure 3.7 Determining transfection efficiencies in 603B and LTPA cells. Merged light and 
fluorescent microscope images and transfection efficiencies of 603B and LTPA cells transfected with 
the peGFP-N1 plasmid encoding the green fluorescent protein (GFP) using different transfection 
reagents. (A) Transfections using polyethylenimine (PEI). Different amounts of PEI (2.5, 1.6 and 
0.6 µg) were added to cells in 6-well plates to determine the best working condition. Cells were 
imaged for GFP expression at 24 and 48 hours following transfection. Transfection efficiency was 
determined by expressing the number of GFP-positive cells as percentage of the number of total cells 
per field of view. Data are the average transfection efficiency calculated from 3 fields per view and 
SD, typical of two separate experiments. Scale bar: 100 µm.  
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Figure 1.7 contd. Determining transfection efficiencies in 603B and LTPA cells. (B) Transfections 
using Effectene reagent with different DNA:Effectene ratios as indicated. Cells were examined for 
GFP expressing at 48 hours following transfection. (C) Transfections using the calcium phosphate 
transfection method.  
 
  
 
  
1
:1
0
1
:2
5
1
:5
0
1
:1
0
1
:2
5
1
:5
00
5
10
15
Ratio DNA:Effectene
603B LTPA
%
 t
ra
n
sf
e
c
ti
o
n
 e
ff
ic
ie
n
c
y
6
0
3
B
L
T
P
A
0
1
2
3
%
 t
ra
n
sf
e
c
ti
o
n
 e
ff
ic
ie
n
c
y
B
C
 92 
 
3.3.2. Testing the cloned pcDNA3.1- mERβ expression constructs for correct functioning 
3.3.2.a The mERβv1 and mERβv2 proteins are ectopically expressed 
Initially, the constructs coding for the mERβ proteins were tested for correct functioning. To 
test whether these constructs produce proteins, 603B and HEK293 cells were transiently 
transfected with purified pcDNA3.1 plasmid DNA containing the insert for either the 
mERβv1 (isolated from clone 5) or mERβv2 (isolated from clone 1) cDNA and expression of 
the recombinant proteins was examined by Western Blot and immunocytochemical staining.  
Proteins of the predicted size were generated in HEK293 cells transfected with the mERβv1 
or mERβv2 expression constructs (lane 7 and 8) and low but detectable protein expression 
was observed in 603B cells (lane 3 and 4 in overexposed panel) (Figure 3.8A). Mouse ERβ 
protein was undetectable in controls transfected with an empty pcDNA3.1 expression 
construct (lane 2 and 6) and in non-transfected cells (lane 1 and 5).  
Immunocytochemical staining confirms that the mERβv1 and mERβv2 proteins were 
ectopically expressed and localised in the nucleus of HEK293 and at a lower level in 603B 
cells transiently transfected with the corresponding pcDNA3.1- mERβ expression constructs. 
Mouse ERβ protein was not detected in control cells transfected with an empty pcDNA3.1 
expression construct (Figure 3.8B).  
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Figure 3.8 Analysis for ectopical expression of the mERβ proteins. (A) Western Blot for the 
expression of the mERβ proteins in 603B and HEK293 cells transiently transfected with the 
expression construct coding for either the mERβv1 or mERβv2 cDNA sequences or empty vector as 
control (20 µg total protein/lane). Theoretical molecular weights: mERβv1, 63.23 kDa; mERβv2, 
61.21 kDa. (B) Immunocytochemical staining for the expression of the mERβ proteins in 603B and 
HEK293 cells transiently transfected with the expression construct encoding either the mouse 
mERβv1 or mERβv2 cDNA sequence or empty vector as control. Scale bar: 50 μm. Data are typical of 
three independent experiments. 
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3.3.2.b 603B cells transfected with the mERβv1 and mERβv2 pcDNA3.1 expression 
construct respond to oestrogen 
Following confirmation that the mERβ proteins were ectopically expressed in cells 
transfected with the pcDNA3.1-mERβ constructs, recombinant mERβ proteins were tested for 
functional activity by reporter gene assay. 603B cells were transiently transfected with the 
pcDNA3.1 expression construct coding for either the mERβv1 or mERβv2, the (ERE)3-
pGL3promotor reporter construct and the control RL-TK plasmid before treatment with 
10 nM E2 or 0.1% (v/v) DMSO vehicle in the absence and presence of the ER antagonist 
ICI182,780 for 24 hours followed by dual-glo luciferase assay. Control cells were co-
transfected with an expression construct coding for a different protein not involved in 
oestrogen signalling, here c/EBPβ, or an empty expression construct. Vehicle-treated 603B 
cells expressing recombinant mERβv1 trans-activated the luciferase reporter gene in the 
absence of ICI182,780, a response that was significantly further induced following treatment 
with 10 nM E2 (Figure 3.9). Co-treatment with 100 nM of the ER antagonist ICI182,780 
significantly reduced luciferase reporter gene expression in mERβv1-expressing cells treated 
with E2 in the absence of ICI182,780 confirming that the increase in luciferase reporter gene 
expression in response to E2 is mediated by the mERβv1. ICI182,780 also significantly 
reduced luciferase reporter gene expression over cells treated with the vehicle alone 
suggesting that the mERβv1 is able to trans-activate the ERE-reporter gene construct in the 
absence of an exogenous ligand such as E2, potentially because of oestrogens present in 
complete cell culture media.  
In 603B cells expressing recombinant mERβv2, a small significant increase in luciferase 
activity by 1.52 fold following exposure to 10 nM E2 was observed over vehicle treated cells 
(Figure 3.9). Recombinant mERβv2-expressing 603B cells which were treated with the 
vehicle alone, however, exhibited high levels of basal luciferase activity compared to 
pcDNA3.1-mERβv1 transfected vehicle-treated cells. Co-treatment of mERβv2-expressing 
cells with 100 nM ICI182,780 significantly reduced luciferase reporter gene activity over 
vehicle and E2 treated cells to similar levels seen in mERβv1-expressing cells. These findings 
suggest that recombinant mERβv2 trans-activates the (ERE)3-pGL3promotor reporter 
construct in the absence of a ligand, either because it exhibits near complete constitutive 
activity or because the protein is activated by oestrogens present in the culture medium.  
603B cells transfected with an empty form of the pcDNA3.1 expression construct or a 
pcDNA3.1 vector coding for c/EBPβ did not trans-active the luciferase reporter gene in 
response to 0.1% (v/v) DMSO vehicle or 10 nM E2 nor did co-treatment with 100 nM 
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ICI182,780 reduce luciferase reporter gene expression over vehicle and E2 treated cells in the 
absence of ICI182,780 (Figure 3.9). This confirms that trans-activation of the luciferase 
reporter gene as seen in cells expressing the mERβv1 and mERβv2 proteins is a result of 
active ERβ proteins expression and also shows that no squelching effects are taking place.  
 
Figure 3.9 Testing the mERβ expression constructs for functional activity. Luciferase reporter 
gene ((ERE)3-pGL3promotor) assay in 603B cells co-transfected with expression constructs coding for 
the mERβ proteins or control constructs as indicated. Cells were treated with 0.1% (v/v) DMSO 
vehicle or 10 nM E2 (± ICI182,780) for 24 hours followed by dual-luciferase assay. Mean and SD of 
n=3, typical of 3 separate experiments. Data are expressed in fold change versus mERβv1-transfected 
cells treated with DMSO vehicle. *Significantly different (p<0.05) over the equivalent expression 
vector transfected cells treated with DMSO vehicle; #Significantly different versus equivalent 
treatments in the absence of ICI182,780 (compound only)-treated cells using Student’s t-test (two-
tailed) with Holm-Bonferroni post-hoc modifications.  
3.3.2.c Recombinant mERβv1 – but not mERβv2 – trans-activates the (ERE)3-
pGL3promotor reporter construct in a dose-dependent manner 
To further test if the mERβv1 or mERβv2 proteins trans-activate the luciferase reporter 
construct in a dose-dependent manner, cells were treated with a range of E2 concentrations 
starting at 10 pM and increasing serially by a factor of 10 to a maximum of 10 μM for 
24 hours followed by dual-glo luciferase assay. Figure 3.10 demonstrates that activation of 
the mERβv1 – but not the mERβv2 – is concentration dependent with the mERβv1 
responding to E2 at a concentration as low as 1 nM. A statistically significant increase in 
luciferase activity in mERβv2-expressing cells was observed at 10 nM and 10 μM. Despite 
this, the fold induction was very low and therefore it is likely not biologically significant. 
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603B cells transfected with an empty expression construct did not respond to E2 at any tested 
concentration. 
Overall, these results suggest that the cloned pcDNA3.1-mERβv1 construct generates 
functional protein capable of trans-activating the (ERE)3-pGL3promotor reporter construct 
and that 603B cells produce co-factors that allow for mERβ responsiveness. Although 
recombinant mERβv2 did not trans-activate the (ERE)3-pGL3promotor reporter construct in a 
dose-dependent manner, high basal levels of luciferase activities compared to mERβv1-
expressing cells were observed suggesting that the pcDNA3.1-mERβv2 construct produces 
functionally active protein, likely to possess nearly complete constitutive activity or being 
almost fully activated by oestrogenic compounds present in cell culture media.  
 
Figure 3.10 E2 activates the mERβv1 – but not the mERβv2 – in a dose-dependent manner. 
Luciferase reporter gene ((ERE)3-pGL3promotor) assay in 603B cells co-transfected with expression 
constructs coding for the mERβv1, mERβv2 or an empty control vector. Cells were treated with 
increasing concentrations of E2 (vehicle: 0.1% (v/v) DMSO) for 24 hours followed by dual-luciferase 
assay. Mean and SD of n=3, typical of 3 separate experiments. Data are expressed in fold change 
versus the equivalent expression vector transfected DMSO vehicle-treated cells. *Significantly 
different (p<0.05) over the equivalent expression vector transfected cells treated with DMSO vehicle 
using One-way ANOVA with Dunnett’s post-hoc modifications.  
 
3.3.2.d Recombinant mERβv1 and mERβv2 proteins are not activated by background 
oestrogenic chemicals in culture media  
Complete cell culture media generally contain a number of oestrogenic compounds which can 
result in high background levels of some nuclear receptor activities. Compounds reported to 
have oestrogenic activity include phenol red, a pH indicator present in most culture media 
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(Berthois et al., 1986). Furthermore, a number of steroid hormones are naturally present in the 
culture media supplement foetal bovine serum (FBS). They vary from one batch to another 
and may influence ER activities in vitro. 
Since 603B cells transfected with the pcDNA3.1-mERβv1 and pcDNA3.1-mERβv2  
expression construct trans-activated the (ERE)3-pGL3promotor reporter construct in the 
absence of E2, it was examined whether recombinant mERβv1 and mERβv2 proteins are 
activated by oestrogenic compounds or steroid hormones present in the cell culture medium. 
Testing for E2-induced activation of the mERβv1 and mERβv2 proteins was carried out in 
603B cells incubated in phenol red-free (phenol red (-)) or phenol red-containing (phenol red 
(+)) medium supplemented with 10% (v/v) FBS treated with activated charcoal/dextran 
(referred to as ‘stripped’ FBS) which removes endogenous steroid hormones and other low 
molecular weight compounds from the serum, and compared to cells grown in medium with 
non-stripped FBS (referred to as ‘normal’ medium). Figure 3.11A demonstrates that treatment 
of cells expressing the mERβv1 with 100 nM ICI182,780 similarly decreased luciferase 
reporter gene activity over vehicle treated cells in normal medium as well as in phenol red (+) 
and phenol red (-) media supplemented with stripped FBS suggesting that the mERβv1 is 
capable of trans-activating the (ERE)3-pGL3promotor reporter construct independent of 
oestrogenic compounds in the medium. Furthermore, there was little difference in the fold 
change of E2-induced increase in reporter gene activity between cells grown in normal 
medium and phenol red (+) medium with stripped FBS. Recombinant mERβv1-expressing 
cells grown in phenol red (-) medium containing stripped FBS show a slightly greater E2-
induced increase in luciferase reporter gene activity which, however, was not significantly 
different compared to the E2-mediated response of cells in normal medium and phenol red (+) 
medium with stripped FBS. Co-treatment with 100 nM ICI182,780 significantly reduced 
luciferase reporter gene activity over E2-treated cells within all media. 
In 603B expressing recombinant mERβv2, treatment with 100 nM ICI182,780 significantly 
decreased luciferase reporter gene activity over vehicle treated cells in the absence of E2 in 
normal as well as in phenol red (+) and phenol red (-) medium containing stripped FBS 
indicating that recombinant mERβv2 protein trans-activates the (ERE)3-pGL3promotor 
reporter construct independent of a ligand (Figure 3.11B). Treatment with 10 nM E2 similarly 
resulted in a low significant increase in reporter gene expression over vehicle treated cells 
across all media which, however, was not significantly decreased by co-treatment with 
100 nM ICI182,780. 
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Since results have shown that recombinant mERβv1 and mERβv2 proteins trans-activated the 
(ERE)3-pGL3promotor reporter construct in the absence of an exogenously added ligand in 
normal as well as medium containing stripped FBS, it is unlikely that the mERβ proteins are 
activated by background oestrogenic chemicals and steroid hormones present in normal 
culture media. This suggests that recombinant mERβv1 exhibits partial, and mERβv2 almost 
complete constitutive activities in vitro in this assay. Since stripping of FBS made little 
difference compared to results obtained from cells grown in medium containing non-stripped 
FBS, normal medium was used for all following experiments. 
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Figure 3.11 Recombinant mERβ proteins are not activated by background oestrogenic chemicals 
in cell culture media. Luciferase reporter gene ((ERE)3-pGL3promotor) assay in 603B cells co-
transfected with expression constructs coding for (A) the mERβv1 or (B) mERβv2. Cells were grown 
in normal medium, in medium supplemented with stripped FBS (phenol red (+) stripped) or in phenol 
red-free medium containing stripped FBS (phenol red (-) stripped) for 24 hours prior to transfection. 
Cells were then pre-treated with 100 nM ICI182,780 or 0.1% (v/v) DMSO vehicle as indicated for 6 
hours followed by treatment with 10 nM E2 or 0.1% (v/v) DMSO vehicle (+/- 100 nM ICI182,780) for 
24 hours. Mean and SD of n=3. Data are expressed in fold change versus DMSO vehicle-treated cells 
grown in the respective medium. *Significantly different (p<0.05) over DMSO vehicle-treated cells 
grown in the equivalent medium; #Significantly different versus equivalent treatments in the absence 
of ICI182,780 using Student’s t-test (two-tailed) with Holm-Bonferroni post-hoc modifications. 
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3.3.2.e The mERβv2 is nearly completely constitutively active 
In order to verify that the mERβv2 is almost completely constitutively active, and to find a 
way to test for activation of this mERβ variant, 603B cells transfected with the expression 
construct encoding the mERβv2, the (ERE)3-pGL3promotor reporter and the RL-TK vector 
were pre-treated with 100 nM ICI182,780 (or 0.1% (v/v) DMSO) vehicle for 7 hours to de-
activate the mERβv2 protein. Following removal of ICI182,780 and several washes with 1x 
PBS to reduce the levels of antagonist, cells were treated with increasing concentration of E2 
(10 pM – 1 µM) with or without 100 nM ICI182,780. Figure 3.12 demonstrates that following 
de-activation of the mERβv2 with ICI182,780, E2 treatment resulted in a dose-dependent 
increase in luciferase activity both in cells treated with E2 + ICI182,780 as well as in cells 
treated with E2 in the absence of ICI182,780. Cells that were pre-treated with ICI182,780 and 
then treated with E2 in the absence of the ER antagonist, showed a significant response over 
vehicle treated cells at a lower E2 concentration (100 pM) compared to cells that were pre-
treated with ICI182,780 and then treated with E2 + 100 nM ICI182,780, which showed a  
significant response to E2 at a concentration of 10 nM (Figure 3.12).  
Overall these results confirm that recombinant mERβv2 protein is constitutively active and 
that de-activating the mERβv2 with ICI182,780 followed by washing out and treatment with a 
compound of interest represents a more sensitive way to test for activation of this protein 
compared to pre-treating cells with ICI182,780 followed by treatment with a compound of 
interest in the presence of ICI182,780. This is likely because in the presence of ICI182,780, 
E2 has to competitively displace the ER antagonist from the mERβv2, which leads to reduced 
sensitivity of the assay.  
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Figure 3.12 Testing for constitutive activity of the mERβv2 protein. Luciferase reporter gene 
((ERE)3-pGL3promotor) assay in 603B cells co-transfected with expression constructs coding for the 
mERβv2. Cells were pre-treated with 100 nM ICI182,780 or 0.1% (v/v) DMSO vehicle for 7 hours 
followed by several washes with 1x PBS to remove ICI182,780 from the cells. Cells were then treated 
with a range of E2 concentration ± ICI182,780 for 24 hours (light grey = pre-treated with DMSO 
vehicle, then treatment with E2; dark grey = pre-treated with 100 nM ICI, then treatment with E2 + 
100 nM ICI; shaded = pre-treated with 100 nM ICI, several wash steps with PBS to remove 
antagonist, then treatment with E2 only). Mean and SD of n=3, typical of 3 separate experiments. Data 
are expressed in fold change versus DMSO vehicle-treated cells in the absence of ICI182,780. 
*
,&,$
Significantly different (p<0.05) over DMSO vehicle-treated cells in the respective group using 
One-way ANOVA with Dunnett’s post-hoc modifications. 
3.3.3. Testing the cloned pcDNA3.1-mERα expression construct for correct functioning 
3.3.3.a Recombinant mERα protein is expressed in 603B cells 
The construct coding for the mERα was tested for correct functioning. To test whether the 
generated construct produces protein, 603B and HEK293 cells were transiently transfected 
with pcDNA3.1 plasmid DNA containing the insert for the mERα cDNA purified from clone 
4 and clone 6 followed by analysis for expression of the recombinant mERα protein by 
Western Blot.  
Figure 3.13 shows that proteins of the predicted size were generated in HEK293 cells 
transfected with the pcDNA3.1-mERα expression construct purified from clone 4 and 6 (see 
lane 7 and 8). Low but detectable mERα expression was observed in 603B cells transfected 
with the pcDNA3.1-mERα expression construct (lane 3 and 4) but also in cells transfected 
with an empty pcDNA3.1 construct (lane 2). This suggests that mERα protein may be 
endogenously expressed in 603B cells or that transfection induced the expression of mERα or 
a protein of similar size. The mERα was not detectable in HEK293 cells transfected with an 
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empty pcDNA3.1 expression construct (lane 6) or in non-transfected HEK293 and 603B cells 
(lane 1 and 5). The human breast cancer cell line MCF-7 as well as mouse uterine and liver 
tissue, known to express high levels of the ERα, were included as controls.  
 
Figure 3.13 Analysis for ectopical expression of the mERα protein. Western Blot for the 
expression of the mERα protein in 603B and HEK293 cells transiently transfected with the expression 
construct coding for either the mERα from clone 4 (C4) or clone 6 (C6) or empty vector as control 
(20 µg total protein/lane). Theoretical molecular weight of ERα: 67 kDa. 
 
3.3.3.b 603B cells transfected with the pcDNA3.1-mERα construct do not 
significantly respond to E2 
Following confirmation that the mERα protein is ectopically expressed in 603B cells, 
recombinant mERα protein was tested for functional activity by reporter gene assay. Figure 
3.14 shows that transfected 603B cells expressing the mERα from either clone 4 (C4) or clone 
6 (C6) did not significantly respond to treatment with 10 nM E2. Although the combined 
treatment of E2 + 100 nM ICI182,780 reduced luciferase activity over E2-only treated cell 
from both clone 4 and 6, the decrease was not significant. Although cells transfected with an 
empty expression construct were shown to express the mERα/a protein of similar size by 
Western blot (see Figure 3.13), they show lower levels of basal luciferase activity compared 
to cells transfected with the pcDNA3.1-mERα expression constructs (Figure 3.14). This 
suggests that potentially endogenously expressed mERα is not functional and that 
recombinant mERα is partially able to trans-activate the (ERE)3-pGL3promotor reporter 
construct when compared to cells transfected with an empty construct.  
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Figure 3.14 Testing of recombinant mERα protein for functional activity. (ERE)3-pGL3promotor 
luciferase reporter gene assay in 603B cells co-transfected with the expression constructs isolated from 
clone 4 (C4) or 6 (C6) coding for the mERα protein or an empty vector. Cells were treated with 
vehicle or 10 nM E2 (± 100 nM ICI182,780) for 24 hours followed by dual-luciferase assay. Mean and 
SD of n=3, typical of 3 separate experiments. Data are expressed in fold change versus mERα C4-
transfected cells treated with DMSO vehicle. Data was tested for statistical significance using 
Student’s t-test (two-tailed) with Holm-Bonferroni post-hoc modifications. 
3.3.3.c Testing different cell lines for mERα responsiveness  
Cell line-dependent differences in availability and functionality of co-activators and adaptor 
proteins required for ERα-mediated transcription of the reporter gene in response to 
oestrogens have been described (Klinge, 2000). To determine whether the lack of a significant 
response in 603B cells transfected with the mERα expression construct following exposure to 
E2 is due to the absence of co-factors necessary for ERα responsiveness, several other cell 
lines were transfected with the pcDNA3.1-mERα construct purified from clone 6 and 
examined for their ability to trans-activate the (ERE)3-pGL3promotor reporter construct 
compared to 603B cells. Cell lines tested were the mouse ductal LTPA cell line, the rat 
pancreatic acinar cell line AR42J-B13 (B13) as well as HEK293 cells, the latter because they 
have been shown to express high levels of recombinant mERα protein (see Figure 3.13). All 
cell lines were treated with 0.1% (v/v) DMSO vehicle and 10 nM E2 as well as with a range 
of oestrogens including the natural, less potent oestrogens oestrone (E1, 10 μM) and oestriol 
(E3, 10 μM), the synthetic oestrogen ethinyl estradiol (EE, 10 nM) and the known 
xenoestrogens butyl paraben (BP, 10 μM) and genistein (10 μM) with or without co-treatment 
with 100 nM ICI182,780. 
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Figure 3.15A demonstrates that recombinant mERα-expressing 603B cells show a significant 
increase in luciferase reporter gene activity in response to E1, butyl paraben and genistein 
compared to DMSO vehicle treated cells. The increase following exposure to butyl paraben 
and genistein – but not E1 - was reduced by co-treatment with 100 nM ICI182,780. 
ICI182,780 also reduced luciferase activity in DMSO vehicle treated cells compared to 
vehicle treated cells in the absence of ICI182,780 suggesting that recombinant mERα is 
partially active. E2, E3 and EE exposure did not result in a significant increase in reporter 
gene expression over DMSO vehicle treated cells. 603B cells transfected with an empty 
expression construct showed low basal luciferase activity compared to cells expressing the 
mERα with butyl paraben and genistein treatments causing an increase in luciferase activity 
over empty vector-DMSO vehicle treated cells. This increase in luciferase activity was not 
inhibited by co-treatment with ICI 182,780 suggesting that these compounds are able to trans-
activate the (ERE)3-pGL3promotor reporter construct independent of the mERα.  
A significant increase in luciferase reporter gene activity in response to treatment with E2, E1, 
butyl paraben and genistein was observed in LTPA cells transfected with the pcDNA3.1-
mERα construct. With the exception of E1, this increase was reduced by co-treatment with 
ICI182,780 (Figure 3.15B). Co-treatment with ICI182,780 also did not reduce luciferase 
activity over cells treated with E3 in the absence of the ER antagonist. E1 and E3 are less 
potent than E2 and thus were used at a higher concentration. At a concentration of 10 µM, 
however, it is likely E1 and E3 competitively displaced ICI182,780 from the mERα. This may 
account for why the ER antagonist did not reduce luciferase activity when co-treated with E1 
and E3. LTPA cells transfected with an empty expression vector show low basal luciferase 
activity compared to cell transfected with the mERα expression construct and do not 
significantly respond to treatment with the indicated (xeno)oestrogens.  
In the ER negative B13 cell line, treatment of recombinant mERα-expressing cells with E1 
caused a significant increase in luciferase activity which was reduced by co-treatment with 
100 nM ICI182,780 (Figure 3.15C). Treatment with the other indicated (xeno)oestrogens did 
not induce a significant response. Cells transfected with an empty expression construct show 
very low levels of basal luciferase activity compared to cells transfected with the mERα 
expression construct and treatment with oestrogens did not lead to an increase in luciferase 
activity.  
In HEK293 cells, cells transfected with the mERα expression construct show a significant 
increase in luciferase reporter gene activity following the treatment with E1 and butyl paraben, 
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the latter which was decreased by co-treatment with ICI182,780 (Figure 3.15D). Mouse ERα-
expressing HEK293 cells did not respond to E2 or any of the other indicated xeno(oestrogens). 
Control cells transfected with an empty construct show low levels of basal luciferase activity 
over mERα expressing cells and did not respond to treatment with (xeno)oestrogens. 
These data suggest that in general all of the cell lines employed possess co-factors required 
for mERα responsiveness since cells co-transfected with the expression construct coding for 
the mERα show higher basal luciferase activities compared to cells transfected with an empty 
construct. A mERα-mediated significant increase in luciferase reporter gene activity in 
response to treatment with E2 over DMSO vehicle treated cells, however, was only observed 
in LTPA cells, although the fold induction (1.32) was small  (Figure 3.15B). These findings 
indicate that the mERα is functionally active and that LTPA cells possess co-factors required 
for E2-induced trans-activtion of the (ERE)3-pGL3promotor reporter construct.  
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Figure 3.15 Examining different cell lines for mERα responsivness. (ERE)3-pGL3promotor 
luciferase reporter gene assay in (A) 603B (B) LTPA cells co-transfected with the pcDNA3.1 
expression construct encoding the mERα (pcDNA3.1-mERα (C6)) or an empty expression construct 
(empty vector) followed by treatment with a range of natural, synthetic and xeno-oestrogens as 
indicated (+/- ICI182,780) for 24 hours before dual-luciferase assay. Mean and SD of n=3, typical of 
two separate experiments. Data are expressed in fold change versus pcDNA3.1-mERα(C6)-transfected 
cells treated with DMSO vehicle in the absence of ICI182,780. *Significantly different (p<0.05) over 
equivalent expression construct DMSO vehicle-treated cells in the absence of ICI182,780  using One-
way ANOVA with Dunnett’s post-hoc modifications. #Significantly different (p<0.05) versus 
equivalent treatments in the absence of ICI182,780 using the Student’s t-test (two-tailed) with Holm-
Bonferroni post-hoc modifications. BP, butyl paraben. 
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Figure 3.15 contd. Examining different cell lines for mERα responsivness. (ERE)3-pGL3promotor 
luciferase reporter gene assay in (C) B13 and (D) HEK293 cells co-transfected with the pcDNA3.1 
expression construct encoding the mERα (pcDNA3.1-mERα (C6)) or an empty expression construct 
(empty vector) followed by treatment with a range of natural, synthetic and xeno-oestrogens as 
indicated (+/- ICI182,780) for 24 hours before dual-luciferase assay. 
 
3.3.3.d Co-transfecting mERα-expressing LTPA cells with the 3XERE TATA luc 
reporter gene construct increases their response to E2 
Since 603B cells did not respond to treatment with E2 and the response of mERα-expressing 
LTPA cells to E2 was small, it was examined whether this response could be improved by 
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using a different ERE reporter gene construct. The construct 3XERE TATA luc was 
employed as it has previously been shown to respond to mERα activation (La Sala et al., 
2010). Compared to the (ERE)3-pGL3promotor construct, the ERE of the 3XERE TATA luc 
construct contains a different nucleotide spacer sequence as demonstrated in Figure 3.16. 
Spacer sequences have been shown to determine transcriptional responses (Shu et al., 2010).  
 
Figure 3.16 ERE of the (ERE)3-pGL3promotor and 3XERE TATA luc reporter constructs. 
  
To test and compare the 3XERE TATA luc reporter construct to the previously used (ERE)3-
pGL3promotor reporter construct, LTPA and 603B cells were transfected with either the 
3XERE TATA luc or the (ERE)3-pGL3promotor construct, the expression construct coding 
for the mERα or an empty construct, and the RL-TK control vector before treatment with 0.1% 
(v/v) DMSO vehicle or 10 nM E2 ( ± 100 nM ICI182,780) for 24 hours and dual-luciferase 
assay. 
Figure 3.17A demonstrates that mERα-expressing 603B cells co-transfected with the (ERE)3-
pGL3promotor reporter construct do not significantly respond to treatment with E2 over 
DMSO vehicle treated cells. Similarly, in 603B cells co-transfected with the 3XERE TATA 
luc construct, treatment with E2 did not result in a significant increase in luciferase reporter 
gene expression over vehicle treated cells (Figure 3.17B). As seen with both reporter 
constructs, ICI182,780 significantly reduced luciferase reporter gene activity over DMSO 
vehicle treated cells suggesting that the mERα is capable of trans-activating both reporter 
constructs in 603B cells in the absence of a ligand. ICI182,780 also reduced luciferase 
reporter gene activity over E2 treated cells. Control 603B cells transfected with an empty 
expression construct show lower levels of basal luciferase activity in both (ERE)3-
pGL3promotor (Figure 3.17A) and 3XERE TATA luc (Figure 3.17B) co-transfected cells 
confirming that the increase in luciferase reporter gene expression as seen in cells transfected 
with the mERα-pcDNA3.1 construct is mediated by the mERα.  
In LTPA cells, co-transfection of the mERα-pcDNA3.1 construct with the (ERE)3-
pGL3promotor construct resulted in a significant increase in luciferase reporter gene activity 
in response to treatment with E2 (Figure 3.17C). This response was further increased when 
the (ERE)3-pGL3promotor construct was replaced by the 3XERE TATA luc construct (Figure 
5’ - GGTCA  CAG TGACC - 3’ 3XERE TATA luc
5’ - GGTCA  ATT TGACC - 3’ (ERE)3-pGL3promotor
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3.17D). ICI182,780 significantly reduced luciferase reporter gene activity over DMSO vehicle 
treated cells in both (ERE)3-pGL3promotor and 3XERE TATA luc reporter construct co-
transfected cells suggesting that the mERα is capable of trans-activating both reporter 
constructs in LTPA cells in the absence of a ligand. ICI182,780 also reduced luciferase 
reporter gene activity over E2 treated cells confirming that the E2-induced increase in 
luciferase reporter gene activity is mediated by the mERα. LTPA control cells co-transfected 
with an empty expression construct and the (ERE)3-pGL3promotor reporter construct show an 
increase in luciferase reporter gene expression in response to E2 which, however, was not 
decreased by co-treatment with ICI182,780 (Figure 3.17C). LTPA cells co-transfected with an 
empty expression construct and the 3XERE TATA luc reporter construct show very low 
levels of basal luciferase activities and do not respond to treatment with E2 (Figure 3.17D). 
Considered together, these data suggest that recombinant mERα is functionally active in 
LTPA, but not in 603B cells. The greatest mERα-mediated response following exposure to E2 
can be seen in LTPA cells when co-transfected with the 3XERE TATA luc reporter construct. 
Therefore, LTPA cells in combination with the 3XERE TATA luc construct were used to test 
for activation of the mERα in vitro.   
 
 
 
 110 
 
 
Figure 3.17 Examining the response of the (ERE)3-pGL3promotor reporter construct and the 
3XERE TATA construct to mERα activation in 603B and LTPA cells. 603B cells were co-
transfected with the expression construct encoding the mERα or an empty construct and with (A) the 
(ERE)3-pGL3promotor reporter construct or (B) the 3XERE TATA luc reporter construct before 
treatment with DMSO vehicle or 10 nM E2 (+/- 100 nM ICI182,780) for 24 hours and dual-luciferase 
assay. LTPA cells were co-transfected with the expression construct encoding the mERα or an empty 
construct and with (C) the (ERE)3-pGL3promotor reporter construct or (D) the 3XERE TATA luc 
reporter construct before treatment with DMSO vehicle or 10 nM E2 (+/- 100 nM ICI182,780) for 24 
hours and dual-luciferase assay. Mean and SD of n=3, typical of 2 separate experiments. Data are 
expressed in fold change versus pcDNA3.1-mERα -transfected cells treated with DMSO vehicle in the 
absence of ICI182,780. * Significantly different  (p<0.05) over equivalent epression construct DMSO 
vehicle-treated cells in the absence of ICI182,780. #Significantly different versus equivalent 
treatments in the absence of ICI182,780 using the Student’s t-test (two-tailed) with Holm-Bonferroni 
post-hoc modifications.  
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3.3.3.e The mERα is ectopically expressed in LTPA cells 
To verify that the mERα construct produces protein in LTPA cells, LTPA cells were 
transiently transfected with purified pcDNA3.1 plasmid DNA containing the mERα cDNA 
insert and expression of recombinant protein was examined by Western Blot and 
immunocytochemical staining.  
Figure 3.18A demonstrates that a protein of the predicted size was generated in HEK293 cells 
(lane 6) and low but detectable protein expression was observed in LTPA cells (lane 3). 
Positive controls MCF7 and mouse uterus show high levels of ERα expression. ERα protein 
was undetectable in LTPA and HEK293 controls transfected with an empty pcDNA3.1 
expression construct (lane 2 and 5) an in non-transfected cells (lane 1 and 4).  
Immunocytochemical staining confirms that the mERα is ectopically expressed in HEK293 
and on a lower level in LTPA cells transiently transfected with the pcDNA3.1-mERα 
expression constructs, exhibiting nuclear localisation. Mouse ERα protein was not detected in 
LTPA and HEK293 control cells transfected with an empty pcDNA3.1 construct (Figure 
3.18B).  
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Figure 3.18 Analysis for ectopical expression of the mERα protein in LTPA cells. (A) Western 
Blot for the expression of the mERα protein in LTPA and HEK293 control cells transiently transfected 
with the expression construct coding for the mERα cDNA sequence or empty vector as control (20 µg 
total protein/lane). Theoretical molecular weights: mERα, 67 kDa; GAPDH, 39 kDa (B) 
Immunocytochemical staining for the expression of the mERα protein in LTPA and HEK293 control 
cells transiently transfected with the expression construct encoding the mERα cDNA sequence or 
empty vector as control. Scale bar: 50 μm. 
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3.3.3.f Confirmation of correct functioning of recombinant mERα protein in LTPA 
cells when co-transfected with the 3XERE TATA luc construct 
To verify the results that the mERα construct in combination with the 3XERE TATA luc 
reporter construct functions correctly, LTPA cells were transfected with the pcDNA3.1 
expression construct coding for the mERα, an empty expression construct or a construct 
coding for the c/EBPβ for the purpose of investigating squelching effects and their response to 
E2 was examined. Figure 3.19 shows that the mERα was activated by 10 nM E2. Cells 
transfected with an empty expression construct or the construct coding for the c/EBPβ gene 
show a reduced level of basal luciferase activity compared to cells transfected with the 
pcDNA3.1-mERα expression construct and they do not respond to 10 nM E2 treatment.  
 
Figure 3.19 Testing the mERα expression construct for functional activity in LTPA cells. 
Luciferase reporter gene (3XERE TATA luc) assay in LTPA cells co-transfected with expression 
constructs coding for the mERα or control constructs as indicated. Cells were treated with 0.1% 
DMSO vehicle or 10 nM E2 (± ICI182,780) for 24 hours followed by dual-luciferase assay. Mean and 
SD of n=3, typical of 3 separate experiments. Data are expressed in fold change versus mERα-
transfected cells treated with DMSO vehicle. *Significantly different (p<0.05) over the equivalent 
expression vector transfected cells treated with DMSO vehicle; #Significantly different versus 
equivalent treatments in the absence of ICI182,780 using Student’s t-test (two-tailed) with Holm-
Bonferroni post-hoc modifications.  
 
3.3.3.g Recombinant mERα trans-activates the 3XERE TATA luc reporter construct in 
a dose-dependent manner 
Dose-dependent activation of the mERα by E2 was investigated. LTPA cells expressing 
recombinant mERα in combination with the 3XERE TATA luc construct were treated with 
increasing concentrations of E2 (10 pM – 10 μM). Figure 3.20 demonstrates that the mERα 
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was activated in a dose-dependent manner, whereas control cells transfected with an empty 
expression construct did not respond to E2 at any concentration.  
These results suggest that recombinant mERα protein in combination with the 3XERE TATA 
luc construct functions correctly and therefore, this system was used for all further 
experiments testing for mERα activation. 
 
Figure 3.20 E2 activates the mERα in a dose-dependent manner. Luciferase reporter gene (3XERE 
TATA luc) assay in LTPA cells co-transfected with the pcDNA3.1 expression constructs coding for 
the mERα or an empty control construct. Cells were treated with increasing concentrations of E2 
(vehicle: 0.1% DMSO) for 24 hours followed by dual-luciferase assay. Mean and SD of n=3, typical 
of 3 separate experiments. Data are expressed in fold change versus the equivalent expression vector 
transfected DMSO vehicle-treated cells. *Significantly different (p<0.05) over the equivalent 
expression vector transfected cells treated with DMSO vehicle using One-way ANOVA with 
Dunnett’s post-hoc modifications. 
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3.4. Discussion 
Data in this chapter has demonstrated that a mouse-based in vitro trans-activation reporter 
gene assay capable of examining transcriptional activities of recombinant mERα, mERβv1 
and the mERβv2 proteins was successfully developed.  
Although a number of in vitro assays exist that allow for chemicals to be tested for interaction 
with the ER and modulation of ER signalling, cell-based reporter gene trans-activation assays 
are commonly employed as they allow for both agonistic and antagonistic activities of 
xenobiotics to be detected. Cell-based reporter gene assays require the use of a cell line 
expressing the ER, either endogenously or recombinantly transfected.  
Since data in this chapter has shown that the mouse cell lines 603B and LTPA do not express 
detectable levels of the ERs (Figure 3.1, Figure 3.2), the mERα, mERβv1 and mERβv2 
cDNAs were cloned for ectopical expression of the ER proteins in these cell lines. 
Recombinant mERα, mERβv1 and mERβv2 protein expression in LTPA (mERα, Figure 3.18) 
and 603B (mERβ, Figure 3.8) cells was low compared to transfected control HEK293 cells, 
likely because data have shown that 603B and LTPA cells have low transfection efficiencies 
when using Effectene transfection reagent which, however, resulted in highest transfection 
efficiencies among all transfection methods tested (Figure 3.7).  
Testing for functional activity of the generated pcDNA3.1-mER expression constructs has 
shown that 603B cells transfected with the construct coding for the mERβv1 trans-activated 
the (ERE)3-pGL3promotor in the absence of E2, suggesting that the mERβv1 is partially 
constitutively active (Figure 3.9). Treatment with E2, however, further significantly induced 
luciferase reporter gene expression over vehicle treated cells confirming that recombinant 
mERβv1 is functionally active and that 603B cells possess co-factors required for mERβv1 
responsiveness. 603B cells expressing recombinant mERβv2 appeared to almost fully trans-
activate the (ERE)3-pGL3promotor reporter construct in the absence of E2 and treatment with 
ICI182,780 reduced luciferase reporter gene activity over vehicle treated cells to levels similar 
as seen in mERβv1-expressing cells treated with the ER antagonist. E2 exposure further 
activated recombinant mERβv2 over vehicle treated cells although the fold induction was 
small (Figure 3.9). These data suggest that recombinant mERβv2 protein is nearly completely 
constitutively active in vitro.  
Complete cell culture media generally contain a number of oestrogenic compounds and 
steroid hormones which could account for activation of the mERβ proteins under normal 
culture conditions. Culture of recombinant mERβv1 and mERβv2 expressing cells in media 
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supplemented with stripped serum, however, resulted in similar reporter gene activities as 
seen in cells grown in ‘normal’ medium (Figure 3.11) suggesting that background oestrogenic 
chemicals are not likely to be responsible for the observed constitutive activities of the mERβ 
proteins.  
Further investigations into whether recombinant mERβv2 is constitutively active have shown 
that following de-activation with ICI182,780, the mERβv2 protein is activated by E2 in a 
dose-dependent manner (Figure 3.12). In mERβv2-expressing cells that were, following de-
activation, treated with a range of E2 concentration in the presence of 100 nM ICI182,780, a 
significant increase in reporter gene activity was observed at a E2 concentration of 10 nM. 
ICI182,780 is a competitive antagonist and these data indicate that at 10 nM, E2 
competitively displaces ICI182,780 from the mERβv2. In comparison, mERβv2-expressing 
cells that were, following pre-treatment with ICI182780, treated with E2 in the absence of the 
ER antagonist show a significant response to E2 at a much lower concentration (100 pM), 
likely because E2 does not have to compete with ICI182,780 for binding and activation of the 
mERβv2. All in all these data confirm that the mERβv2 protein is near complete 
constitutively active in vitro in this assay and that activation of the protein by oestrogenic 
compounds can be examined by first de-activating the mERβv2 with ICI182,780 followed by 
treatment with the compound of interest. 
A reason as to why the mERβv1 protein exhibits partial and the mERβv2 nearly complete 
constitutive activity in this assay may be because they are activated in response to growth 
factor signalling. Interactions between oestrogens and growth factors play important roles in 
cell proliferation and tumour growth in oestrogen-mediated cancers in the mammary gland 
and uterus (Hayashi et al., 2003). It has been reported that in ovariectomized mice actions of 
oestrogens can be mimicked by epidermal growth factor (EGF) (Nelson et al., 1991; Ignar-
Trowbridge et al., 1992), an effect abolished in ERα knock-out mice (Curtis et al., 1996). 
Several studies employing ERE-containing reporter gene constructs have confirmed that 
growth factors can exert their actions through the ER. These studies have described reporter 
gene activities in the absence of oestrogen in a number of cell lines which were mediated by 
growth factors such as EGF (Ignar-Trowbridge et al., 1993; Bunone et al., 1996; El-Tanani 
and Green, 1997)), transforming growth factor alpha (TGF-α) (Ignar-Trowbridge et al., 1996) 
insulin-like growth factor-1 (IGF-1) (Ma et al., 1994; Newton et al., 1994) and several others 
(Ishida et al., 2010). Growth factor-dependent activation of the ERs is largely mediated by 
direct phosphorylation carried out by a number of growth factor receptor tyrosine kinases 
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leading to stimulation of the ligand-independent transcriptional potential of the ERs (Smith, 
1998; Ali and Coombes, 2002). 
To explain the differences in transcriptional activity between the mERβv1 and the mERβv2, 
their structural properties were compared. According to the National Centre for 
Biotechnology Information (NCBI), the mERβv2 lacks an in-frame exon in the coding region 
creating a protein lacking 18 amino acids (383 – 400) in the ligand binding domain compared 
to mERβv1. This deletion may affect the type and affinity of ligands capable of binding to the 
mERβv2 which is likely to account for the differences in transcriptional activity observed 
between the two mERβ isoforms. Constitutive activity of the mERβv2 has not been reported 
elsewhere. Interestingly, in the literature the mERβv2 is commonly described to contain an 18 
amino acid insertion in the ligand binding domain (Lu et al., 1998; Lu et al., 2000; Zhao et al., 
2005) which is opposite to the information given on NCBI which states that the mERβv2 
contains an 18 amino acid deletion. Protein sequence alignments of the mERβv1 and mERβv2 
with the human ERβ wild type (hERβ) (Appendix D) show that there is greater sequence 
homology between the mERβv2 and the hERβ than there is between the mERβv1 and the 
hERβ. Indeed, the mERβv1 contains a 18 amino acid insertion compared to the hERβ 
indicating that the mERβv1 as referred to on NCBI is regarded as the mERβ isoform 2 (ERβ2) 
in the literature whereas the mERβv2 on NCBI is considered to be the mouse ERβ wild type 
or ERβ isoform 1 (ERβ1). Information regarding the mouse ER proteins as seen on NCBI and 
the data found in the literature is summarised in Table 3.1.  
 
 
  
1
1
8
 
GENE NCBI ref mRNA NCBI ref protein 
Our 
nomenclature 
Human 
orthologue 
Comments 
Esr1 
NM_007956.5 
Transcript Variant: This 
variant (1) encodes the 
longer isoform (1). 
Variants 1, 2 and 3 encode 
the same protein. 
NP_031982.1  
Estrogen receptor 
isoform 1 [Mus 
musculus] – from 
transcript variant 1 
mERα hERα 
First mER to be identified and cloned (White et al., 1987). Orthologue 
identified in rat (Koike et al., 1987) and human (Green et al., 1986; Greene 
et al., 1986). 
Esr2 
NM_207707.1 
Transcript Variant: This 
variant (1) encodes the 
longer isoform (1). 
NP_997590.1 
Estrogen receptor 
beta isoform 1 [Mus 
musculus] 
mERβv1  
Identified to contain 54 nucleotides inserted in frame between exon 5 and 6 
compared to “wild type” mER (or “ERβ1”), no equivalent of this transcript 
was detected in any of the four human tissues analysed (Lu et al., 1998).  
Orthologue identified in rat - termed ERβ2 - bound estradiol with a lower 
affinity (Kd 5.1 nM) than either ERα (0.19 nM) or “ERβ1” (0.14 nM) and 
activated transcription in response to estradiol but at a 1000-fold greater 
estradiol concentration than for “ERβ1” (Chu and Fuller, 1997; Petersen et 
al., 1998). Recombinant mERβ2 protein had markedly reduced ligand 
binding (KD=17.7 +/- 4.7 nM) compared with “mERb1” (KD=0.56 +/- 0.19 
nM). Using a ‘novel raloxifene responsive’ gene reporter system estradiol 
and LY117018 activated both mERα and “mERβ1” on this promoter was 
identical, and this protein was only slightly less than that observed (Lu et al., 
2000). 
The binding affinity of estradiol was 14-fold higher for “mERβ1” than for 
“mERβ2”.  In contrast, raloxifene was dramatically (8-fold) “mERβ2” 
selective.  “mERβ2” showed significantly decreased estradiol-induced 
maximal transcriptional activity as compared to “mERβ1” (Zhao et al., 
2005). 
Esr2 
NM_010157.3 
Transcript Variant: This 
variant (2) lacks an in-
frame exon (54 
nucleotides) in the coding 
region, compared to 
variant 1. 
NP_034287.3 
Estrogen receptor 
beta isoform 2. 
This isoform lacks an 
internal segment 
(18 aa), compared to 
isoform 1. 
mERβv2 hERβ 
Originally discovered “wild type” mERβ, protein that shares, respectively, 
97% and 60% identity with the DNA- and ligand-binding domains of mERα 
(Tremblay et al., 1997).    
Orthologue detected in rat, termed “ERβ1” following detection of other ERβ 
variants (Kuiper et al., 1996; Petersen et al., 1998). Orthologue detected in 
human (Mosselman et al., 1996).   
Table 3.1 Summary of available data for the mER proteins. 
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Testing of the cloned pcDNA3.1-mERα expression construct for functional activity has 
shown that the greatest fold change in luciferase activity following E2 exposure over vehicle 
treated cells was observed in the mouse ductal LTPA cell line when co-transfected with the 
3XERE TATA luc reporter construct (Figure 3.17). A possible explanation for why a mERα-
mediated significant increase in luciferase activity following E2 exposure was observed in 
LTPA – but not in 603B or in any of the other tested cell lines could be due to differences in 
availability and functionality of co-activators and adaptor proteins required for ERα-mediated 
transcription of the reporter gene in response to E2. In a review paper, Klinge et al. (2001) 
have listed natural ERE sequences from 38 oestrogen-responsive genes along with their ER 
binding affinities and transcriptional activation in different cell lines. These data show that 
cell line-dependent differences in the amount of transcriptional activation from the same ERE 
exist suggesting that cell specific factors such as the quantity and type of co-activators 
available are involved in determining ER transcriptional activation (Klinge, 2001).  
Although an increase in luciferase reporter gene activity in mERα-expressing cells in response 
to E2 was only observed in LTPA cells, other tested cell lines have shown an increase in 
reporter gene activity in response to treatment with other oestrogenic compounds. For 
example, E1, butyl paraben and genistein but not E2 significantly induced luciferase reporter 
gene expression in 603B cells (Figure 3.15A). A response following exposure to E1 and butyl 
paraben – but not E2 – was also observed in HEK293 cells (Figure 3.15D). Binding of a 
ligand to the ER induces specific conformational changes which are ligand-specific. 
Depending on ER conformation, a different set of cofactor proteins required for 
transcriptional induction is recruited to interact with the ER and the transcription machinery 
determining ER transcriptional responses (Yi et al., 2002). 
Not only does the type of ligand determine ER-mediated transcriptional responses, but also 
the ERE sequence found in promotor regions of oestrogen responsive genes. Mouse ERα-
expressing LTPA cells co-transfected with the (ERE)3-pGL3promotor reporter construct 
showed a significant increase in luciferase activity following treatment with E2 (Figure 
3.17C), however, this response was further enhanced by replacing the (ERE)3-pGL3promotor 
with the 3XERE TATA luc construct (Figure 3.17D). Both the (ERE)3-pGL3promotor and the 
3XERE TATA luc reporter constructs contain three copies of the minimal consensus ERE 
palindrome 5’-GGTCAnnnTGACC-3’ (n = any nucleotide). The reporter constructs, however, 
differ in their tri-nucleotide spacer sequence and immediate ERE flanking nucleotides. The 
3XERE TATA luc reporter construct contains three copies of the vitellogenin ERE with the 
sequence 5’-GGTCA CAG TGACC-3’ whereas the sequence for the (ERE)3-pGL3promotor 
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construct is 5’-GGTCA ATT TGACC-3’. Shu et al. (2010) have reported that EREs with a 
tri-nucleotide spacer sequence of C(A/T)G are enriched within the genome and gel shift as 
well as reporter gene assays have shown that ERα binding affinity to EREs is highest for the 
spacer sequence C(A/T)G with stronger E2-stimulated transcriptional responses compared to 
other tri-nucleotide spacers. ER-ERE binding affinity is not only determined by the spacer 
sequence but also by the immediate ERE flanking nucleotides. ERα binds with highest 
affinity to the Xenopus vitellogenin A2 ERE compared to other natural EREs (Klinge, 2001). 
The xenopus vitellogenin A2 gene has a 19 bp palindromic ERE with 14 of the directly 5’ 
flanking nucleotides being either A or T (70% AT rich) (Walker et al., 1984). DNA enriched 
with A and T nucleotides is reported to be more readily deformed which is believed to be 
required for facilitation of interaction between the transcription machinery located at different 
sites (Kerppola and Curran, 1991). The 14 5’-flanking nucleotides of the 3xERE TATA luc 
reporter construct contain 70% A/T nucleotides (5’-TGATATCAGATCTA-3’). In 
comparison, 5’ flanking nucleotides of the (ERE)3-pGL3promotor construct contain less than 
30% A or T nucleotides (5’-GGTACCGAGCTCGG-3’). These differences between the 
reporter constructs could explain why an enhanced transcriptional activity is seen in LTPA 
cells co-transfected with the 3XERE TATA luc reporter construct compared to cells co-
transfected with the (ERE)3-pGL3promotor construct. The expression of recombinant mERα 
protein (Figure 3.18) and E2-mediated dose-dependent activation of the mERα in LTPA cells 
has been shown (Figure 3.20) confirming that the pcDNA3.1- mERα expression construct 
creates functional protein.  
Overall, data in this chapter demonstrate that a mouse-based in vitro trans-activation reporter 
gene assay to test for activation or inhibition of the mERα, mERβv1 and mERβv2 proteins 
has been successfully developed. Using this assay, a variety of compounds can be tested for 
oestrogenic activity in mice. As a result this assay will assist in determining which ER-
targeting chemicals can be used to examine the potential adverse effects that oestrogenic 
chemicals may have in vivo in mice.  
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Chapter 4. Oral tartrazine exposure causes hepatic and gastrointestinal 
inflammation in vivo independent of the ER 
A number of xenoestrogens are found in our diet and these chemicals can both be natural (e.g., 
isoflavones (Kuiper et al., 1998)) or man-made (e.g., bisphenol A (Laws et al., 2000)). A 
platform of human-based reporter gene in vitro assays exist enabling chemicals to be rapidly 
screened for potential oestrogenic activity in humans. Using these assays, the food additive 
tartrazine has previously been shown to have xenoestrogenic properties since it activated the 
human ERα in vitro (Datta and Lundin-Schiller, 2008; Axon et al., 2012). 
Tartrazine (E102, also known as FD & C Yellow No. 5) is a synthetic yellow azo dye 
commonly found in a variety of food items and pharmaceuticals. As stated by the European 
Food Safety Agency (EFSA), the food dye consists of 3-carboxy-5-hydroxy-1-(4'-
sulphophenyl)-4-(4'-sulphophenylazo)pyrazole trisodium salt with sodium chloride and/or 
sodium sulfate as the principal uncoloured components. The purity is at least 85% of total 
colouring matter with the remaining 15% being sodium chloride/sulfate, water insoluble 
matter, subsidiary colouring matters and other organic contaminants such as 5-oxo-1-(4-
sulphophenyl)-2-pyrazoline-3-carboxylic acid (OSPCA) (EFSA, 2009). 
The food colourant has a history of causing intolerance reactions in a small fraction of the 
exposed population estimated to be 0.12% (Elhkim et al., 2007). Reported intolerance 
reactions to tartrazine often comprise of urticaria and bronchoconstriction and have been 
stated to occur more likely in individuals with aspirin-intolerance (Freedman, 1977; Weber et 
al., 1979; Rajan et al., 2014). Tartrazine is also thought to cause hyperactivity in children 
(Schab and Trinh, 2004).  
The safety of tartrazine was first assessed in 1966 by the Joint FAO/WHO Expert Committee 
on Food Additives (JECFA) specifying an Acceptable Daily Intake (ADI) of 0-7.5 mg/kg 
body weight/day (JECFA, 1966). Although the publication of new studies lead to the re-
assessment of tartrazine safety by the EU Scientific Committee for Food (SCF) in 1975 and 
1984, the Nordic Council of Ministers in 2002 and most recently, by the European Food 
Safety Authority (EFSA) in 2009, the previously established ADI of 7.5 mg/kg body 
weight/day remained (EFSA, 2009).  
Although limited data regarding the metabolism of tartrazine is available, the food dye when 
administered orally is understood to be mainly metabolised by the intestinal microflora to 
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sulfanilic acid (SA) (which may further be subject to N-acetylation (SA-NAc)) and, via 1-(4-
sulfophenyl)-3-carboxy-4-amino-5-pyrazolone (SCAP), to sulfophenylhydrazine (SPH) (see 
Figure 4.1). These metabolites are predominantly excreted in the urine and only a minor 
proportion (<5%) of intact tartrazine is absorbed (Jones et al., 1964; Roxon et al., 1967; Ryan 
et al., 1969a; Ryan et al., 1969b). I.p. injection of 2.4 mg/kg bw of 14C-tartrazine was found 
to result in excretion of unchanged tartrazine since 64-96% of the dose was recovered intact in 
the urine within 24 hours in rats and rabbits and no other metabolites were detected.  I.p. 
administration of higher doses led to urinary detection of free and conjugated sulfanilic acid 
(Jones et al., 1964). 
Since oestrogens (and therefore potentially xenoestrogens) are cholestatic, it was hypothesised 
that tartrazine is an activator of the mouse ER and that, if significant absorption occurs, oral 
tartrazine administration will result in cholestasis in mice. 
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Figure 4.1 Tartrazine metabolism. Tartrazine is metabolised by intestinal microorganisms to 
sulfanilic acid (SA) and, via 1-(4-sulfophenyl)-3-carboxy-4-amino-5-pyrazolone (SCAP), to 4-
sulfophenylhydrazine (SPH). Sulfanilic acid may further be N-acetylated (SA-NAc).  
 
  
Tartrazine (T)
Sulfanilic acid (SA) 1-(4-sulfophenyl)-3-carboxy-4-
amino-5-pyrazolone (SCAP)
Sulfanilic acid N-acetate (SA-NAc) 4-sulfophenylhydrazine (SPH)
+
+3H +4e-
-NH
+H2O
Azo reduction – GI tract
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4.1. In vitro screening of tartrazine, its major gut-derived metabolites and a 
contaminant for mouse ER transcriptional oestrogenic activity 
To test the hypothesis that tartrazine is an activator of the mouse ERs, the food dye, its major 
gut-derived metabolites and a contaminant were examined for oestrogenic activity using the 
mouse-based reporter gene assay developed in Chapter 3. 
4.1.1. Tartrazine, metabolites and a contaminant are not activators of the mouse ERs 
4.1.1.a Tartrazine, metabolites and a contaminant are not activators of the mERα 
To determine if tartrazine, its gut derived metabolites and a contaminant are activators of the 
mERα, LTPA cells were transiently transfected with the pcDNA3.1 expression construct 
coding for the mERα, the 3XERE TATA luc reporter construct and the RL-TK control 
construct followed by treatment with E2 or tartrazine, metabolites and the contaminant 
starting at a concentration of 100 pM and increasing serially by a factor of 10 to a maximum 
of 100 µM (E2: maximum of 10 µM) and dual-luciferase assay.  
Figure 4.2 demonstrates that E2 activated the mERα in a dose-dependent manner with a 
significant increase in reporter gene expression detectable at concentrations as low as 100 pM. 
There was no evidence for trans-activation of the reporter construct following exposure to 
tartrazine (T) or its main gut-derived metabolites sulfanilic acid (SA), 4-sulfophenylhydrazine 
(SPH) and 1-(4-sulfophenyl)-3-carboxy-4-amino-5-pyrazolone (SCAP) as well as the 
contaminant 5-oxo-1-(4-sulfophenyl)-2-pyrazoline-3-carcoxylic acid (OSPCA) at 
concentrations up to 100 µM. The metabolite sulfanilic acid N-acetate (SA-NAc) induced a 
statistically significant small increase in reporter gene activity at 100 pM, 100 nM and 1 µM 
which, however, was not dose-dependent and therefore likely not biologically significant.  
These data suggest that tartrazine, its metabolites and a contaminant are not activators of the 
mERα.  
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Figure 4.2 Tartrazine, its gut-derived metabolites and a contaminant are not activators of the 
mERα. Luciferase reporter gene assay in LTPA cells transiently transfected with the pcDNA3.1 
expression constructs coding for the mERα, the 3XERE TATA luc reporter construct and the RL-TK 
control vector for 24 hours before treatment with increasing concentrations of (A) E2, tartrazine and 
the gut-derived tartrazine metabolites sulfanilic acid (SA), (B) 4-sulfophenylhydrazine (SPH), 1-(4-
sulfophenyl)-3-carboxy-4-amino-5-pyrazolone (SCAP), sulfanilic acid N-acetate (SA-NAc) as well as 
the tartrazine contaminant 5-oxo-1-(4-sulfophenyl)-2-pyrazoline-3-carcoxylic acid (OSPCA) for 24 
hours and dual-luciferase assay. Mean and SD of n=3, typical of two separate experiments. Data are 
expressed in fold change versus vehicle-treated cells (vehicle: 0.1% (v/v) DMSO (E2; tartrazine) or 
0.1% (v/v) 1x PBS (SA; SPH; SCAP; SA-NAc; OSPCA)). *Significantly different (p<0.05) over cells 
treated with DMSO or 1x PBS vehicle using One-way ANOVA with Dunnett’s post-hoc 
modifications. 
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4.1.1.b Tartrazine, metabolites and a contaminant are not activators of the mERβ 
Since tartrazine and its metaboliotes did not activate the mERα, it was investigated whether 
these compounds are activators of the mERβ proteins. Activation of the mERβv1 was 
examined first. 603B cells were transiently transfected with the pcDNA3.1 expression 
construct coding for the mERβv1, the (ERE)3-pGL3promotor reporter construct and the RL-
TK control construct followed by treatment with E2, tartrazine, its metabolites and a 
contaminant at concentrations ranging from 100 pM to 100 µM (E2: maximum of 10 µM) and 
dual-luciferase assay.  
Figure 4.3 shows that E2 activated recombinant mERβv1 in a dose-dependent manner at 
concentrations as low as 1 nM whereas treatment with tartrazine, its gut-derived metabolites 
SA, SPH, SCAP, SA-NAc and the contaminant OSPCA did not result in dose-dependent 
trans-activation of the reporter construct at concentrations up to 100 μM. These data indicate 
that these compounds are not activators of the mERβv1. 
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Figure 4.3 Tartrazine, its gut-derived metabolites and a contaminant are not activators of the 
mERβv1. Luciferase reporter gene assay in 603B cells transiently transfected with the pcDNA3.1 
expression constructs coding for the mERβv1, the (ERE)3-pGL3promotor reporter construct and the 
RL-TK control vector for 24 hours before treatment with increasing concentrations of (A) E2, 
tartrazine and the gut-derived tartrazine metabolites sulfanilic acid (SA) and (B), 4-
sulfophenylhydrazine (SPH), 1-(4-sulfophenyl)-3-carboxy-4-amino-5-pyrazolone (SCAP), sulfanilic 
acid N-acetate (SA-NAc) as well as the tartrazine contaminant 5-oxo-1-(4-sulfophenyl)-2-pyrazoline-
3-carcoxylic acid (OSPCA) for 24 hours and dual-luciferase assay. Mean and SD of n=3, typical of 
two separate experiments. Data are expressed in fold change versus vehicle-treated cells (vehicle: 
0.1% (v/v) DMSO (E2; tartrazine) or 0.1% (v/v) 1x PBS (SA; SPH; SCAP; SA-NAc; OSPCA)). 
*Significantly different (p<0.05) over cells treated with DMSO or 1x PBS vehicle using One-way 
ANOVA with Dunnett’s post-hoc modifications. 
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To examine if tartrazine, metabolites and the contaminant are activators of the mERβv2, 603B 
cells were transiently transfected with the pcDNA3.1-mERβv2 expression construct, the 
(ERE)3-pGL3promotor reporter construct and the RL-TK control construct. Since data have 
shown that recombinant mERβv2 protein exhibits constitutive activity in vitro in this assay 
(Figure 3.12, Chapter 3), mERβv2-expressing 603B cells were pre-treated with 100 nM 
ICI182,780 followed by several wash steps to de-activate the mERβv2 and to render the 
protein susceptible to potential activation by subsequent exposure to E2 and tartrazine and its 
metabolites.  
Figure 4.4 demonstrates that treatment with E2 resulted in a dose-dependent increase in 
reporter gene activity at concentrations as low as 100 pM. There was no evidence for trans-
activation of the reporter construct following exposure to tartrazine and its main gut-derived 
metabolites SA, SPH, SCAP, and SA-NAc as well as the contaminant OSPCA at 
concentrations up to 100 µM suggesting that these compounds are not activators of the 
mERβv2.  
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Figure 4.4 Tartrazine, its gut-derived metabolites and a contaminant are not activators of the 
mERβv2. Luciferase reporter gene assay in 603B cells transiently transfected with the pcDNA3.1 
expression constructs coding for the mERβv2, the (ERE)3-pGL3promotor reporter construct and the 
RL-TK control vector for 24 hours. Cells were pre-treated with 100 nM ICI182,780 for 6 hours to 
inactivate constitutive mERβv2 transcriptional function followed by wash-out and treatment with 
increasing concentrations of (A) E2, tartrazine and the gut-derived tartrazine metabolites sulfanilic 
acid (SA) and (B) 4-sulfophenylhydrazine (SPH), 1-(4-sulfophenyl)-3-carboxy-4-amino-5-pyrazolone 
(SCAP), sulfanilic acid N-acetate (SA-NAc) as well as the tartrazine contaminant 5-oxo-1-(4-
sulfophenyl)-2-pyrazoline-3-carcoxylic acid (OSPCA) for 24 hours and dual-luciferase assay. Mean 
and SD of n=3, typical of two separate experiments. Data are expressed in fold change versus vehicle-
treated cells (vehicle: 0.1% (v/v) DMSO (E2; tartrazine) or 0.1% (v/v) 1x PBS (SA; SPH; SCAP; SA-
NAc; OSPCA)). *Significantly different (p<0.05) over cells treated with DMSO or 1x PBS vehicle 
using One-way ANOVA with Dunnett’s post-hoc modifications. 
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4.1.2. Tartrazine, its metabolites and a contaminant have no antagonistic effects on mER 
activity 
Xenoestrogens are often defined as chemicals with oestrogenic activity. ER antagonistic 
effects, however, can also result in disruption of natural oestrogen signalling causing adverse 
effects. Since tartrazine and its gut-derived metabolites did not activate the mER proteins, it 
was examined whether these compounds affect oestrogen signalling by exhibiting ER-
antagonistic effects.  
4.1.2.a Tartrazine, its metabolites and a contaminant are not antagonists of the mERα 
In order to determine if tartrazine, its metabolites and a contaminant are antagonists of the 
mERα, LTPA cells were transiently transfected with the pcDNA3.1 expression construct 
coding for the mERα, the 3XERE TATA luc reporter construct and the RL-TK control 
construct. This was followed by pre-treatment with the vehicle control, 100 nM of the ER 
antagonist ICI182,780 or tartrazine and its metabolites SA, SPH, SA-NAc and SCAP as well 
as the contaminant OSPCA (100 nM – 100 µM, serially increasing by a factor of 10) for 6 
hours. After 6 hours, cells were treated with ICI182,780, tartrazine or its metabolites at the 
indicated concentrations in the presence of 1 nM E2 (corresponding to the estimated half 
maximal effective concentration (EC50)) for 24 hours and Firefly and Renilla luciferase 
activities were determined by dual-luciferase assay.  
Figure 4.5 shows that exposure to 1 nM E2 in the absence of antagonist resulted in trans-
activation of the reporter construct over control vehicle treated cells which was reduced by 
co-treatment with 100 nM ICI182,780. Neither tartrazine, nor its metabolites or contaminant, 
inhibited the E2-dependent increase in reporter gene activity at concentrations up to 100 μM 
suggesting that these compounds are not antagonists of the mERα.  
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Figure 4.5 Tartrazine, its gut-derived metabolites and a contaminant are not mERα antagonists. 
Luciferase reporter gene assay in LTPA cells transiently transfected with the pcDNA3.1 expression 
constructs coding for the mERα, the 3XERE TATA luc reporter construct and the RL-TK control 
vector for 24 hours. Cells were pre-treated with 0.1% (v/v) control vehicle (DMSO or 1x PBS), 100 
nM of the ER antagonist ICI182,780 or with tartrazine and its metabolites sulfanilic acid (SA), 4-
sulfophenylhydrazine (SPH), 1-(4-sulfophenyl)-3-carboxy-4-amino-5-pyrazolone (SCAP), sulfanilic 
acid N-acetate (SA-NAc) as well as the tartrazine contaminant 5-oxo-1-(4-sulfophenyl)-2-pyrazoline-
3-carcoxylic acid (OSPCA) (100 nM – 100 μM) as potential mERα antagonists for 6 hours. Cells were 
then treated with vehicle, 100 nM of ICI182,780 or with tartrazine and its metabolites (100 nM – 100 
μM) in the presence of 1 nM E2 for 24 hours followed by dual-luciferase assay. Mean and SD of n=3, 
typical of two separate experiments. Data are expressed in fold change versus vehicle-treated cells 
(vehicle: 0.1% (v/v) DMSO (E2; tartrazine) or 0.1% (v/v) 1x PBS (SA; SPH; SCAP; SA-NAc; 
OSPCA)). *Significantly different (p<0.05) over cells treated with vehicle only using Student’s t-test 
(two-tailed). #Significantly different (p<0.05) over cells treated with 1 nM  E2 in the absence of ER 
antagonists using One-way ANOVA with Dunnett’s post-hoc test. 
 
4.1.2.b Tartrazine, its metabolites and a contaminant are not antagonists of the 
mERβv1 and mERβv2  
Since tartrazine, its gut-derived metabolites and a contaminant did not exhibit mERα 
antagonistic effects, it was examined whether these compounds are antagonists of the 
mERβv1 and mERβv2 proteins. 603B cells were transfected with the pcDNA3.1 expression 
construct coding for the mERβv1 or mERβv2, the (ERE)3-pGL3promotor reporter construct 
and the RL-TK control construct followed by pre-treatment with the control vehicle, 100 nM 
ICI182,780 or tartrazine and its metabolites SA, SPH, SA-NAc and SCAP as well as the 
contaminant OSPCA (100 nM – 100 µM, serially increasing by a factor of 10) for 6 hours. 
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Following pre-treatment, cells were treated with ICI182,780, tartrazine or its metabolites at 
the indicated concentrations in the presence of 1 nM E2 for 24 hours followed by dual-
luciferase assay. 
Figure 4.6A demonstrates that there was an E2-mediated increase in reporter gene activity in 
603B cells expressing recombinant mERβv1 over control vehicle treated cells which was 
decreased when co-treated with 100 nM ICI182,780. Treatment with tartrazine, its gut-
derived metabolites or the contaminant did not inhibit the E2-mediated increase in reporter 
gene expression at any tested concentration up to 100 µM suggesting that these compounds 
are not antagonist of the mERβv1. 
In 603B cells expressing recombinant mERβv2, E2 exposure (1 nM) resulted in trans-
activation of the reporter construct over control vehicle cells, a response that was inhibited by 
co-treatment with 100 nM ICI182,780 (Figure 4.6B). Tartrazine treatment resulted in a 
statistically significant decrease of E2-induced reporter gene activities at a concentration of 
10 μM, however, tartrazine did not exhibit antagonistic effects on mERβv2 activity in a dose-
dependent manner. There was no evidence for inhibition of E2-dependent trans-activation of 
reporter gene expression by the gut-derived tartrazine metabolites and the contaminant 
indicating that these compounds are not mERβv2 antagonists.     
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Figure 4.6 Tartrazine, its gut-derived metabolites and a contaminant are not mERβv1 and 
mERβv2 antagonists. Luciferase reporter gene assay in 603B cells transiently transfected with the 
(ERE)3-pGL3promotor reporter construct and the RL-TK control vector as well as with the pcDNA3.1 
expression constructs coding for (A) the mERβv1 or (B) the mERβv2. After transfection for 24 hours, 
cells were pre-treated with 0.1% (v/v) control vehicle (DMSO or 1x PBS), 100 nM of the ER 
antagonist ICI182,780 or with tartrazine and its metabolites sulfanilic acid (SA), 4-
sulfophenylhydrazine (SPH), 1-(4-sulfophenyl)-3-carboxy-4-amino-5-pyrazolone (SCAP), sulfanilic 
acid N-acetate (SA-NAc) as well as the tartrazine contaminant 5-oxo-1-(4-sulfophenyl)-2-pyrazoline-
3-carcoxylic acid (OSPCA) (100 nM – 100 μM) as potential mERα antagonists for 6 hours. Cells were 
then treated with vehicle, 100 nM of ICI182,780 or with tartrazine and its metabolites (100 nM – 100 
μM) in the presence of 1 nM E2 for 24 hours followed by dual-luciferase assay. Mean and SD of n=3, 
typical of two separate experiments. Data are expressed in fold change versus vehicle-treated cells 
(vehicle: 0.1% (v/v) DMSO (E2; tartrazine) or 0.1% (v/v) 1x PBS (SA; SPH; SCAP; SA-NAc; 
OSPCA)). *Significantly different (p<0.05) over cells treated with vehicle only using Student’s t-test 
(two-tailed). #Significantly different (p<0.05) over cells treated with 1 nM  E2 in the absence of 
antagonists using One-way ANOVA with Dunnett’s post-hoc test. 
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4.2. Tartrazine, its gut-derived metabolites and a contaminant of the food additive 
inhibit murine hepatic dopamine sulfotransferase  
Previous research has shown that i.p. injection of tartrazine caused a mild cholestatic liver 
injury in vivo in mice (Axon, Thesis 2012). Since data in this chapter indicate, however, that 
tartrazine, its gut-derived metabolites and a contaminant are not activators of the mouse ERs, 
it is likely that this injury occurred independent of the ER. In order to find a possible 
mechanism by which tartrazine caused a cholestatic injury, and considering the chemical 
structure of tartrazine and its metabolites, the ability of the food dye to inhibit 
sulfotransferases (SULTs) was investigated.  
SULTs are cytosolic enzymes which play an important role in the detoxification of various 
xeno- and endobiotic compounds including drugs, steroid hormones, bile salts and 
monoamine neurotransmitters (Weinshilboum et al., 1997). The SULT-mediated transfer of a 
sulfo group from a donor molecule, usually 3’-phosphoadenosine 5’-phosphosulfate (PAPS) 
to a compound to be metabolised often makes the acceptor molecule more water soluble 
rendering it less biologically active and promoting its excretion (Gamage et al., 2006). In 
terms of SULTs and cholestasis, SULT-mediated sulfation is critical for the detoxification of 
bile acids. If accumulation due to impaired SULT-mediated elimination occurs, bile acids 
may have toxic cholestatic effects in the liver (Leuschner et al., 1977). In addition, SULTs 
mediate the inactivation process of oestrogens; sulfonated oestrogens are unable to bind to 
and thus activate the ERs (Song, 2001). Since oestrogens are cholestatic, impaired 
inactivation can lead to a build-up of ‘active’ oestrogen in the liver which in turn may cause 
cholestasis (Strott, 1996). 
In order to examine if tartrazine, its gut-derived metabolites and a contaminant are inhibitors 
of murine hepatic SULTs, cytosolic (S9) fractions were prepared from wt C57Bl/6 mice and 
the ability of hepatic SULTs to transfer a radio-labelled sulfonyl group [
35
S] from PAP[
35
S] as 
sulphate donor to an acceptor substrate in the absence and presence of potential or known 
inhibitors was investigated. Since a number of SULT isozymes with substrate specificity exist, 
the experiment was performed using several different substrates as outlined in Table 4.1. 
These substrates have previously been reported to be subject to sulfonation by different SULT 
isozymes (Hernández et al., 1992; Kauffman et al., 1998; Dajani et al., 1999; Ozawa et al., 
1999).  
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Substrate Final concentration 
2-naphthol 100 μM 
p-nitrophenol (p-NP) 4 μM 
Dopamine (with pargyline) 60 μM (with pargyline at 1 mM) 
4-methylumbelliferone (4-MU) 10 μM 
Oestrone (E1) 1 μM 
Dehydroepiandrosterone (DHEA) 5 μM 
Inhibitors  
Pentachlorphenol (PCP) 10 μM 
Quercetin 50 μM 
Table 4.1 SULT substrates and known inhibitors and their final concentration as used in the 
sulfotransferase [
35
S]-PAPS radiometric activity assay. 
 
Figure 4.7 demonstrates that the SULT inhibitors PCP and quercetin significantly inhibited 
SULT-mediated sulfonation of all substrates compared to the DMSO vehicle control. There 
was no evidence, however, for inhibition of substrate sulfonation by tartrazine, its four gut- 
derived metabolites SA, SA-Nac, SPH, SCAP and the contaminant OSPCA at 100 μM.  
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Figure 4.7 Tartrazine, its gut-derived metabolites and a contaminant are not inhibitors of 
murine hepatic sulfotransferases at 100 μM. Sulfotransferase [35S]-PAPS radiometric activity assay 
in murine hepatic S9 fractions prepared from livers of wt C57Bl/6 mice. Utilisation of [
35
S]- PAPS 
was determined in S9 fractions incubated with the indicated substrates alone (vehicle) or in 
combination with inhibitors PCP, quercertin or tartrazine, its gut derived metabolites (SA, SA-NAc, 
SPH, SCAP) and the contaminant OSPCA. Results were normalised to protein concentration. Data are 
mean and SD of n=3, typical of one experiment. *Significantly different (p<0.05) versus vehicle 
control using One-way ANOVA with Dunnett’s post-hoc modifications. 
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Tartrazine has previously been reported to be an inhibitor of human hepatic sulfotransferases 
in human S9 fractions using a variety of substrates with the most potent inhibition (94 +/- 3% 
inhibition at 6.7µM tartrazine) observed with dopamine as substrate (Bamforth et al., 1993). 
Although data in this chapter has shown that tartrazine, its metabolites and a contaminant are 
not inhibitors of SULT-dependent dopamine sulfation at 100 μM, there is the potential that 
murine SULTs are less sensitive to inhibition and that higher concentrations are required for 
tartrazine and metabolites to see an inhibitory effect. Correspondingly, the effect of tartrazine, 
its metabolites and a major contaminant of the food additive on mouse hepatic S9 dopamine 
sulfation at higher concentrations was investigated.  
Figure 4.8 shows that tartrazine, all four metabolites and the contaminant OSPCA inhibited 
SULT-mediated dopamine sulfation in a dose-dependent manner in hepatic S9 extracts. SCAP 
and OSPCA appeared to be the most potent inhibitors of murine dopamine sulfotransferases 
with statistically significant inhibition observed at 500 µM (Figure 4.8). 
These data indicate that tartrazine, its metabolites and the contaminant inhibit murine hepatic 
sulfotransferases. SULT inhibition and impaired inactivation of bile acids and oestrogens may, 
therefore, play a role in the mechanism by which direct tartrazine exposure caused mild 
cholestatic liver injury. 
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Figure 4.8 Tartrazine, its four gut-derived metabolites and the contaminant OSPCA inhibit dopamine sulfotranferase in a dose-dependent manner. 
Sulfotransferase [
35
S]-PAPS radiometric activity assay in murine hepatic S9 fractions prepared from livers of wt C57Bl/6 mice. Utilisation of [
35
S]-PAPS was 
determined in S9 fractions incubated with the indicated substrates alone (vehicle) or in combination with inhibitors PCP, quercertin or tartrazine, its gut derived 
metabolites (SA, SA-NAc, SPH, SCAP) and the contaminant OSPCA at concentrations as indicated. Results were normalised to protein concentration. Data are 
mean and SD of n=3, typical of one experiment. *Significantly different (p<0.05) versus vehicle control using One-way ANOVA with Dunnett’s post-hoc 
modifications. 
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4.3. In vivo: Effects of orally administered tartrazine  
Although i.p. injection (avoiding the need for uptake by the gut) of tartrazine caused a 
cholestatic injury in mice, the primary exposure of the food additive in humans is via oral 
administration of tartrazine-containing food items. To test its food additive relevance, it was 
investigated whether tartrazine causes a cholestatic liver injury in vivo following oral 
exposure. Tartrazine was therefore administered to mice by oral gavage. Due to its water 
solubility, absorption of unchanged tartrazine by the gut is generally low (<5%) (EFSA, 2009). 
Alcohol consumption, however, has been shown to cause liver injury by making the gut 
permeable to gram-negative bacteria residing within the gut and bacterial components such as 
endotoxin. We therefore hypothesised that chronic alcohol consumption could also increase 
the gut leakiness of orally administered compounds such as tartrazine. The combined 
administration of tartrazine and ethanol is also relevant since many alcoholic drinks contain 
tartrazine and the EFSA has listed maximum reported use levels of tartrazine in alcoholic 
beverages of up to 200 mg/L (EFSA, 2009).  
To determine if tartrazine has adverse hepatic effects on the background of alcohol-induced 
hepatic injury, transgenic (tg) NF-κB-luc mice were employed. NF-κB-luc mice express 
luciferase under the control of three copies of an NF-κB response element allowing for NF-κB 
activity and thus inflammatory processes to be detected and monitored by live in vivo imaging 
(Carlsen et al., 2002). Following administration of luciferin to animals, luciferase, which is 
expressed in cells with active NF-κB signalling, metabolises luciferin to produce light and 
NF-κB activity can be detected and localised within the animal using the In Vivo Imaging 
System (IVIS). NF-κB is activated in response to a variety of stimuli, including tissue injury, 
and as a key regulator of the immune response, plays a crucial role in tissue regeneration, 
inflammation and disease progression (Luedde and Schwabe, 2011). NF-κB is essentially 
active in all chronic liver diseases including in alcohol-induced and cholestatic liver 
conditions (Mandrekar and Szabo, 2009; Kosters and Karpen, 2010) and stimulates the 
release of pro-inflammatory (e.g. TNFα) and fibrogenic (e.g. TGFβ) cytokines which, 
amongst others, are produced by hepatic Kupffer cells and myofibroblasts respectively 
(Dooley and ten Dijke, 2012; Sunami et al., 2012; Schon and Weiskirchen, 2014). NF-κB-luc 
mice therefore represent a valuable tool for monitoring NF-κB activity and thus inflammation 
and injury in the liver in response to different treatments.  
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4.3.1. Two weeks of alcohol pre-treatment is needed to see an increase in gut 
permeability 
To determine how long it may take for alcohol to show an increase in gut permeability by 
using the detection of liver inflammation as readout, a pilot study was conducted. Mice (wt or 
tg NF-kB-luc mice) were assigned to four groups (1 mouse per group) and dosed as outlined 
in Table 4.2 for 14 days, twice daily by oral gavage (except for the hepatotoxic compound 
alpha-naphthyl isothiocyanate (ANIT) (Desmet et al., 1968), used as a positive control for 
liver injury, which was dosed once at the beginning of the study). To account for the energy 
content of ethanol, the mouse in the control group was dosed with dextrose from an aqueous 
solution. Liver and abdominal inflammation was assessed at the beginning of the study and 
then at 3, 6, 10 and 14 days by live in vivo imaging and calculated using the IVIS software for 
integrated photon emission.  
Group Animal numbers Treatment 
Wt 1♂ C57Bl/6 wt 
Dosed with 6.32 g/kg dextrose twice 
daily for 14 days 
Dextrose 1♂ tg NF-kB-luc, calorific control 
Dosed with 6.32 g/kg dextrose twice 
daily for 14 days 
Ethanol 1♂ tg NF-kB-luc  
Dosed with 3 g/kg ethanol twice daily 
for 14 days 
ANIT 
1♂ tg NF-kB-luc, positive control for 
liver inflammation 
Dosed with 50 mg/kg ANIT once at 
beginning of study 
Table 4.2 Gut permeability pilot study groups and dosing regimen. Ethanol was dosed at 3 g 
ethanol/kg body weight from a 20% ethanol solution. Dextrose was dosed at 6.32 g/kg body weight to 
control for the calorific content of ethanol. ANIT was dissolved in olive oil (12.5 mg/ml) and dosed at 
50 mg/kg body weight. All treatments were administered by oral gavage.  
 
Exposure to the hepatotoxin ANIT caused an increase in luminescence in the upper abdominal 
region (location of the liver) after 3 days with a peak signal observed on day 6 (Figure 4.9). 
The signal remained elevated until the end of the study (day 14) (Figure 4.9F). Although on a 
lower level, ethanol treatment resulted in an increase in luminescence in the upper abdominal 
region after 14 days compared to dextrose treatment (Figure 4.9F). An increase in 
luminescence following treatment with ethanol was also observed in the lower abdominal 
region of the mouse (corresponding to the gastrointestinal (GI) tract) (Figure 4.9G). The wild 
type control mouse did not show any detectable NF-κB-driven luminescent signal.  
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Assuming that the luminescence signal in the upper abdominal region caused by the liver 
toxin ANIT is localised to the liver, it may be concluded that live in vivo imaging in tg NF-
κB-luc mice can be used to detect hepatic injury. Since an increase in luminescence was 
observed in the upper abdominal region following administration of ethanol for 14 days, data 
of this study suggest that 2 weeks of ethanol treatment induces a hepatic injury, likely due to 
an increase in gut permeability. These results suggest that two weeks of pre-treatment with 
ethanol is necessary to increase gut permeability.  
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Figure 4.9 Two weeks of treatment with ethanol causes an increase in NF-κB activity in the upper abdominal (hepatic) and lower abdominal 
(gastrointestinal) region. Male adult C57Bl/6 wt or tg NF-κB-luc mice were dosed with dextrose or ethanol twice daily by oral gavage for 14 days or ANIT 
which was dosed once at beginning of study (n=1 per group). (A-E) IVIS images of treated mice at 0, 3, 6, 10 and 12 days, respectively. Mice were treated as 
indicated and imaged at different time points. For imaging, mice were anesthetised using isoflurane and injected with 200 µl of D-luciferin (15 mg/ml) 
intraperitoneally. Mice were imaged 10 minutes after injection with D-luciferin. (F-G) Quantified upper (hepatic) and lower (gastrointestinal) abdominal 
luminescence of treated mice.  
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4.3.2. Oral tartrazine exposure causes a mild inflammatory response in the liver and 
gastrointestinal tract which is reduced by combined alcohol exposure 
To determine the toxicological relevance of the hepatic effects observed with tartrazine 
exposure after i.p. injection (Axon, Thesis 2012) mice were orally exposed to tartrazine at 50 
mg/kg bw/day (6.6 fold of the current ADI) for 10 weeks. Female adult NF-κB-luc mice and 
male adult wt mice were dosed as outlined in Table 4.3. Mice were pre-treated with ethanol 
twice daily by oral gavage for 14 days to increase gut permeability. Control mice were pre-
dosed with dextrose solution to control for the calorific content of ethanol. After pre-treatment, 
mice were administered tartrazine in either ethanol or dextrose solution by oral gavage twice 
daily for 10 consecutive weeks. Control mice received ethanol or dextrose solution alone. NF-
κB-luc mice were imaged for inflammation at different time points by IVIS.  
 Group Animal numbers Treatment 
Dextrose 
3♀ tg NF-kB-luc 
3♂ C57Bl/6 wt 
Pre-treated with 6.32 g/kg bw dextrose 
from a 0.33 g/ml dextrose solution then 
dosed with dextrose solution 
Tartrazine 
4♀ tg NF-kB-luc 
6♂ C57Bl/6 wt 
Pre-treated with 6.32 g/kg bw dextrose 
from a 0.33 g/ml dextrose solution then 
dosed with 50 mg/kg bw tartrazine in 
dextrose solution 
Ethanol 
4♀ tg NF-kB-luc 
6♂ C57Bl/6 wt 
Pre-treated with 3 g/kg bw ethanol from a 
20% ethanol solution then dosed with 
ethanol solution 
Ethanol+Tartrazine 
4♀ tg NF-kB-luc 
6♂ C57Bl/6 wt 
Pre-treated with 3 g/kg bw ethanol from a 
20% ethanol solution then dosed with 50 
mg/kg bw tartrazine in ethanol solution 
All groups were pre-treated for 2 weeks and then dosed as described for 10 consecutive weeks.  
All dosing was carried out by oral gavage, twice daily. 
Table 4.3 Oral tartrazine study treatment groups and dosing regimen. Wt, wild type; tg, 
transgenic; bw, body weight.  
 
Body weights of both female tg NF-κB-luc and male wt mice were assessed weekly in order 
to determine if ethanol and dextrose, both having a high calorific content, have an effect on 
weight gain and for the purpose of monitoring the animals’ health. Figure 4.10 shows that 
exposure to dextrose and ethanol with and without addition of tartrazine did not affect body 
weights in both female NF-κB-luc and male wt mice over the course of the study. 
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Figure 4.10 Dextrose and ethanol treatments in the absence and presence of tartrazine do not 
affect mouse body weights over the course of the study. Body weights of (A) female adult tg NF-
κB-luc and (B) male adult C57Bl/6 wt mice following dosing with either ethanol or dextrose twice 
daily by oral gavage for 2 weeks (pre-treatment) and then additionally with or without tartrazine for a 
further 10 weeks. Mice in the control groups were dosed with ethanol or dextrose solution alone. Body 
weights of all animals were measured weekly. Data are the mean of the following animal numbers: 
Tg: dextrose, n=3; tartrazine, n=3, ethanol, n=4, ethanol+tartrazine, n=4. Wt: dextrose, n=3; tartrazine, 
n=6, ethanol, n=6, ethanol+tartrazine, n=6.  
 
Treated female tg NF-κB-luc mice were imaged for inflammation in vivo at different time 
points by IVIS.  IVIS imaging reveals that there was a statistically significant increase in NF-
κB driven luciferase expression in the lower abdominal region (location of the gastrointestinal 
tract) after 10 and 12 weeks in mice exposed to tartrazine in the absence of ethanol when 
compared to control mice treated with dextrose solution alone (Figure 4.11C). A significant 
increase in luminescence in mice treated with tartrazine was also observed in the upper 
abdominal (hepatic) region by 12 weeks (Figure 4.11B). Exposure to ethanol did not have any 
apparent inflammatory effects and combined ethanol+tartrazine treatment inhibited the 
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increase in NF-κB driven luciferase expression associated with tartrazine only treatment in 
both the gastrointestinal and hepatic regions (Figure 4.11B, C).    
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Figure 4.11  Orally administered tartrazine causes gastrointestinal and hepatic inflammation. Female adult NF-κB-luc mice were initially dosed with either 
ethanol or dextrose twice daily by oral gavage for 2 weeks (pre-treatment) and then additionally with or without tartrazine for a further 10 weeks. Mice in the control 
groups were dosed with ethanol or dextrose solution alone. (A) IVIS images of treated mice as indicated at different time points. For imaging, mice were 
anesthetised using isoflurane and injected with 200 µl of D-luciferin (15 mg/ml) intraperitoneally. Mice were imaged 10 minutes after injection with D-luciferin. (B, 
C) Quantified upper (hepatic) and lower (gastrointestinal) abdominal luminescence of treated mice at the indicated times. Data are the mean and standard deviation 
of the following animal numbers: dextrose, n=3; tartrazine, n=3, ethanol, n=4, ethanol+tartrazine, n=4.*Significantly different (p<0.05) from dextrose control vehicle 
treated mice at the same time point using one-way ANOVA with Bonferroni post-hoc modifications.   
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To confirm the source of the luminescent signal seen in the upper and lower abdominal 
regions in live animal imaging, individual organs (liver, kidney, spleen and GI tract) were 
examined ex-vivo by IVIS at the end of the study (Figure 4.12A).  Integrated photon emission 
analysis of light emission profiles of the organs show a statistically significant increase in 
hepatic luminescence in mice treated with tartrazine compared to control mice treated with 
dextrose (Figure 4.12B). This increase, however, was inhibited by the combined treatment of 
ethanol and tartrazine. An inflammatory response was also observed in the GI tract of mice 
treated with tartrazine, ethanol and tartrazine+ethanol although these were not significantly 
different compared to dextrose treated control mice (Figure 4.12B).  
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Figure 4.12 IVIS analysis of individual organs ex-vivo. (A) Representative ex-vivo IVIS images of 
adult female NF-κB-luc mouse organs at 12 weeks after study begin (termination of the study). For ex-
vivo imaging of organs, mice were injected with 200 µl of D-luciferin (15 mg/ml) intraperitoneally. 10 
minutes after injection with D-luciferin, mice were terminated by Schedule I method and organs 
dissected and imaged. (B) Quantified luminescence of the organs. Data are the mean and standard 
deviation of the following animal numbers: dextrose, n=3; tartrazine, n=3, ethanol, n=4, 
ethanol+tartrazine, n=4) *significantly different (p<0.05) from dextrose control vehicle treated mice 
using One-way ANOVA with Bonferroni post-hoc modifications.    
 
A common method to assess if the liver is affected by a certain treatment is by determining 
the liver to body weight ratio (Bailey et al., 2004). Accordingly, after 12 weeks at termination 
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of the study, livers from treated male adult C57Bl/6 wild type mice were dissected and 
weighed and the ratio of liver weight/body weight was calculated. Figure 4.13 shows that 
exposure to ethanol both in the absence and presence of tartrazine caused a statistically 
increase in liver/body weight ratio compared to dextrose treated control mice suggesting that 
ethanol treatment caused an enlargement of the liver. No difference between ethanol and 
ethanol+tartrazine treatment was observed. These data indicate that exposure to ethanol has 
an effect on the liver.  
 
Figure 4.13 Exposure to ethanol increases the liver/body weight ratio. After 12 weeks at 
termination of the study, livers from treated male adult C57Bl/6 wild type mice were dissected and 
weighed and the liver/body weight ratio determined. Data are the mean and standard deviation of the 
following animal numbers: dextrose, n=3; tartrazine, n=6, ethanol, n=6, ethanol+tartrazine, n=6.  
*significantly different (p<0.05) from dextrose control vehicle treated mice using One-way ANOVA 
with Bonferroni post-hoc modifications.    
 
To examine if histological changes occurred in the liver following treatment, livers from 
treated C57Bl/6 wild type mice were harvested at the end of the study which were then fixed, 
processed and sections were stained with haematoxylin and eosin (H&E). Sera of treated mice 
were collected at termination of the study to analyse the activity of ALP and ALT enzymes 
which are biomarkers for cholangiocyte and hepatocyte injury, respectively.  
Since cholestatic liver disorders such as PBC are commonly asscociated with inflammatory 
infiltration in the periportal regions of the liver lobule (Jones, 2007), and E2 exposure has 
been shown to result in portal tract inflammation in mice (Axon et al., 2010), portal tracts in 
H&E stained liver sections of treated mice were examined. Histological examination 
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demonstrated that no apparent histological differences in the portal tract regions could be 
observed between the treatment and control groups (Figure 4.14).  
Analysis for ALP activities confirms that there was no evidence for cholestasis in any of the 
treatment groups (Figure 4.15A). Although not statistically significant, a three-fold increase in 
ALT activities in animals exposed to ethanol was observed over dextrose-treated control 
animals which was the only evidence of mild hepatocellular injury (Figure 4.15B).  
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Figure 4.14 Oral tartrazine exposure does not cause any apparent hepatic histological changes. 
Representative H&E stained liver sections of the following animal numbers: dextrose, n=3; tartrazine, 
n=6, ethanol, n=6, ethanol+tartrazine, n=6. Scale bar: 100 μm. Male adult C57Bl/6 wt mice were 
initially dosed with either ethanol or dextrose twice daily by oral gavage for 2 weeks (pre-treatment) 
and then additionally with or without tartrazine for a further 10 weeks. Mice in the control groups 
were dosed with ethanol or dextrose solution alone.  
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Figure 4.15 Oral tartrazine exposure does not induce clinical markers for cholestasis. (A) Serum 
ALP measurements at termination of the study. (B) Serum ALT measurements at termination of the 
study. Male adult C57Bl/6 wt mice were initially dosed with either ethanol or dextrose twice daily by 
oral gavage for 2 weeks (pre-treatment) and then additionally with or without tartrazine for a further 
10 weeks. Mice in the control groups were dosed with ethanol or dextrose solution alone. Serum 
enzyme data are the mean and standard deviation of the following animal numbers: dextrose, n=3; 
tartrazine, n=6, ethanol, n=6, ethanol+tartrazine, n=6. For statistical analysis, One-way ANOVA with 
Bonferroni post-hoc modifications was performed.  
 
Chronic alcohol consumption commonly leads to the development of hepatic steatosis which 
is often one of the first pathological changes observed in alcohol-mediated liver disease (Ji 
and Kaplowitz, 2003; Kang et al., 2009). Since no apparent histological changes in H&E 
stained liver sections were observed in ethanol exposed mice compared to control mice, it was 
investigated whether oral ethanol treatment caused hepatic steatosis in this study. Frozen liver 
sections were prepared from snap-frozen liver tissue which was harvested from wt mice at 
termination of the study at 12 weeks. Frozen liver sections were stained with the fat-soluble 
dye Oil Red O which stains and visualises triglycerides and lipids in fatty tissues. Archived 
frozen steatotic liver tissue from an obese mouse model (gifted by Dr Fiona Oakley, 
Newcastle University) was similarly stained and used as positive control. 
Figure 4.16 demonstrates that staining of steatotic liver tissue with Oil Red O results in the 
visualisation of lipids which appear bright red. No such staining was observed in livers from 
animals treated with dextrose and ethanol (both with and without tartrazine) indicating that 
oral exposure to ethanol did not result in hepatic steatosis in this study.  
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Figure 4.16 Chronic ethanol exposure does not lead to hepatic steatosis. Representative Oil Red O 
stained frozen liver sections of treated mice (dextrose, n=3; tartrazine, n=6, ethanol, n=6, 
ethanol+tartrazine, n=6). Male adult C57Bl/6 wild type mice were initially dosed with either ethanol 
or dextrose twice daily by oral gavage for 2 weeks (pre-treatment) and then additionally with or 
without tartrazine for a further 10 weeks. Mice in the control groups were dosed with ethanol or 
dextrose solution alone. After 12 weeks at termination of the study, liver tissue was harvested and 
snap-frozen in liquid N2. Frozen tissue was sectioned (10 μm) and stained with Oil Red O and 
counterstained with haematoxylin. Frozen liver tissue from an obese mouse model (steatotic liver) was 
used as positive control. Images are representative of treatment groups. Scale bar: 100 μm.  
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Results from this study thus suggest that oral tartrazine exposure over the course of 10 weeks 
caused a mild inflammatory response in the liver and gastrointestinal tract. Such response, 
however, was not associated with any apparent signs of liver injury. The combined treatment 
of tartrazine and ethanol inhibited the increase in inflammation as seen with tartrazine 
treatment alone. Oral exposure to ethanol did not result in apparent hepatic injury.  
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4.4. Discussion 
Tartrazine is a sulfonated azo dye and is often used as a colouring in a variety of food items. 
The food additive is known to cause intolerance reactions in susceptible individuals, even at 
dose-levels within the ADI (EFSA, 2009).  
It has previously been reported that tartrazine is an activator of the human ERα in vitro (Datta 
and Lundin-Schiller, 2008; Axon et al., 2012) and i.p. injection of tartrazine into mice 
resulted in mild cholestatic liver injury (Axon, Thesis 2012). Since oestrogens are cholestatic, 
it was hypothesised that tartrazine caused cholestasis in mice by exhibiting oestrogenic 
properties and by interacting with the murine ERs. Data in this chapter demonstrates that 
tartrazine and its gut-derived metabolites SA, SA-NAc, SPH and SCAP as well as the 
contaminant OSPCA did not activate or inhibited recombinant mERα, mERβv1 and mERβv2 
proteins in vitro (Figure 4.2 – Figure 4.6). These findings suggest that tartrazine does not have 
oestrogenic activity in mice and that cholestatic injury in mice following direct tartrazine 
exposure occurred independent of the ER.  
The mechanism by which oestrogens cause cholestasis is thought to either be an ERα-
dependent suppression of hepatic transporter expression (Yamamoto et al., 2006) and/or 
inhibition of hepatic bile acid transporters that leads to impaired bile acid secretion and thus 
cholestasis and subsequent liver toxicity (Stieger et al., 2000). Since impairment of SULT-
mediated sulfonation of some bile acids, which is essential for their secretion, can cause 
cholestasis, and tartrazine has been reported to significantly inhibit dopamine sulfotransferase 
in human hepatic S9 fractions (Bamforth et al., 1993), the effects of tartrazine on murine 
hepatic sulfotransferase activities were examined. Data in this chapter shows that tartrazine, 
four of its gut-derived, sulfonated metabolites and a major sulfonated contaminant of the food 
additive inhibited dopamine sulfotransferases in a dose-dependent manner in hepatic S9 
extracts at concentrations >100 μM suggesting that SULT inhibition may play a role in the 
mechanism by which direct tartrazine exposure caused mild cholestatic liver injury. Since 
tartrazine inhibited human dopamine sulfotransferase at a concentration of 6.7 µM (Bamforth 
et al., 1993), the mouse seems to be a less sensitive model for any potential cholestatic effects 
of tartrazine.  
Although data in this chapter suggest that tartrazine is not a mouse ER activator, findings 
from Axon (Thesis) (2012) suggest that if sufficient absorption occurs, intake of tartrazine 
may have mild adverse hepatic effects. Since tartrazine is present in food items and 
pharmaceuticals, and to conduct a biologically relevant study, the food additive was 
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administered via the oral route and hepatic as well as other organ effects were examined in 
mice in vivo. Due to low absorption of intact tartrazine by the gut, the food dye was 
administered in combination with ethanol which has been reported to increase gut 
permeability to bacteria and bacterial components residing within the gut (Enomoto et al., 
2001). In a pilot study to determine the duration of ethanol pre-treatment necessary to see an 
increase in gut permeability by the means of monitoring liver inflammation, 2 weeks of oral 
ethanol administration of 3 g/kg body weight twice daily (total of 6 g ethanol/kg body weight 
per day) resulted in an increase in NF-κB mediated luminescence in the upper and lower 
abdominal regions (locations of the liver and GI tract, respectively) compared to control 
dextrose treated mice suggesting that 2 weeks of ethanol pre-treatment is necessary to 
increase gut permeability (Figure 4.9).  
An alcohol-mediated increase in gut permeability in mice has been reported both after acute 
and chronic exposure to ethanol. Lippai et al. have shown that an orally administered single 
dose of 5 g/kg body weight of ethanol from a 50% ethanol solution on 3 consecutive days 
caused an increase in serum endotoxin levels as indicator for increased intestinal permeability 
(Lippai et al., 2014). Chronic alcohol feeding of a 5% (v/v) ethanol containing Lieber-DeCarli 
liquid diet for 5 weeks showed similar results (Lippai et al., 2014). An increase in serum 
endotoxin levels is linked to activation of hepatic Kupffer cells which release TNFα, 
Interleukin (IL)-1 and IL-12 as well as ROS and RNS leading to liver inflammation and 
injury (Ajakaiye et al., 2011). Activation of Kupffer cells by endotoxin has been reported to 
be mediated by the Toll-like receptor 4 (TLR4) (Uesugi et al., 2001; Petrasek et al., 2010). 
Binding of endotoxin to TLR4 further leads to activation of the NF-κB signalling pathway 
(Fitzgerald et al., 2003; Takeda and Akira, 2004). The observed increase in NF-kB activity in 
the hepatic region following ethanol exposure in this chapter therefore suggests that alcohol 
increased gut permeability which led to endotoxin-mediated activation of NF-κB. The 
observation that NF-κB activity is increased in gastrointestinal region in mice treated with 
ethanol compared to the control group is consistent with other findings (Lippai et al., 2014).  
Following determination of duration of ethanol pre-treatment necessary to increase gut 
permeability, in vivo effects of oral tartrazine exposure were investigated. IVIS data has 
shown that oral tartrazine administration caused a mild inflammatory response in the liver and 
gastrointestinal tract after 10 weeks, an effect that was abolished when tartrazine was 
administered in combination with ethanol (Figure 4.11). Ex-vivo imaging of the liver and gut 
confirmed these findings (Figure 4.12). A possible explanation as to why combined tartrazine 
and ethanol exposure reduced the apparent inflammatory effect of tartrazine alone may be 
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because research has shown that ethanol is an inhibitor of NF-κB in vivo. NF-κB activation is 
required to result in the expression of luciferase in tg NF-κB-luc mice that were employed to 
monitor inflammation in this study (Pruett and Fan, 2009).  
Despite evidence of an inflammatory response in the liver following tartrazine exposure, signs 
for cholestatic liver injury by means of hepatic histological changes and serum ALP levels 
were not detectable in any of the treatment groups (Figure 4.14, Figure 4.15A). A non-
significant three-fold increase in serum ALT levels as well as an increase liver/body weight 
ratio and mild hepatic inflammation was the only evidence of mild hepatocellular injury in 
ethanol treated mice (Figure 4.12, Figure 4.13, Figure 4.15B). A similar fold increase in ALT 
activity has been reported in other studies after chronic alcohol exposure for 4-16 weeks (Yin 
et al., 1999; Uesugi et al., 2001; Ji and Kaplowitz, 2003; Kang et al., 2009). 
Hepatic steatosis is one of the earliest signs of alcohol-induced liver damage. In this study, 
mice exposed to ethanol (3 g/kg body weight) twice daily by gavage for 12 weeks did not 
show any signs of steatosis (Figure 4.16). This is contradictory to findings from other studies. 
For example, Kirpich et al. (2012a) have reported steatotic conditions detected by Oil Red O 
staining as early as after 3 ethanol binges (4.5 g/kg body weight) administered in 12 hour 
intervals (Kirpich et al., 2012a). Meanwhile, Yang et al., (2014) show that steatosis occurs in 
mice gavaged with ethanol (4 g/kg, 30% (v/v) in saline) every 12 hours for 5 days (Yang et al., 
2014). In both studies, C57Bl/6 mice were employed. Mice received a greater amount of 
ethanol per binge, however, which is likely to result in higher blood alcohol levels 
determining the severity of liver damage. Although conducted in a different strain (SV129 
background), Wu et al. (2012) demonstrate that steatosis can be induced in mice with ethanol 
binges of 3g/kg body weight following twice daily administration by gavage for 4 days (Wu 
et al., 2012).  
The most crucial factors for inducing ethanol-dependent liver injury are the quantity of 
alcohol consumed, the length of alcohol administration as well as the method by which 
alcohol is delivered to the animal. For studies requiring the use of chronic ethanol exposure, 
administration by oral gavage is not commonly employed. Instead, it is more common to 
administer alcohol by using the Lieber-deCarli ethanol feeding model which provides ethanol 
to mice via a nutrient competent liquid diet available to animals ad libitum (DeCarli and 
Lieber, 1967; Lieber and DeCarli, 1982; Lieber and DeCarli, 1989; Bertola et al., 2013). 
Using this feeding technique, mild forms of liver injury are commonly observed in mice after 
4-6 weeks as manifested by mild steatosis, inflammation and elevated serum ALT activity 
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(Cohen et al., 2010; Mandrekar et al., 2011; Nath et al., 2011; Leung et al., 2012; 
Liangpunsakul et al., 2012). Intake of the Lieber-DeCarli liquid diet for longer time periods 
up to 12 weeks has been reported to result in pronounced steatosis but serum ALT levels were 
only slightly elevated (Zhong et al., 2010). Using this ethanol feeding model, mice consume 
an avergae of 12-25 g ethanol/kg body weight/day and therefore receive at least 2-4 times the 
amount of ethanol per day compared to the ethanol delivery method chosen for the oral 
tartrazine study (Ajmo et al., 2008; Hritz et al., 2008; D’Souza El-Guindy et al., 2010; Zhong 
et al., 2010). 
Another frequently used model to examine the effects of chronic alcohol exposure is the 
intragastric infusion model (Tsukamoto et al., 1984; Ueno et al., 2012). Using this model, 
mice are exposed to up to 28 g ethanol/kg body weight/day via a surgically implanted canulla 
which results in high blood alcohol levels and more severe forms of liver injury including 
steatosis, inflammation, necrosis and significanlty elevated serum ALT levels (Kono et al., 
2000; French, 2001; Uesugi et al., 2002; Ueno et al., 2012; Mathews et al., 2014). Limitations 
of this ethanol administration method include the requirement of surgical skills, intensive 
medical care as well as expensive equipment. Further, this model does not account for alcohol 
exposure via the oral route.     
Administration of alcohol by oral gavage as used in this study is mainly employed to examine 
the effects of acute or ‘binge’ ethanol exposure. Using this method, single or multiple doses 
of 4-6 g ethanol/kg body weight are typically administered to mice. This model has shown to 
cause steatosis and mild infiltration of inflammatory cells (Brandon-Warner et al., 2012; 
Shukla et al., 2013). Although administration of ethanol by oral gavage is predominantly used 
to mimic acute or ‘binge’ effects of alcohol intake, a model administering alcohol by oral 
gavage for chronic exposure has been successfully conducted in rats (Enomoto et al., 1999). 
In that study, rats were dosed with 5 g/kg body weight of ethanol once a day and liver damage 
was assessed at different time points. The reported results demonstrated that after 2 weeks of 
daily single ethanol administration, mild steatosis was observed in the liver. Eight weeks of 
treatment caused marked steatosis, as well as mild necrosis and inflammation. It should be 
noted, however, that rats were simultaneously fed with a liquid diet in which 35% of the daily 
calorie intake were from corn oil and 47% from maltose dextrin. The presence of unsaturated 
fat has been reported to be necessary for the induction of liver injury and led to an increase in 
blood endotoxin levels and gut permeability (Kirpich et al., 2012b). With regards to the oral 
tartrazine in vivo study, dosing of mice twice daily with 3 g ethanol/kg body weight is likely 
to result in lower alcohol blood levels compared to a single injection of 5 g/kg body 
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weight/day. High blood alcohol levels are critical to induce liver injury. Combined, these 
factors may explain why the administration of ethanol for 12 weeks did not result in any 
apparent hepatic injury in this study. 
In conclusion, data in this chapter suggest that the cholestatic effects of tartrazine in mice are 
not mediated by the ER. As a result the mouse is not a good experimental model for studying 
the potential xenoestrogenic activity of tartrazine in vivo. Alcohol administration to mice by 
oral gavage twice daily for 12 consecutive weeks did not result in any apparent signs of liver 
injury. It is questionable whether ethanol treatment resulted in an increase in gut permeability, 
therefore, and if enough tartrazine was absorbed to cause adverse hepatic effects similar to 
those seen after direct exposure. 
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Chapter 5. An examination of the potential adverse hepatic effects of 
xenoestrogens present within the environment 
There is increasing concern regarding man-made endocrine disrupting chemicals within the 
environment and the health risks these chemicals may pose. Primary biliary cholangitis (PBC), 
a chronic cholestatic liver disease of unknown aetiology is often considered to be an 
autoimmune disease because of the presence of anti-mitochondrial antibodies in many PBC 
patients (Kaplan and Gershwin, 2005; Bogdanos and Komorowski, 2011). Although several 
studies have linked genetic pre-disposition to disease development (Jones et al., 1999; Parikh-
Patel et al., 2001; Invernizzi et al., 2004; Selmi et al., 2004), there is supporting evidence that 
PBC may in part be triggered by environmental factors. Studies of its geographic distribution 
have revealed that the prevalence of PBC is not random and that therefore environmental risk 
factors such as differences in the exposure to environmental toxins may contribute to the 
pathogenesis of PBC (Metcalf et al., 1997; Prince et al., 2001; Ala et al., 2006). The 
involvement of man-made toxins has been demonstrated by Gershwin et al., (2005) who 
could link PBC to the use of hair dyes and nail polish (Gershwin et al., 2005). In regards to 
environmental risk factors, living in areas of heavy coal mining has also been implicated in 
the pathogenesis of PBC (Smyk et al., 2010). In 2006, Ala et al. (2006) have reported that the 
prevalence of patients with PBC is increased in close proximity to toxic waste sites in New 
York City further linking PBC to the exposure to environmental toxins (Ala et al., 2006). The 
actual chemical trigger and causative mechanisms, however, remain to be elucidated.  
Given the ability of oestrogens to cause cholestasis (Ozkan et al., 2015), and the link that 
exists between the cholestatic disorder PBC and proximity to toxic waste sites, it was 
hypothesised that the environment around a waste tip site contains a variety of xenoestrogens. 
5.1. Extracts from soil samples around a waste site contain activators of the human 
ERα        
To test the hypothesis that waste sites contain xenoestrogens which may have endocrine 
disrupting effects, thirteen soil samples were collected in close proximity to an urban waste 
site. Chemicals were extracted into three different solvents, namely PBS, ethanol and 
chloroform as described in Section 2.17. Since chloroform is not readily soluble in water, the 
solvent was evaporated off and soil extract residues were resuspended in the same volume of 
sterile DMSO to ease the use of chloroform extracts in cell culture. Separate soil samples 
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were also taken from three different control sites in rural areas and private gardens not in 
close proximity to waste sites. To test if these soil extracts contain xenoestrogens capable of 
activating the hER, a reporter gene assay developed by Axon et al. (2012) was employed. 
This assay uses the oestrogen responsive human breast cancer cell line MCF-7 which 
expresses the hERα. To test the functionality of the assay, MCF-7 cells were transfected with 
the (ERE)3-pGL3promotor luciferase reporter construct and the RL-TK control vector for 24 
hours followed by treatment with 10 nM E2 or 0.1% (v/v) DMSO vehicle in the absence and 
presence of 100 nM ICI182,780 for 24 hours and dual-luciferase assay. Figure 5.1 
demonstrates that ICI182,780 reduced luciferase activity over DMSO vehicle treated cells in 
the absence of the ER antagonist suggesting that the hERα is partially active, likely due to 
oestrogenic chemicals present in cell culture media. Treatment with E2 significantly further 
increased luciferase activity over DMSO vehicle treated cells. This suggests that MCF-7 cells 
respond to treatment with oestrogen and that the assay functions correctly. The E2-mediated 
increase in reporter gene activity was inhibited by co-treatment with ICI182,780 indicating 
that the observed increase in luciferase reporter gene expression is mediated by the hERα.    
 
Figure 5.1 E2 activates the hERα in MCF-7 cells. Luciferase reporter gene assay in MCF-7 cells co-
transfected with the (ERE)3-pGL3promotor reporter construct and the RL-TK control vector. 
Following transfection for 24 hours, cells were pre-treated with 100 nM ICI182,780 or with DMSO 
vehicle (0.1% v/v) as indicated for 6 hours followed by treatment with 10 nM E2 or DMSO vehicle ± 
100 nM ICI182,780 for 24 hours and dual luciferase assay. Mean and SD of n=3, typical of 3 separate 
experiments. Data are expressed in fold change versus DMSO vehicle-treated cells in the absence of 
ICI182,780. *Significantly different (p<0.05) versus DMSO vehicle-treated cells in the absence of 
ICI182,780 using Student’s t-test (two-tailed). #Significantly different (p<0.05) versus equivalent 
treatments in the absence of ICI182,780 using the Student’s t-test (two-tailed) with Holm-Bonferroni 
post-hoc modifications. 
 
Following validation of correct functioning of the MCF-7 cell-based reporter gene assay, it 
was investigated whether extracts from soil samples collected from around an urban waste site 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
F
o
ld
 c
h
a
n
g
e
 (
E
R
E
) 3
-p
G
L
3
p
r
o
m
o
to
r
lu
c
if
e
r
a
se
 r
e
p
o
r
te
r
 a
c
ti
v
it
y
(R
L
-T
K
 n
o
r
m
a
li
se
d
)
DMSO
vehicle
10 nM E2
*
#
#
- + - +100 nM ICI182,780
 163 
 
contain xenoestrogens capable of activating the hERα. MCF-7 cells were transiently 
transfected with the (ERE)3-pGL3promotor reporter construct and the RL-TK control vector 
for 24 hours. This was followed by treatment with waste site and control sites PBS soil 
extracts, ethanol soil extracts and chloforform extracts (in DMSO) for 24 hours and dual-
luciferase assay. Control cells were treated with the solvent stock used in the soil extraction 
procedure (1x PBS and ethanol extracts) or DMSO (chloroform extracts) (solvent stocks were 
labelled as ‘solvent control’).  
Figure 5.2A shows that treatment with 0.1% (v/v) of soil extracts in 1x PBS (soil extracts 
were effectively diluted in medium by a factor of 1000) resulted in statistically significant 
increases in luciferase reporter gene activity in several sampling sites around the waste tip and 
to levels similar or greater than those induced by treatment with a saturating concentration of 
10 nM E2. In contrast, treatment with diluted PBS soil extracts from 3 separate control sites 
did not result in a significant increase in reporter gene expression. Several ethanol soil 
extracts (Figure 5.2B) and chloroform soil extracts (in DMSO) (Figure 5.2C) in close 
proximity to the waste site similarly significantly induced reporter gene expression over 
solvent control with extracts from control sites showing little or no xenoestrogenic activity. 
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Figure 5.2 Soil sample extracts in close proximity to a waste site contain a chemical(s) that 
activate the hERα. (ERE)3-pGL3promotor luciferase reporter gene assay in MCF-7 cells. Cells were 
transfected with the (ERE)3-pGL3promotor reporter construct and the RL-TK control vector for 24 
hours before treatment with 0.1% (v/v) of (A) PBS soil extracts (B) ethanol soil extracts or (C) 
chloroform soil extracts (in DMSO) or 10 nM E2 for 24 hours and dual luciferase assay. Data are 
mean and SD of n=3 from the same experiment, expressed in fold change versus solvent control-
treated (same solvent as was used for the extraction process) or control vehicle-treated (0.1% v/v 
DMSO) cells. *Significantly different (p<0.05) versus solvent control-treated or control vehicle-
treated cells cells using One-way ANOVA with Dunnett’s post-hoc modifications. 
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To further investigate if waste site soil extracts activate the hERα in a dose-dependent manner, 
MCF-7 cells transfected with the (ERE)3-pGL3promotor reporter and RL-TK construct were 
treated with a range of dilutions of soil sample extracts. Since waste site soil extracts in 
ethanol appeared to contain the highest levels of xenoestrogens with many of the ethanol soil 
extracts activating the hERα to levels greater than those induced by treatment with a 
saturating concentration of 10 nM E2, ethanol soil extracts were used for all further 
investigations. MCF-7 cells were treated with a range of dilutions of ethanol soil extracts 
from waste tip sampling sites 3 and 12 and control site 3 starting at a dilution of 1:200 
(constituting a final 0.5% v/v) and serially diluted up to a dilution of 1:10,000,000 
(constituting a final 0.00001% v/v). Control cells were treated with 0.5% (v/v) of ethanol 
solvent used for the extraction procedure (solvent control). Figure 5.3A demonstrates that 
waste site ethanol soil extracts 3 and 12 increased luciferase reporter gene expression in a 
dose-dependent manner, with a significant increase detected at a dilution as low as 1/100,000 
(constituting a final 0.001% v/v) for waste site sample site 12 and 1/1000 (0.1%) for waste 
site sample site 3. A dose-dependent increase in reporter gene expression was not observed in 
cells treated with a range of dilutions from ethanol soil extract from control site 3 (Figure 
5.3A).  A dose-dependent increase in luciferase expression was also observed in cells treated 
with a range of concentrations of E2 (Figure 5.3B), however, the curve appeared flat and was 
not sigmoidal as seen following treatment with waste site soil extracts (Figure 5.3A). 
Although statistically significant at concentrations in the range from 10 pm to 10 µM, a dose-
dependent increase in reporter gene expression was not observed in cells treated with a range 
of concentrations of EE (Figure 5.3B).   
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Figure 5.3 Ethanol waste site soil extracts activate the hERα in a dose-dependent manner. 
Concentration dependent (ERE)3-pGL3promotor luciferase reporter gene assay in MCF-7 cells. Cells 
were transfected with the (ERE)3-pGL3promotor reporter construct and the RL-TK control vector for 
24 hours. (A) Cells were treated with the indicated dilution in medium of waste site ethanol soil 
extract 3 and 12 or control site soil extract 3 for 24 hours and dual-luciferase assay. Control cells 
(solvent control) were treated with 0.5% (v/v) of ethanol solvent used for the soil extractions. (B) Cells 
were treated with the indicated concentrations of oestradiol (E2) or ethinyl oestradiol (EE) for 24 
hours and dual luciferase assay. Control cells (vehicle) were treated with 0.1% (v/v) DMSO vehicle. 
Data are mean and SD of n=3, typical of 3 separate experiments, expressed in fold change versus 
vehicle-treated cells. *Significantly different (p<0.05) versus DMSO vehicle-treated cells using One-
way ANOVA with Dunnett’s post-hoc modifications.  
 
To confirm that the increase in luciferase reporter gene expression following treatment with 
soil sample extracts from around a waste site is mediated by the hERα, MCF-7 cells 
transiently transfected with the (ERE)3-pGL3promotor reporter and RL-TK construct were 
treated with ethanol extracts from waste tip sites that have been shown to induce reporter gene 
expression (see Figure 5.2B) in the absence and presence of the ER antagonist ICI182,780. 
Figure 5.4 demonstrates that all ethanol waste site soil extracts screened significantly induced 
reporter gene expression over cells treated with ethanol solvent (solvent control) to levels 
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similar or greater as seen with exposure to 10 nM E2. In all cases, co-treatment with 100 nM 
ICI182,780 significantly reduced luciferase reporter gene expression over equivalent 
treatments with waste site soil extracts in the absence of ICI182,780 verifying that the 
observed increase following waste site soil extract exposure is mediated by the hERα.   
These data indicate that extracts from soil samples collected in close proximity to an urban 
waste site contain a chemical/chemicals capable of activating the hERα in a human cell-based 
reporter gene assay. 
 
 
Figure 5.4 Waste site ethanol soil extract-dependent activation of the hERα is inhibited by 
ICI182,780. Luciferase reporter gene assay in MCF-7 cells transfected with the (ERE)3-
pGL3promotor reporter construct and the RL-TK control vector. Following transfection for 24 hours, 
cells were pre-treated with 100 nM ICI182,780 or with DMSO vehicle (0.1% v/v) as indicated for 6 
hours followed by treatment with 0.1% (v/v) waste site ethanol soil extracts as indicated or 10 nM E2 
in the presence and absence of 100 nM ICI182,780 for 24 hours and dual luciferase assay. Control 
cells were treated with 0.1% (v/v) ethanol solvent used for extraction (solvent control) or with 0.1% 
(v/v) DMSO vehicle (control vehicle). Data are mean and SD of n=3 from the same experiment, 
expressed in fold change versus solvent control-treated or control vehicle-treated cells. *Significantly 
different (p<0.05) versus solvent control-treated or control vehicle-treated cells using One-way 
ANOVA with Dunnett’s post-hoc modifications. #Significantly different (p<0.05) versus equivalent 
treatments in the absence of ICI182,780 using Student’s t-test (two-tailed) with Holm-Bonferroni post-
hoc modifications. 
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5.2. Extracts from soil samples around a waste site activate the murine ERs 
In order to investigate the potential effects of xenoestrogen exposure in vivo, ethanol extracts 
from around an urban waste tip site were examined for their potential to activate the murine 
ERs for use in an in vivo mouse model. Activation of the mERs was tested using the reporter 
gene assays as developed in Chapter 3.  
5.2.1. Extracts from soil samples around a waste site activate the mERα 
The potential of waste site soil extracts to activate the mERα was examined in LTPA cells. 
LTPA cells were transiently transfected with the previously constructed pcDNA3.1-mERα 
expression construct encoding the mERα, the 3XERE TATA luc reporter construct as well as 
the RL-TK control construct before treatment with 0.1% (v/v) of ethanol waste site soil 
extracts and ethanol control sites soil extracts in the absence and presence of 100 nM 
ICI182,780 for 24 hours. Control cells were treated with the ethanol solvent stock used in the 
soil extraction procedure (solvent control).  
Figure 5.5 demonstrates that the ethanol waste site soil extracts which activated the hERα in 
MCF-7 cells similarly increased luciferase reporter gene expression in LTPA cells expressing 
recombinant mERα over solvent control treated cells to levels similar or greater as seen with a 
biologically saturating concentration of 10 nM E2 or 10 nM EE. This effect was inhibited by 
co-treatment with 100 nM ICI182,780. No such increase was observed following the 
treatment with soil sample ethanol extracts from the control sites.  
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Figure 5.5. Waste site ethanol soil extracts activate recombinant mERα. Luciferase reporter gene 
assay (3XERE TATA luc) in LTPA cells co-transfected with the pcDNA3.1-mERα expression 
construct encoding the mERα. Following transfection for 24 hours, cells were pre-treated with 100 nM 
ICI182,780 or with DMSO vehicle (0.1% v/v) as indicated for 6 hours followed by treatment with 
0.1% (v/v) waste site ethanol soil extracts, control sites ethanol soil extracts, 10 nM E2 or 10 nM EE 
in the presence and absence of 100 nM ICI182,780 for 24 hours and dual luciferase assay. Control 
cells were treated with 0.1% v/v ethanol solvent used for extraction (solvent control) or with 0.1% 
(v/v) DMSO vehicle (control vehicle). Data are mean and SD of n=3, typical of two separate 
experiments and expressed in fold change versus solvent control-treated or control vehicle-treated 
cells. *Significantly different (p<0.05) versus solvent control-treated or control vehicle-treated cells 
using One-way ANOVA with Dunnett’s post-hoc modifications. #Significantly different (p<0.05) 
versus equivalent treatments in the absence of ICI182,780 using Student’s t-test (two-tailed) with 
Holm-Bonferroni post-hoc modifications. 
5.2.2. Extracts from soil samples around a waste site activate the mERβv1 
The potential of waste site soil extracts to activate the mERβ proteins was examined in 603B 
cells. To test for activation of the mERβv1, 603B cells were transiently transfected with the 
previously constructed pcDNA3.1-mERβv1 expression construct encoding the mERβv1, the 
(ERE)3-pGL3promotor reporter construct as well as the RL-TK control construct before 
treatment with 0.1% (v/v) of waste site soil extracts and control sites soil extracts in ethanol in 
the absence and presence of 100 nM ICI182,780 for 24 hours.  
Figure 5.6 shows that almost all waste site ethanol extracts induced an increase in reporter 
gene expression in 603B cells expressing recombinant mERβv1 to levels similar or greater as 
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seen with 10 nM E2 or 10 nM EE. These increases were inhibited by co-treatment with 
100 nM ICI182,780. Treatment with ethanol extracts from control sites soil samples did not 
result in an increase in luciferase reporter gene expression.  
 
Figure 5.6 Waste site ethanol soil extracts activate recombinant mERβv1. Luciferase reporter 
gene assay ((ERE)3-pGL3promotor) in 603B cells co-transfected with the pcDNA3.1 expression 
construct encoding the mERβv1. Following transfection for 24 hours, cells were pre-treated with 
100 nM ICI182,780 or with DMSO vehicle (0.1% v/v) as indicated for 6 hours followed by treatment 
with 0.1% (v/v) waste site ethanol soil extracts, control sites ethanol soil extracts, 10 nM E2 or 10 nM 
EE in the presence or absence of 100 nM ICI182,780 for 24 hours and dual luciferase assay. Control 
cells were treated with 0.1% (v/v) ethanol solvent used for extraction (solvent control) or with 0.1% 
(v/v) DMSO vehicle (control vehicle). Data are mean and SD of n=3, typical of two separate 
experiments and expressed in fold change versus solvent control-treated or control vehicle-treated 
cells. *Significantly different (p<0.05) versus solvent control-treated or control vehicle-treated cells 
using One-way ANOVA with Dunnett’s post-hoc modifications. #Significantly different (p<0.05) 
versus equivalent treatments in the absence of ICI182,780 using Student’s t-test (two-tailed) with 
Holm-Bonferroni post-hoc modifications.  
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5.2.3. Extracts from soil samples around a waste site irreversibly activate the mERβv2 
To test for activation of the mERβv2, 603B cells were transiently transfected with the 
previously constructed pcDNA3.1-mERβv2 expression construct encoding the mERβv2 
protein, the (ERE)3-pGL3promotor reporter construct as well as the RL-TK control construct. 
Constitutively active recombinant mERβv2 was de-activated by treatment with 100 nM 
ICI182,780 for 6 hours followed by several wash steps with sterile 1xPBS before treatment 
with 0.1% (v/v) of waste site soil extracts and control sites soil extracts in ethanol in the 
absence and presence of 100 nM ICI182,780 for 24 hours.  
Figure 5.7 shows that several ethanol waste site soil extracts induced an increase in reporter 
gene activity in 603B cells expressing recombinant mERβv2 but not to the same levels as 
seen with exposure to 10 nM E2 or 10 nM EE. In some cases, ethanol waste site soil extracts 
that activated the mERβv1 also activated the mERβv2, such as soil samples 3, 4, 6, 8 and 12 
(see also Figure 5.6). Other soil sample extracts such as sample 1 and 2, however, only 
induced luciferase reporter gene expression in cells expressing recombinant mERβv1 (Figure 
5.6). Interestingly, despite effective antagonism by ICI182,780 versus E2- or EE-activation of 
mERβv2, the ER antagonist failed to antagonise the increase in luciferase reporter gene 
expression after exposure to the majority of waste site ethanol soil extracts, such as soil 
samples 3, 4, 9 and 12 suggesting that these irreversibly activate the mERβv2. Treatment with 
ethanol extracts from control sites soil samples did not show any detectable oestrogenic 
activity in this assay.  
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Figure 5.7 Waste site ethanol soil extracts irreversibly activate the mERβv2. Luciferase reporter 
gene assay ((ERE)3-pGL3promotor) in 603B cells co-transfected with the pcDNA3.1 expression 
construct encoding the mERβv2.  Following transfection for 24 hours cells were pre-treated with 100 
nM ICI182,780 for 6 hours to de-activate constitutively active mERβv2 followed by several wash 
steps with PBS. Cells were then treated with 0.1% (v/v) waste site ethanol soil extracts, control sites 
ethanol soil extracts, 10 nM E2 or 10 nM EE in the presence or absence of 100 nM ICI182,780 for 24 
hours and dual luciferase assay. Control cells were treated with 0.1% (v/v) ethanol solvent used for 
extraction (solvent control) or with 0.1% (v/v) DMSO vehicle (control vehicle). Data are mean and SD 
of n=3, typical of two separate experiments and expressed in fold change versus solvent control-
treated or control vehicle-treated cells. *Significantly different (p<0.05) versus solvent control-treated 
or control vehicle-treated cells using One-way ANOVA with Dunnett’s post-hoc modifications. 
#Significantly different (p<0.05) versus equivalent treatments in the absence of ICI182,780 using 
Student’s t-test (two-tailed) with Holm-Bonferroni post-hoc modifications. 
5.3. An acute effect of xenoestrogen exposure is an inflammatory response in the liver 
Prior to investigations of potential adverse hepatic effects caused by xenoestrogens present in 
waste site soil extracts, it was first established whether tg NF-κB-luc mice can be employed as 
animal model to assess the potential adverse hepatic effects of xenoestrogens in vivo. 
Accordingly, male adult tg NF-κB-luc mice were acutely exposed to the known 
xenoestrogens EE and butyl paraben by single i.p. injection on 3 consecutive days, essentially 
as described in Table 5.1. The hepatotoxin ANIT known to cause periportal liver injury and 
which was used as a positive control was dosed once at the beginning of the study by oral 
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gavage. On day 4, whole body IVIS imaging was used to determine inflammation within the 
liver prior to termination of animals by cervical dislocation and collection of blood and livers.   
Group Animal numbers Treatment 
Vehicle 3♂ tg NF-kB-luc  
Dosed with vehicle (90% olive oil/10% 
ethanol v/v) 
ANIT 
1♂ tg NF-kB-luc, positive control for 
liver inflammation 
Dosed with 50 mg/kg bw ANIT once at 
beginning of study by oral gavage 
EE 3♂ tg NF-kB-luc  Dosed with 0.5 mg/kg bw EE 
Butyl 
paraben 
3♂ tg NF-kB-luc  Dosed with 50 mg/kg bw butyl paraben 
Except for ANIT, all treatments were administered by single i.p. injection at 0, 24, and 48 hours at 
0.5 ml/100g bw. At 72 hours, animals were imaged by IVIS before termination by cervical 
dislocation and collection of blood and livers for further analysis 
Table 5.1 Dosing regimen for in vivo study investigating the acute effects of xenoestrogen 
exposure. EE and butyl paraben were dissolved in and dosed from a 90% olive oil/10% ethanol (v/v) 
solution. ANIT was dissolved in olive oil (12.5 mg/ml) and dosed at 50 mg/kg body weight. Tg,  
transgenic; bw, body weight.  
 
Figure 5.8 shows that exposure to the hepatotoxin ANIT caused an increase in luminescence 
in the upper abdominal region (location of the liver). A statistically significant increase in NF-
κB driven luciferase expression in the upper abdominal (hepatic) region was also observed 
following exposure to the synthetic oestrogen ethinyl oestradiol (EE) when compared to 
animals administered with vehicle alone. Exposure to the well known xenoestrogen butyl 
paraben did not result in a significant increase in luciferase expression in the hepatic region. 
These data demonstrate that acute i.p. administration of some xenoestrogen to mice, which 
models a systemic exposure, leads to an inflammatory response within the liver.   
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Figure 5.8 Exposure to EE causes an inflammatory response in the liver. Male adult tg NF-κB-luc 
mice were dosed with EE, butyl paraben or vehicle (90% olive oil/10% ethanol v/v) by i.p. injection at 
0, 24 and 48 hours. The hepatotoxin ANIT was dosed once at the beginning of the study by oral 
gavage. (A) IVIS images of treated mice at 72 hours from beginning of the study. For imaging, mice 
were anesthetised using isoflurane and injected with 200 µl of D-luciferin (15 mg/ml) 
intraperitoneally. Mice were imaged 10 minutes after injection with D-luciferin. (B) Quantified upper 
(hepatic) abdominal luminescence of treated mice. IVIS data are the mean and standard deviation of 
the following animal numbers: vehicle: n=3; ANIT: n=1, EE: n=3; butyl paraben: n=3.  *Significantly 
different (p<0.05) versus vehicle control group using One-way ANOVA with Bonferroni post-hoc 
modifications. 
 
To examine if histological changes occurred in the liver following treatment, livers from 
treated tg NF-kB-luc mice were harvested at the end of the study which were then fixed, 
processed and sections were stained with haematoxylin and eosin (H&E). Sera of treated mice 
were collected at termination of the study to analyse the activity of serum ALP enzymes, a 
marker for periportal injury.  
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Histological examination of portal tracts demonstrated that exposure to ANIT resulted in 
necrotic changes and recruitment of inflammatory cells whereas no apparent histological 
differences in the portal tract regions could be observed in liver sections of EE, butyl paraben 
and vehicle control groups (Figure 5.9).  
Analysis for serum ALP activities showed that ANIT markedly increased ALP activities in 
the serum, however, no statistical analysis could be performed since data are from n=1 
(Figure 5.10). A statistically significant increase in serum ALP activities was observed in 
mice exposed to EE whereas butyl paraben treatment did not result in detectable differences 
in serum ALP activities compared to vehicle-treated animals (Figure 5.10).  
Although no biologically significant histological changes were observed, overall data in this 
section confirm that the liver is a target for the adverse effects of xenoestrogens and that the 
liver imaging approach by IVIS provides a refined method for assessing the potential adverse 
hepatic effects of xenoestrogens.   
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Figure 5.9 Acute exposure to EE does not cause any apparent hepatic histological changes. 
Representative H&E stained liver sections of treated animals (vehicle: n=3; ANIT: n=1, EE: n=3; 
butyl paraben: n=3). Scale bar: 100 μm. Male adult tg NF-κB-luc mice were dosed with EE, butyl 
paraben or vehicle (90% olive oil/10% ethanol) by i.p. injection at 0, 24 and 48 hours. The hepatotoxin 
ANIT was dosed once at the beginning of the study by oral gavage. At 72 hours, mice were terminated 
by cervical dislocation and their livers collected.  
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Figure 5.10 Acute exposure to EE leads to an increase in ALP serum levels. Serum ALP 
measurements at termination of the study. Male adult tg NF-κB-luc mice were dosed with EE, butyl 
paraben or vehicle (90% olive oil/10% ethanol) by i.p. injection at 0, 24 and 48 hours. The hepatotoxin 
ANIT was dosed once at the beginning of the study by oral gavage. At 72 hours, mice were terminated 
by cervical dislocation and their blood collected. Serum enzyme data are the mean and standard 
deviation of the following animal numbers: vehicle: n=3; ANIT: n=1, EE: n=3; butyl paraben: n=3 
*Significantly different (p<0.05) versus vehicle control group using One-way ANOVA with 
Bonferroni post-hoc modifications. 
5.4. In vivo study: an examination of adverse hepatic effects caused by oestrogen 
positive soil extract  
As exposure to known xenoestrogens was found to have adverse hepatic effects in vivo in 
mice (Section 5.3), it was examined whether soil extracts from around an urban waste tip with 
oestrogenic activity also have adverse hepatic effects in vivo.  
To calculate the amount of oestrogen positive soil extract required to potentially result in a 
similar hepatic effect as seen with EE, it was estimated that the concentration of 
xenoestrogen(s) in soil extracts is 10 µM since treatment of cells at a dilution of 1/1000 
resulted in a similar increase in reporter gene expression as observed with 10 nM E2 or 10 nM 
EE (see Figure 5.5 and Figure 5.6). Assuming that all xenoestrogens in the soil extracts have a 
similar molecular weight to EE, 1 ml of soil extract would contain 2.9 µg of xenoestrogens. 
Exposure of animals to 500 µg/kg body weight EE (12.5 µg EE for a mouse weighing 25 g) 
was shown to result in a readable IVIS signal and increases in serum ALP activities. 
Therefore, to see a similar effect following exposure to xenoestrogens, a 25 g mouse would 
have to receive 4.3 ml of soil extract. Assuming, however, that injection of 500 µg/kg body 
weight EE lies above the top of the dose response curve and due to limited availability of soil 
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extracts remaining after previous analysis, it was estimated that around 1 ml of soil extract 
was required per mouse.  
Several oestrogen positive waste site ethanol soil extracts which activated the mERs (see 
Section 5.2) were combined to yield a sufficient volume for injection into mice. Ethanol 
extracts of oestrogen negative control sites were similarly combined. Combined soil extracts 
were then dried down to 5%
 
of their volume and then diluted with olive oil 1:9 (10% ethanol 
soil extract/90% olive oil).  
5.4.1. Combined oestrogen positive ethanol soil extracts activate the mERs 
Prior to examination of potential in vivo hepatic effects of the soil extracts, the oestrogenic 
potential of combined soil extracts was tested in the developed mouse-based reporter gene 
assays. Figure 5.11A confirms that exposure to combined oestrogen positive soil extracts 
resulted in a statistically significant increase in luciferase reporter gene expression in LTPA 
cells expressing recombinant mERα to levels greater than seen with 10 nM E2 or 10 nM EE. 
Treatment with combined oestrogen negative soil extracts did not result in a detectable 
increase. Treatment with oestrogen positive soil ethanol extracts further resulted in an 
increase in luciferase reporter gene activity in 603B cells expressing recombinant mERβv1 
(Figure 5.11B) and mERβv2 (Figure 5.11C) to levels similar or greater as seen with 10 nM E2 
or 10 nM EE with combined oestrogen negative soil ethanol extracts having no effect.    
These data confirm that combined soil oestrogen positive soil extracts activated the mERα, 
mERβv1 and mERβv2 which indicates that they retained their oestrogenic activity in mice. 
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Figure 5.11 Confirmation of activation of recombinant mERα, mERβv1 and mERβv2 proteins 
by combined oestrogen positive waste site soil extracts.  (A) Luciferase reporter gene assay 
(3XERE TATA luc) in LTPA cells co-transfected with the pcDNA3.1 expression construct encoding 
the mERα. Following transfection for 24 hours cells were treated with 0.1% (v/v) of combined 
oestrogen positive waste site soil extracts or combined oestrogen negative control sites soil extracts, 
10 nM E2 or 10 nM EE for 24 hours and dual-luciferase assay. Control cells were treated with 0.1% 
(v/v) vehicle (vehicle control, 80% olive oil/20% ethanol) or with 0.1% (v/v) DMSO vehicle. (B) 
Luciferase reporter gene assay ((ERE)3-pGL3promotor) in 603B cells co-transfected with the 
pcDNA3.1 expression construct encoding the mERβv1. Following transfection for 24 hours cells were 
treated as described above. (C) Luciferase reporter gene assay ((ERE)3-pGL3promotor) in 603B cells 
co-transfected with the pcDNA3.1 expression construct encoding the mERβv2. Following transfection 
for 24 hours cells were pre-treated with 100 nM ICI182,780 for 6 hours to de-activate constitutively 
active mERβv2 followed by several wash steps with 1x PBS. Cells were then treated as described 
above. Data are mean and SD of 3 separate treatments from the same experiment, expressed in fold 
change versus vehicle control-treated or DMSO vehicle-treated cells. *Significantly different (p<0.05) 
versus vehicle control or DMSO vehicle-treated cells using One-way ANOVA with Dunnett’s post-
hoc modifications.  
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5.4.2. Acute exposure to oestrogen positive soil extract results in cholangiopathic injury 
in the absence of any hepatocellular injury 
Following confirmation that combined oestrogenic waste site soil extracts activate the mERs, 
soil extracts were injected into mice to examine their potential to cause adverse hepatic effects.  
Male adult tg NF-κB-luc mice were acutely exposed to combined oestrogen positive or 
combined oestrogen negative soil extracts in 10% ethanol/90% olive oil (v/v) by i.p. injection 
to mimic systemic exposure. Due to the volume of soil extracts available, mice could only be 
injected with soil extracts once. The positive control group was exposed to EE in 10% 
ethanol/90% olive oil (v/v) whereas animals in the vehicle control group received the vehicle 
(10 % ethanol/90% olive oil v/v) alone. Treatment groups and dosing regimen are outlined in 
Table 5.2. 
Group Animal numbers Treatment 
Vehicle 3♂ tg NF-kB-luc  
Dosed with vehicle (90% olive oil/10% 
ethanol v/v) 
EE 3♂ tg NF-kB-luc  Dosed with 0.5 mg/kg bw EE 
Oestrogen negative soil 
extracts 
3♂ tg NF-kB-luc 
Dosed with combined oestrogen 
negative soil extracts from 3 separate 
control sites 
Oestrogen positive soil 
extracts 
3♂ tg NF-kB-luc  
Dosed with combined oestrogen positive 
soil extracts from soil samples collected 
around an urban waste site 
All treatments were administered by single i.p. injection at 2 ml/100g bw. Mice were imaged for 
inflammation by IVIS at 0, 1, 6 and 24 hours post injection. Following imaging, animals were 
terminated by cervical dislocation and their blood and liver were collected for further analysis. 
Table 5.2 Dosing regimen for soil sample extracts exposure in vivo study. Combined oestrogen 
negative and oestrogen positive ethanol soil extracts were concentrated to 5% of their original volume 
and diluted 1:9 with olive oil (10% ethanol soil extracts/90% olive oil v/v). EE was dissolved in and 
dosed from a 90% olive oil/10% ethanol (v/v) solution. Tg, transgenic; bw, body weight.  
 
Figure 5.12 demonstrates that significant increases in luminescence in the upper abdominal 
region (location of the liver) were undetectable in animals exposed to EE, combined 
oestrogen positive or combined oestrogen negative soil extracts compared to the vehicle 
control group at all indicated time points. It appears that at 6 hours post injection, luminescent 
signal and therefore NF-κB activity throughout the whole abdomen was increased in all the 
treatment groups as well as in animals receiving the vehicle, likely due to i.p. injection of 
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large volumes of dosing solutions (0.5 ml for a 25 g mouse) (Figure 5.12). IVIS images 
indicate that the increase in luminescent signal was decreased at 24 hours post injection 
(Figure 5.12). These data suggest that exposure to oestrogen positive soil extracts did not 
result in an apparent inflammatory response in the liver compared to vehicle treated mice and 
mice exposed to oestrogen negative soil extracts. 
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Figure 5.12 Acute exposure to combined oestrogen positive waste site soil extracts does not cause 
a detectable inflammatory response in the liver. Male adult tg NF-κB-luc mice were dosed with EE, 
combined oestrogen positive waste site soil extracts or combined oestrogen negative control sites soil 
extracts by single i.p. injection. Mice in the control group received vehicle (90% olive oil/10% ethanol 
v/v) alone. (A) IVIS images of treated mice at 0, 1, 6 and 24 hours post injection. For imaging, mice 
were anesthetised using isoflurane and injected with 200 µl of D-luciferin (15 mg/ml) 
intraperitoneally. Mice were imaged 10 minutes after injection with D-luciferin. (B) Quantified upper 
(hepatic) abdominal luminescence of treated mice at the indicated time points. IVIS data are the mean 
and standard deviation of the following animal numbers: vehicle: n=3; EE: n=3; oestrogen positive 
soil extracts: n=3; oestrogen negative soil extracts: n=3. For statistical analysis, One-way ANOVA 
with Bonferroni post hoc-modifications (p<0.05) was used.  
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To examine if histological changes occurred in the liver following treatment, livers from 
treated tg NF-kB-luc mice were harvested at the end of the study which were then fixed, 
processed and sections were stained with haematoxylin and eosin (H&E). Sera of treated mice 
were collected at termination of the study to analyse the activity of serum ALP enzymes.  
Histological examination of portal tracts demonstrated that no apparent histological changes 
in the portal tract regions could be observed in liver sections of EE, oestrogen positive soil 
extracts and oestrogen negative soil extracts treated animals compared to the vehicle control 
group (Figure 5.13). In liver sections from all treatment groups, however, the presence of fat 
droplets (steatosis) was observed, likely due to large administration volumes of the dosing 
solution which contained 90% (v/v) olive oil. Despite the lack of any biologically relevant 
histological changes, Figure 5.14A demonstrates that exposure to the combined oestrogen 
positive soil extracts resulted in a significant increase in ALP activity, a marker for cholestatic 
injury compared to both vehicle treated mice and mice exposed to oestrogen negative soil 
extracts, although there was a significant decrease in ALT activity (Figure 5.14B), a marker 
for hepatocellular injury, compared to the vehicle control group. Exposure to EE also resulted 
in a small but significant increase in ALP activity compared to the vehicle control group 
whereas ALT activities remained unchanged. Exposure to oestrogen negative soil extracts did 
not result in any significant changes in serum enzyme activities.    
Although no biologically relevant histological changes were observed, data in this section 
suggest that soil samples collected from around an urban waste site contain xenoestrogens that 
induce clinical chemical markers for cholestatic liver injury. Overall, these data indicate that 
exposure to environmental xenoestrogens in close proximity to waste sites may have adverse 
hepatic effects. 
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Figure 5.13 Exposure to oestrogen positive waste site soil extracts does not cause any apparent 
hepatic histological changes. Representative H&E stained liver sections of treated animals (vehicle: 
n=3; EE: n=3; oestrogen positive soil extracts: n=3; oestrogen negative soil extracts: n=3). Scale bar: 
100 μm. Male adult tg NF-κB-luc mice were dosed with EE, combined oestrogen positive waste site 
soil extracts or combined oestrogen negative control sites soil extracts by single i.p. injection. Mice in 
the control group received vehicle (80% olive oil/20% ethanol) alone. At 24 hours after injection, 
animals were terminated by cervical dislocation and their livers collected.  
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Figure 5.14 Exposure to oestrogen positive waste site soil extracts leads to an increase in ALP 
serum levels. (A) Serum ALP measurements at termination of the study. (B) Serum ALT 
measurements at termination of the study. Male adult tg NF-κB-luc mice were dosed with EE, 
combined oestrogen positive waste site soil extracts or combined oestrogen negative control sites soil 
extracts by single i.p. injection. Mice in the control group received vehicle (80% olive oil/20% 
ethanol) alone. At 24 hours after injection, animals were terminated by cervical dislocation and their 
blood collected. Serum enzyme data are the mean and standard deviation of the following animal 
numbers: vehicle: n=3; EE: n=3; oestrogen negative soil extracts: n=3; oestrogen positive soil extracts: 
n=3. *Significantly different (p<0.05) using One-way ANOVA with Bonferroni post-hoc 
modifications. 
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5.5. Discussion 
Data in this chapter demonstrate that xenoestrogens can be extracted from and detected in soil 
samples. Soil extracts in close proximity to a waste site were found to contain higher levels of 
detectable xenoestrogens compared to those prepared from soil samples collected at control 
sites not expected to be contaminated with chemicals. To my knowledge, this is the first time 
this approach has been used to help identify potential environmental risk factors associated 
with adverse health effects due to endocrine disruption.   
Using an ER-dependent reporter gene assay, several soil samples collected from around an 
urban waste site activated the hERα, an effect that was dose-dependent, suggesting that these 
extracts contain a chemical or a variety of chemicals with xenoestrogenic activity (Figure 5.2, 
Figure 5.3). In contrast, soil extracts prepared from soil sampled from three separate control 
sites did not activate the hERα. The observation that the waste site soil extract-induced 
increase in reporter gene activity is inhibited by the ER antagonist ICI182,780 further 
confirms that trans-activation of the reporter construct occurred via activation of the ER 
(Figure 5.4).  
In order to test the potential endocrine disrupting effects of xenoestrogens present in waste 
site soil samples in vivo, it was decided to employ a mouse model due to the abundance of 
transgenic mouse lines available for potential use in follow on studies.  Prior to administration 
of soil extracts to mice, however, it was examined if waste site soil extracts are also activators 
of the mERs in context of a murine cell line using previously established reporter gene assays.  
Results have shown that several waste site ethanol soil extracts activated the mERα in a 
similar manner to the hERα and activation was inhibited by co-treatment with ICI182,780 
(Figure 5.5). Control sites soil extracts did not exhibit any detectable oestrogenic activity. 
Similarly, several waste site ethanol soil extracts also activated the mERβv1 an effect which 
was antagonised by ICI182,780 (Figure 5.6). Interestingly, the majority of waste site ethanol 
soil extracts irreversibly activated the mERβv2 since activation of this receptor by soil-based 
xenoestrogens, as opposed to activation by E2 or EE, was not antagonised by ICI182,780 
(Figure 5.7). Assuming that xenoestrogens bind to the mERβv2 in a similar manner as E2 and 
EE, this finding suggests that xenoestrogens present in waste site soil extracts may dissociate 
from the receptor at a significantly reduced rate. Another possible explanation is that 
xenoestrogens activate the mERβv2 via a different mechanism such as interacting and binding 
to the receptor through an alternative binding site which could prevent ICI182,780-mediated 
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antagonism. This suggests that soil-based xenoestrogens may have ‘super-activating’ 
characteristics with an ERβ variant. 
Since waste site soil extracts activated murine ERs, the mouse was considered a good model 
for examining potential endocrine disruptor properties of these extract in vivo. The usability 
of transgenic NF-κB mice and the ability to detect xenoestrogen-induced hepatic adverse 
effects in this mouse model was explored first. Acute exposure of NF-κB mice to the known 
xenoestrogen EE, but not butyl paraben, caused a detectable inflammatory response in the 
liver and EE treatment further showed an increase in serum ALP activity, a clinical chemical 
marker for cholestasis (Figure 5.8, Figure 5.10). Histological changes in the portal tract 
regions of H&E stained liver sections, however, were not detected (Figure 5.9). An 
explanation for this could be that 1) the time of exposure was insufficient to cause any 
histological effects and 2) histological analysis was limited to the sections used which only 
represent a fraction of the liver’s response. In contrast, IVIS imaging determines 
inflammation throughout the organ and might show hepatic responses to treatments not 
detectable in liver sections. Taken together, findings suggest that NF-κB mice represent a 
refined model for assessing the potential adverse hepatic effects of xenoestrogens, a model 
that will also allow examining inflammation at various time points without the need for 
animal termination.  
EE is known to be able to induce cholestatic injury and is often used in in vivo rodent studies 
to induce oestrogen-mediated cholestasis (Rodriguez-Garay, 2003). Although butyl paraben 
did not have any adverse hepatic effects in this study, it is known to have oestrogenic activity 
in rodents in vivo (Routledge et al., 1998) but the development of cholestasis as a result of 
butyl paraben administration has not been reported. Shah and Verma (2001) have shown that 
chronic butyl paraben exposure by i.p. injection caused oxidative stress in the liver of mice 
(Shah and Verma, 2011). Although not directly applicable to the liver, another study reported 
that butyl paraben inhibited dermal oestrogen sulfotransferases, enzymes which inactivate 
oestrogens through biotransformation reactions (Prusakiewicz et al., 2007). The inhibition of 
hepatic sulfotransferases by butyl paraben could therefore potentially lead to elevated 
oestrogen levels and prolonged exposure may have cholestatic effects.  
Following confirmation that NF-κB mice can be employed to detect xenoestrogen-mediated 
hepatic adverse effects, ethanol soil extracts that have been shown to activate the mERs in 
vitro (oestrogen positive, see Figure 5.5, Figure 5.6, Figure 5.7) were combined and 
concentrated to test for hepatic adverse effects in mice. Similarly, ethanol soil extracts 
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collected from control sites which exhibited little or no oestrogenic activity in mouse-based 
reporter gene assays (oestrogen negative) were pooled. The potential of combined oestrogen 
positive soil extracts to activate the mERs was confirmed in reporter gene assays, whereas 
combined soil negative extracts showed no significant oestrogenic activity (Figure 5.11).  
Acute exposure (single i.p. injection) of mice to combined oestrogen positive soil extracts did 
not result in a detectable inflammatory response in the liver compared to the vehicle control 
group (Figure 5.12). There was no observation of any biologically relevant histological 
changes in the liver (Figure 5.13) which was expected given that 3 injections on 3 consecutive 
days of EE did not cause any detectable hepatic histological changes (Figure 5.9) despite a 
detectable inflammatory signal (Figure 5.8). A significant increase in serum ALP activities in 
mice exposed to combined oestrogen positive soil extracts was the only evidence for a 
xenoestrogen-mediated cholestatic effect (Figure 5.14A). IVIS data has shown that the 
luminescence signal and therefore NF-κB activity in the abdominal region was increased at 
6 h post injection in all treatment groups. This is likely due to the injection of relatively large 
volumes of vehicle or treatment solutions (20 ml/kg body weight) which were constituted in 
90% olive oil/10% ethanol (v/v). The appearance of fat depositions (steatosis) in H&E stained 
liver sections of all treatment groups (likely caused by olive oil) supports the observation that 
the injection volume was too high. It was decided, however, to inject mice with a relatively 
large volume in order to avoid precipitation of xenoestrogens from the olive oil/ethanol 
solution. The increase in NF-κB activity observed at 6 hours was reduced by 24 hours post 
injection in all treatment and control groups but a significant signal in mice exposed to 
oestrogen positive soil extracts was not detectable. Due to a limited volume of soil extracts 
that was available, it was only possible to expose mice to soil extracts by i.p. injection once 
with 3 mice per group to be able to conduct statistical analysis. Longer treatments may be 
necessary to detect hepatic inflammation by IVIS as observed following exposure to EE and 
butyl paraben which were administered by i.p. injection on 3 consecutive days. 
PBC is believed to be triggered in genetically pre-disposed individuals through exposure to an 
environmental chemical(s)/toxin(s) or infectious agent(s). A link between the exposure to 
oestrogens in the form of hormonal replacement therapy and an increased risk of developing 
PBC exist (Gershwin et al., 2005) suggesting that exposure to xenoestrogens around a waste 
site could, at least in part, pose an environmental risk factor for the development of PBC. 
Taking into consideration several factors including the amount of soil collected and the final 
extraction volume, it seems rather unlikely that exposure to a xenoestrogen alone could be the 
sole trigger for such a disease. On the basis of dose response data for the hERα and 
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approximation of EC50 values it was estimated that, at a dilution of 1/5000, waste site soil 
sample 3 has similar oestrogenic activity as 1 pM E2 (10
-12
 M). This suggests that the 
concentration of xenoestrogens in waste site sample 3 was approximately within the range of 
1-10 nM E2 equivalents. The concentration of E2 equivalents in waste site soil sample 3 was 
therefore calculated to be in the range of 80 – 800 pmol/kg soil. If the oestrogenic activity in 
waste site soil sample 3 was associated solely with E2, this is equivalent to 22-220 nM E2/kg 
soil.  In sexually mature adult women, typical serum E2 concentrations are within 200-
1000 pM. Assuming a serum volume of 4L and that only serum levels of E2 are relevant, this 
suggests total body E2 levels of 800 – 4000 pmoles/person. If complete oral absorption occurs 
and the distribution, metabolism and excretion of the xenoestrogen(s) were similar to E2, an 
exposure to 1-10 kg soil/person to achieve low oestrogenic activity or exposure to 5-50 kg 
soil/person to achieve high E2 levels would be required to obtain biologically equivalent 
levels of E2. Human ERα dose-response data for waste site soil extract 12 has shown that this 
extract was more potent compared to waste site soil extract 3. Employing the above 
assumptions and calculations, however, exposure to 0.1-1 kg soil/person (low oestrogenic 
activity) or 0.5-5 kg soil/person (high oestrogenic activity) would still be required to achieve 
biologically relevant serum levels of E2 equivalents. Estimated concentrations of E2 
equivalents present in waste site ethanol soil extracts 3 and 12 and mass of soil required for 
exposure to result in oestrogenic activity are summarised in Table 5.3.  
 
Waste site extract 3 Waste site extract 12 
Approximate range of concentration of E2 
equivalents in soil extracts 
1 - 10 nM 10 – 100 nM 
Approximate range of concentration of E2 
equivalents per kg soil 
80 – 800 pmoles 800-8000 pmoles 
Range of mass of E2 equivalent per kg soil 22-220 ng 220 – 2200 ng 
Mass of soil required for exposure to 
achieve low oestrogenic activity 
1 – 10 kg 0.1 – 1 kg 
Mass of soil required for exposure to 
achieve high oestrogenic activity 
5 – 50 kg 0.5 – 5 kg 
Table 5.3 Approximate concentration of E2 equivalents in waste site soil extracts 3 and 12 and 
mass of soil required for exposure to achieve low and high oestrogenic activity, respectively. 
 
Taking these estimations into account, exposure to large amounts of waste site soil extracts 
seems to be required for xenoestrogens to cause any adverse hepatic effects through endocrine 
disruption. Considering that some of the soil-based xenoestrogens may have ‘super-activating’ 
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characteristics with an ERβ variant, however, these chemicals could be a component of a 
xenobiotic insult that triggers PBC.  
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Chapter 6. Investigation of ER expression in primary biliary epithelial 
cells 
Biliary epithelial cells (BECs), which line the intrahepatic bile ducts in the liver, play an 
important role in disease progression of various cholestatic liver diseases collectively termed 
cholangiopathies. Cholangiopathies are commonly characterised by the loss of intrahepatic 
bile ducts and therefore also known as ‘Vanishing Bile Duct Syndromes’ (Desmet et al., 
1998). To compensate for a reduction in bile ducts, residual ducts proliferate in the early 
stages of the disease up to a point where the loss of ducts outweighs the proliferative potential 
leading to terminal ductopenia and thus cholestatic conditions (Alvaro et al., 2000b; Alvaro et 
al., 2006b).  
It has been established that the proliferation of BECs is regulated by a number of factors 
including hormones, growth factors and neuropeptides (Alvaro et al., 2000b). More recently, 
it was discovered that in rats, oestrogens are involved in the modulation of the proliferative 
response of BECs to damage in vitro and in vivo and that rat cholangiocytes express ERα and 
ERβ (Alvaro et al., 2002). Both ER subtypes have also been reported to be expressed in BECs 
in several liver diseases in humans (Alvaro et al., 2006a; Torrice et al., 2006) including in the 
most frequent acquired cholangiopathy PBC (Alvaro et al., 2004). In contrast, BECs in 
normal (healthy) liver have not been found to express any ERs (Alvaro et al., 2004).  
Considering the role of oestrogens in BEC proliferation in disease and the finding that, in 
humans, ERs are expressed in BECs in diseased liver including PBC but not in healthy liver, 
one may suggest that a correlation between ER expression in BECs and disease progression 
exists and that oestrogens may play an important role in the modulation of PBC and other 
liver diseases. In fact, PBC predominantly occurs in females (9:1 female/male ratio) and 
commonly affects women in the peri- and post-menopausal period during which oestrogen 
levels decrease (Alvaro et al., 2006b) further highlighting a potential role for oestrogen in 
PBC progression.  
Since oestrogens largely mediate their effect through interaction with the ERs, expression of 
the receptor is required in oestrogen target tissues or cells. Although a number of studies 
regarding ER expression in BECs have been conducted, data especially for ER expression in 
mouse BECs is limited. The aim of this chapter was therefore to investigate if BECs isolated 
from human as well as mouse liver express the ERs.  
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6.1. ER expression in primary hBECs  
To examine the expression of hERα and hERβ in primary hBECs, cells were isolated from 
surgical liver resections as described in Section 2.4. Following isolations, hBECs were 
cultured until they were confluent enough for use in experiments. 
To confirm that cells isolated from human liver tissue are BECs, and to verify that the isolated 
cell population is pure, cells cultured for 4 days following isolation were examined for 
expression of the epithelial marker CK19 and the mesenchymal cell marker vimentin, which 
is often used to test if cells undergo epithelial-to-mesenchymal transdifferentiation (Lamouille 
et al., 2014), by immunocytochemistry. Figure 6.1 demonstrates that the majority of cells in 
the field of view stained positive for CK19 indicating that primarily hBECs were isolated. A 
number of cells, however, stained positive for vimentin indicating that either 1) the isolated 
cell population is not pure and contains cells which are of mesenchymal origin such as 
fibroblasts or that 2) hBECs transdifferentiate from an epithelial to a mesenchymal phenotype 
with time in culture. 
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Figure 6.1 Confirmation of CK19 expression in primary hBECs. Immunocytochemical staining for 
the epithelial marker CK19 and the mesenchymal cell marker vimentin in hBECs isolated from human 
liver tissue. Following isolation, hBECs were cultured for 4 days prior to fixation, blocking and 
staining. No 1° control cells were incubated with the secondary antibody only. Cell nuclei were 
counterstained with DAPI. Scale bars: 50 μm. Data are typical of three separate experiments. 
 
Following confirmation that isolated cells from human liver resections represent a relatively 
pure population of hBECs, it was examined whether hBECs express the ERs. BECs were 
isolated from human liver tissue and cultured for different time periods until hBECs expanded 
enough to be harvested for isolation of RNA and analysis for the expression of hERα and 
hERβ mRNA. Note that hBECs cultured for 3, 7 and 17 days are from the same liver 
resection whereas hBECs for all other time points were isolated from separate liver resections 
(see also Table 6.1). 
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Time in culture Number of passages Liver Resection # Tissue code 
0 days (1) - 1 NHL44 
0 days (2) - 2 NHL43 
3 days - 
3 NHL42 7 days - 
17 days - 
20 days - 4 NHL41 
24 days - 5 
No information 
available 
30 days 1 6 
No information 
available 
41 days 1 7 
No information 
available 
43 days 1 8 
No information 
available 
Table 6.1 Details for culture time, number of passages and source of isolated primary hBECs. 
 
Figure 6.2A shows that cells cultured for 3 days express detectable levels of hERα mRNA 
with reduced, but detectable levels of hERα found in cells cultured for 7 days (liver resection 
#3). ERα mRNA was also detected in hBECs after 24 days in culture (Figure 6.2B, liver 
resection #5). Human BECs cultured for other time periods (i.e. 17, 20, 30, 41 and 43 days) 
did not express any detectable levels of hERα mRNA. There was no evidence for the 
expression of hERβ mRNA in cultured hBECs isolated from any of the 8 liver resections and 
grown for the indicated time periods.  
Cells that were harvested immediately after isolation (0 days (1) and 0 days (2)) did not show 
any detectable levels of hERα and hERβ mRNA (Figure 6.2A). These cells did not express 
detectable levels of CK19 mRNA (as opposed to hBECs that were cultured after isolation), 
however, suggesting that the initial number of hBECs isolated is low and that cells require 
time in culture to expand.  
 195 
 
 
Figure 6.2 Examination for hER mRNA expression in primary hBECs. RT-PCR analysis for 
hERα and hERβ mRNA expression in primary hBECs that were isolated from human liver tissue and 
cultured for (A) 0-20 days or (B) 24-43 days as indicated. Human BECs were also analysed for CK19 
expression to confirm epithelial origin. The human brest cancer cell lines MCF-7 and MDA-231, the 
human BEC cell line H69, the human neuroblastoma cell line SH-SY5Y as well as whole human liver 
were included as positive or negative controls. RNA was isolated from cells and tissue followed by 
RT-PCR (32 PCR cycles) using primers specific for the indicated mRNA sequences. GAPDH was 
used as a loading control. PCR products were separated by agarose electrophoresis and visualised by 
UV transillumination. 
 
Due to generally low numbers of hBECs that can be isolated at any one time and the 
observation that the isolated cell population of hBECs is not pure and contains cells with a 
mesenchymal phenotype (either due to fibroblast contamination or epithelial-to-mesenchymal 
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transdifferentiation of hBECs), analysis for hER protein expression was performed by 
immunocytochemistry rather than Western Blot. Using immunocytochemistry to determine 
ER protein expression will allow examining if the hER is co-localised in cells that stain 
positive for CK19 for verification of potential ER expression in hBECs.  
Figure 6.3 demonstrates that double staining for expression of the epithelial marker CK19 and 
the hERα did not show any detectable levels of hERα protein in isolated hBECs (liver 
resection #2) cultured for 5 days. It appears that the anti-mouse secondary antibody is, 
however, able to bind to Dynabeads used for immunomagnetic purification of hBECs. This 
results in green staining which resembles beads (see also no 1° control). Dynabeads are 
indicated with an arrow in expanded images of hERα staining (A and B).  
Although hERα protein was undetectable in hBECs, staining for hERβ has shown that this 
receptor subtype was detected in some CK19 positive cells, exhibiting nuclear localisation 
(Figure 6.4). Arrows with a drawn-through line indicate nuclear hERβ staining whereas 
arrows with an interrupted line indicate staining of Dynabeads in expanded images (Figure 
6.4, images A and B).  
MCF-7 cells, which express the hERα and HEK293 cells which are ER negative (see Figure 
3.8 and Figure 3.18) were used as controls and were similarly stained. Figure 6.5 
demonstrates that hERα, but not hERβ was detectable in MCF-7 cells with hERα being 
localised in cell nuclei. Double staining of HEK293 cells did not show any detectable levels 
of hERα and hERβ (Figure 6.6).  
These results indicate that although hERα mRNA was detectable in hBECs from 2 separate 
liver resection with culture periods of 3-7 and 24 days (#3 and #5, respectively), hERα protein 
was not shown to be expressed in hBECs isolated from liver resection #2 following culture 
for 5 days. Despite the lack of detection of hERβ mRNA in hBECs from liver resections, 
immunocytochemical analysis has shown that the hERβ protein can be detected in isolated, 
cultured hBECs.  
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Figure 6.3 Analysis for hERα protein expression in primary hBECs. Immunocytochemical double staining for the expression of CK19 and hERα protein in 
primary hBECs isolated from human liver tissue. Following isolation, cells were cultured for 5 days prior to fixation, blocking and staining. No 1° control cells were 
incubated with the secondary antibodies only.  Cell nuclei were counterstained with DAPI. Scale bars: 50 μm. Data are representative of two separate experiments. 
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Figure 6.4 Analysis for hERβ protein expression in primary hBECs. Immunocytochemical double staining for the expression of CK19 and hERβ protein in 
primary hBECs isolated from human liver tissue. Following isolation, cells were cultured for 5 days prior to fixation, blocking and staining. No 1° control cells were 
incubated with the secondary antibodies only.  Cell nuclei were counterstained with DAPI. Scale bars: 50 μm. Data are representative of two separate experiments. 
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Figure 6.5 Analysis for hER protein expression in MCF-7 cells. Immunocytochemical double staining for the expression of CK19 and hERα or hERβ protein in 
MCF-7 cells for verification of correct antibody functioning. No 1° control cells were incubated with the secondary antibodies only.  Cell nuclei were counterstained 
with DAPI. Scale bars: 50 μm. Data are representative of two separate experiments. 
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Figure 6.6 Analysis for hER protein expression in HEK293 cells. Immunocytochemical double staining for the expression of CK19 and hERα or hERβ protein in 
HEK293 cells for verification of correct antibody functioning. No 1° control cells were incubated with the secondary antibodies only. Cell nuclei were 
counterstained with DAPI. Scale bars: 50 μm. Data are representative of two separate experiments. 
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6.2. ER expression in primary mBECs 
Although ERα and ERβ have been reported to be expressed in human and rat BECs and their 
expression markedly upregulated in a disease setting (Alvaro et al., 2000a; Alvaro et al., 
2004), there is limited data in the literature regarding ER expression in mBECs.  
To examine if mBECs express the mERs, primary BECs were isolated from C57Bl/6 wt 
mouse liver as described in Section 2.5. Since Dynabeads used for immunomagnetic 
purification of hBECs are specific to human, they could not be used for the isolation of 
mBECs. Figure 6.7 shows that isolation generated a population of cells which, after 24 hours 
in culture, had similar morphology and which proliferated in culture (see image taken at 48 
hours).  
 
Figure 6.7 Light microscope images of primary mBECs. Images were taken 24 hours (left panel) 
and 48 hours (right panel) after isolation of cells from murine liver.  
 
Immunocytochemical staining of isolated cells from mouse liver for the epithelial marker 
CK19 after 2 days in culture confirmed that mBECs can be isolated without immunomagnetic 
purification with Dynabeads (Figure 6.8). Several cells did not stain positive for CK19 
indicating that isolated cells do not represent a pure population of mBECs. Counting CK19 
positive cells and total cell numbers from 3 separate fields of view revealed that an average of 
57% of isolated cells were mBECs. 
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Figure 6.8 Confirmation of CK19 expression in primary mBECs. Immunocytochemical staining 
for the epithelial marker CK19 in mBECs isolated from mouse liver from C57Bl/6 wt mice. Following 
isolation, mBECs were cultured for 2 days prior to fixation, blocking and staining. No 1° control cells 
were incubated with the secondary antibody only. Cell nuclei were counterstained with DAPI. Scale 
bars: 100 μm. 
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Examination for mER expression by RT-PCR shows that after 6 days in culture, mERα 
mRNA was detectable in primary mBECs, however, there was no evidence for mERβ mRNA 
expression in these cells. Detectable mRNA expression of the epithelial marker CK19 
confirms that the isolated cells were mBECs although the presence of vimentin positive cells 
suggests that during their time in culture, mBECs may have undergone epithelial-
mesenchymal trans-differentiation to fibroblasts or that fibroblasts contaminated isolated 
mBECs and expanded in culture. The hepatocyte marker CYP2E1 was not detectable in 
isolated mBECs indicating that hepatocytes are not part of the isolated cell population. 
Western Blot analysis showed that mERα protein was not detectable in isolated mBECs after 
0 and 2 days in culture. There was evidence for the expression of mERβ protein in mBECs, 
however, at 0 but especially 2 days in culture suggesting that mBECs express the mERβ 
which may increase with time in culture. CYP2E1 protein was detectable in mBECs after 
0 hours, which decreased after 2 days in culture, suggesting that hepatocytes may have been 
present at isolation. Since hepatocytes do not proliferate in culture and if viable, de-
differentiate, they are unlikely, however, to be present in isolated cells grown in cultures. 
Murine uterus, liver and ovary tissues were included as positive and/or negative controls.  
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Figure 6.9 Examination for mER expression in primary mBECs by RT-PCR and Western Blot. 
(A) RT-PCR analysis for mouse hERα and hERβ mRNA expression in primary mBECs that were in 
culture for 6 days, 603B cells and the indicated murine tissues. Mouse BECs were also analysed for 
CK19, Vimentin and CYP2E1 mRNA expression. RNA was isolated from cells as well as murine 
tissue followed by RT-PCR (30 PCR cycles) using primers specific for the indicated mRNA 
sequences. GAPDH was used as a loading control. PCR products were separated by agarose 
electrophoresis and visualised by UV transillumination. (B) Western Blot analysis for mouse ERα and 
ERβ protein expression in primary mBECs that were in culture for 6 days, 603B cells and the 
indicated murine tissues. Total protein was isolated from cells and murine tissue following separation 
by gel electrophoresis and visualisation (20 μg total protein/lane). 
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Since RT-PCR and Western Blot analysis suggest that other cell types other than BECs may 
be present in the cell population, immunocytochemical double staining for the epithelial 
marker CK19 and the mERα or mERβ was performed to verify that the expression of the 
mER proteins is localised to CK19 positive cells (mBECs). Figure 6.10 demonstrates that a 
population of cells cultured for 1 day after isolation stained positive for CK19, however, 
several cells in the field of view were CK19 negative confirming that the cell population was 
not pure. Staining for mERα and mERβ shows that both receptor subtypes were not detectable 
in CK19 positive or negative cells grown in culture for 1 day. 
In isolated cells that were cultured for 4 days, mERα protein was not detected in CK19 
positive cells (Figure 6.11). Staining for mERβ protein demonstrates that there was evidence 
for mERβ protein expression in cells that also stained positive for CK19 with mERβ 
exhibiting nuclear localisation. 
These data suggest that mBECs are unlikely to express detectable levels of the mERs in 
normal liver. Following time in culture which may mimic a disease setting, however, 
expression of mERβ protein was induced.  
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Figure 6.10 Examination for mER expression in primary mBECs (1 day) by immunocytochemistry. Immunocytochemical double staining for the expression of 
CK19 and mERα or mERβ protein in primary hBECs isolated from mouse livers. Following isolation, cells were cultured for 1 day as indicated prior to fixation, 
blocking and staining. No 1° control cells were incubated with the secondary antibodies only. Cell nuclei were counterstained with DAPI. Scale bars: 50 μm. Data 
are representative of two separate experiments. 
  
 
2
0
7
 
 
Figure 6.11 Examination for mER expression in primary mBECs (4 days) by immunocytochemistry. Immunocytochemical double staining for the expression 
of CK19 and mERα or mERβ protein in primary hBECs isolated from mouse livers. Following isolation, cells were cultured for 4 days as indicated prior to fixation, 
blocking and staining. No 1° control cells were incubated with the secondary antibodies only. Cell nuclei were counterstained with DAPI. Scale bars: 50 μm. Data 
are representative of two separate experiments. 
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6.3. Discussion 
Since oestrogens have been shown to modulate the proliferative ability of hBECs in 
cholangiopathies, and their effects are largely mediated through interaction with the ERs, this 
chapter aimed to investigate if isolated human and mouse BECs express the ERs. 
Examination of hBECs for the expression of the hERα and hERβ has shown that hBECs 
hERα mRNA transcript was detected in hBECs isolated from 2 separate liver resections. The 
majority of hBECs isolated did not express any detectable levels of hERα mRNA (Figure 6.2). 
ERα protein was not found to be expressed in any of the isolated hBECs analysed by 
immunocytochemistry (Figure 6.3). Despite the lack of evidence for hERβ mRNA expression 
in all isolated hBECs (Figure 6.2), immunocytochemical staining showed that hBECs express 
detectable levels of hERβ protein after 5 days in culture which was localised to the nucleus 
(Figure 6.4). Access to patient and clinical data was not available and as a result it is unclear 
under which conditions (e.g. the type of liver disease or administered medication) the hERβ 
was expressed in isolated hBECs. Since liver resections are normally performed in patients 
with secondary tumours, and the tissue used was from histologically normal margins, it can be 
assumed that BECs were isolated from normal liver and in a healthy state.  
A predominance of ERβ expression in a disease setting has been reported by several studies. 
Alvaro et al. (2004) have shown that expression of hERβ in hBECs from PBC patients was 
markedly increased (50-65%, percentage of hERβ positive BECs over the total BEC number) 
throughout all stages (I-IV) of the disease. The expression of hERα increased from stage I 
(1%) to stage III (12%) and, interestingly, in the terminal stage of the disease which is 
characterised by severe ductopenic conditions, hERα was found to be undetectable in hBECs 
(Alvaro et al., 2004). Furthermore, it was reported that hERα was co-localised to hBECs 
which stained positive for the proliferation marker PCNA suggesting that the hERα is 
associated with BEC proliferation. In contrast, hERβ expression was linked to an increase in 
the apoptotic markers TUNEL and Fas which were detectable at high levels in disease state 
IV indicating that expression of hERβ may be related to apoptosis in hBECs thus leading to 
ductopenia. BECs from normal liver were not found to express any hERs (Alvaro et al., 2004).  
An increase in ERβ expression in BECs in a disease setting has also been reported in rat 
(Alvaro et al., 2000a). Although rat BECs were shown to express low levels of rat (r) ERα 
and rERβ in healthy liver, rERβ expression was markedly increased in rats subject to bile duct 
ligation, a common model used to induce cholangiocyte injury and proliferation and thus 
cholangiopathic conditions (Alvaro et al., 2006b). This study further showed that proliferation 
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of rBECs was associated with oestrogens and the rERs since treatment with the ER 
antagonists ICI182,780 or tamoxifen inhibited rBEC proliferation in vivo and in vitro (Alvaro 
et al., 2000a). 
In terms of ER expression in the mouse, there was little evidence for the expression of mER 
proteins in isolated mBECs (Figure 6.9, Figure 6.10). It appears that with time in culture, 
however, mBECs expressed detectable levels of mERβ protein as determined by 
immunocytochemical staining and Western Blot. This suggests that mERβ may be 
predominantly expressed in mBECs (Figure 6.9, Figure 6.11). Although limited data is 
available regarding mER expression in mBECs in a disease setting, Xia et al. (2012) have 
reported that both mERα and mERβ mRNA transcripts are expressed in mBECs and that 
expression of both increase in culture (Xia et al., 2012). Similarly, protein and mRNA 
transcripts of mERα and mERβ were shown to be expressed in mBECs with mERα at least in 
females playing a role in the regulation of IL6 expression (Isse et al., 2010). Previous work 
has shown that hepatocytes, but not mBECs stained positive for mERα in mouse liver sections 
of control animals and mERα expression was increased in hepatocytes following injury 
induced by bile duct ligation (Axon, Thesis 2012). ERβ was found to be expressed in mBECs 
but not in hepatocytes in control animals whereas bile duct ligation induced the expression of 
detectable levels of mERβ in hepatocytes suggesting that mERβ is upregulated in a disease 
setting (Axon, Thesis 2012).  
Taking into account data in this chapter as well as data available in the literature, the 
functional role of ERβ in cholangiocytes under normal conditions is likely to be negligible 
since its expression is low. However, considering that ERβ protein was expressed in hBECs 
and mBECs with time in culture and studies reporting that ERβ is markedly upregulated in 
BECs in a disease setting in both human and rat, ERβ could play a role in the modulation of 
disease progression in cholangiopathies, such as in PBC. ERα activation is linked with 
proliferation and growth of target tissues and cells (Diel, 2002) whereas ERβ is largely 
associated with protective modulatory effects against cell proliferation (Gustafsson, 1999). 
Therefore, activation of the ERβ may antagonise ERα-mediated proliferative responses in 
BECs promoting the disappearance of bile ducts and leading to vanishing bile duct syndromes. 
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Chapter 7. General discussion 
Numerous chemicals with potential endocrine disrupting properties are contained in many 
consumer products including foodstuffs, personal care products and household items. With 
the development of new materials for products, tools and devices aimed at improving our 
everyday lives, exposure to endocrine disrupting chemicals has increased and is linked to 
many endocrine-related diseases including reproductive disorders and cancer. Although 
several mechanisms exist through which EDCs may exert their adverse effects, many EDCs 
were found to target and modulate endogenous oestrogen activity by interfering with 
endogenous oestrogen signalling or by disrupting synthesis, metabolism and transport of 
oestrogens. A common mechanism in modulating oestrogen signalling is through interactions 
of oestrogenic chemicals with the ERs, often because they possess structural similarities to 
endogenous oestrogens. Given the cholestatic effects that high systemic levels of endogenous 
oestrogens can have in the liver, the overall aim of this thesis was to establish whether 
exposure to xenoestrogens may cause similar adverse hepatic effects.  
A number of in vitro assays exist that allow for identification of chemicals with 
xenoestrogenic activity. Testing the potential adverse hepatic effects of xenoestrogens while 
simultaneously taking into consideration exposure routes as well as toxicokinetic and 
toxicodynamic effects requires the use of animal models. Since a large number of transgenic 
mouse models exist which can be employed to study the mechanisms behind xenoestrogen-
mediated toxic effects in follow-on research, the mouse as a species was selected for work as 
part of this thesis.   
In order to determine if chemicals are xenoestrogens in a murine context, a mouse-based in 
vitro reporter gene assay was developed. Given the focus of this thesis on the liver and the 
expression and role that ERα plays in hepatocytes and oestrogen-mediated cholestasis, 
hepatocytes were the preferred cell type for assessing the oestrogenic activity of chemicals. 
However, practical limitations regarding the use of hepatocytes exist. Hepatocytes do not 
proliferate in vitro and, therefore, transfection efficiencies are often low. Furthermore, the 
isolation of hepatocytes from mouse liver is time consuming, expensive and requires the 
termination of a large number of animals. Since an in vitro assay was required to be capable 
of semi-high throughput screening of a relatively large number of samples with an appropriate 
number of replicates, the use of mouse hepatocytes did not seem like a realistic option. 
Instead, the mouse pancreatohepatobiliary ductal cell lines 603B and LTPA were employed. 
Given the role of ERs in BECs (i.e., induction of ER expression and ER-mediated BEC 
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proliferation in a disease setting), these were considered as an appropriate alternative to 
hepatocytes.  
Neither 603B, nor LTPA cells expressed detectable levels of the mER subtypes mERα and 
mERβ as determined by RT-PCR, Western Blot and immunocytochemistry. The mERα and 
two mERβ (mERβv1 and mERβv2) cDNA sequences were, therefore, cloned from mouse 
uterine and ovary tissue, respectively, and ectopically expressed in the two cell lines. Both 
mERβ variants, but not the mERα, were effectively functionally activated by oestrogens in the 
BEC cell line 603B. Mouse ERα exhibited functional activity in ductal pancreatic LTPA cells. 
The reason(s) for the differential activities of the mER subtypes in 603B and LTPA cells are 
not known but may be due to differences in cell-line dependent cofactor protein expression 
required for mER transcriptional function. Should this difference extend to human 
pancreatohepatobiliary tissues, it would suggest that hERβ transcriptional function 
predominates in BECs. 
Although both mERβ variants were functionally active in 603B cells, the mERβv2 exhibited 
nearly full constitutive activity and required inactivation by the ER antagonist ICI182,780 
prior to activation by oestrogen. Compared to the mERβv1, mERβv2 lacks an in-frame exon 
in the coding region creating a protein lacking 18 amino acids in the ligand binding domain. 
This deletion might affect the type and affinity of ligands capable of binding to the mERβv2 
which could account for the differences in transcriptional activity observed between the two 
mouse ERβ isoforms. Since constitutive activity of the mERβv2 has not been reported 
elsewhere, however, it may just be a unique observation in the cell line (603B) in which the 
receptor was expressed.  
Several different splice variants of the hERβ have been described in humans (Sotoca et al., 
2012) and interrogation of the NCBI database for the existence of variant hERβ transcripts 
indicates that at least 7 splice variants have thus far been identified, leading to 5 variant 
proteins. Clustal alignment of 5 hERβ variant proteins with mERβv1 and mERβv2 (Appendix 
D) shows that all hERβ proteins lack the 18 amino acid insertion present in mERβv1 and, 
therefore, hERβ proteins are more likely to respond to oestrogens and xenoestrogens similarly 
to the mERβv2 protein.  
Following development of the mouse-based reporter gene assay, the food additive tartrazine 
was tested for its ability to interact with the mERs. The sulfonated food dye tartrazine has 
previously been shown to activate the hERα in reporter gene assays in two independent 
studies (Datta and Lundin-Schiller, 2008; Axon et al., 2012). I.p. injection of tartrazine at a 
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dose of 50 mg/kg bw/day (10 daily doses over 14 days, note the ADI is 7.5 mg/kg bw/day) 
resulted in a mild cholestatic injury in mice (Axon, Thesis 2012). Since oestrogens have been 
suggested to cause cholestasis via ERα-mediated alterations of hepatic transporter expression 
(Yamamoto et al., 2006), it was initially hypothesised that the tartrazine-induced cholestatic 
effects may be associated with activation of the murine ERs. Data in this thesis demonstrate, 
however, that tartrazine, four of its sulfonated gut-derived metabolites and a major sulfonated 
contaminant of the food additive failed to activate/antagonise the mERα in the developed 
mouse-based reporter gene assay.  
Tartrazine, its metabolites and the contaminant were also examined for their ability to interact 
with the mERβ. Data has shown that ERs are unlikely to be expressed in normal BECs but 
ERβ expression was detectable in human and mouse BECs after time in culture. Similar 
results have been reported by other researchers which showed that ERs were undetectable in 
normal liver of humans and at a low level in rat liver (Alvaro et al., 2000a; Alvaro et al., 
2004). In a liver disease setting, however, ERβ expression in BECs was found to be markedly 
increased and thought to influence the proliferation capacity of bile ducts which determines 
disease progression in cholestatic liver conditions (Alvaro et al., 2000a; Alvaro et al., 2004; 
Marzioni et al., 2012). Data in this thesis indicate that tartrazine, four of its sulfonated 
metabolites and a major sulfonated contaminant of the food additive lack mERβv1 and 
mERβv2 agonist or antagonist activities in the developed reporter gene assay. Therefore, the 
observed cholestatic effects caused by tartrazine in mice are likely to occur independent of the 
mERs.  
Cholestatic effects of oestrogens in the liver are thought to be mediated by either an ERα-
dependent suppression of hepatic transporter expression (Yamamoto et al., 2006) and/or 
inhibition of hepatic bile acid transporters that leads to impaired bile acid secretion and thus 
cholestasis and subsequent liver toxicity (Stieger et al., 2000). Given that tartrazine, its 
metabolites/contaminant did not interact with the mERs, ER-mediated suppression of hepatic 
transporter expression is unlikely to account for cholestasis caused by tartrazine. Although the 
effects that tartrazine may have on bile acid transporter activity were not investigated, there is 
a third possible mechanism by which tartrazine may have caused cholestasis. Previous 
research has reported that tartrazine inhibited human sulfotransferases (Bamforth et al., 1993). 
Since sulfation of some bile acids is required for their secretion and excretion (Alnouti, 2009), 
inhibition of sulfotransferases may result in a build-up of bile acids in the liver and thus 
cholestasis. Therefore, the effects of tartrazine on murine hepatic sulphotransferase activities 
were examined. Data demonstrates that tartrazine – and for the first time – that four of its 
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sulfated metabolites and a major sulfated contaminant inhibited dopamine sulfotransferase in 
a dose-dependent manner in murine hepatic S9 fractions.  
Tartrazine is fairly water soluble and, when exposed to via the oral route as a food additive, 
not significantly absorbed intact by the gastrointestinal tract. Therefore, tartrazine-mediated 
cholestatic effects following i.p. injection are likely to be irrelevant in humans, unless the 
adverse hepatic effects can be attributed to any metabolites of tartrazine that are absorbed. To 
test the food additive relevance of these observations, tartrazine was orally administered to 
mice. Since alcohol consumption is associated with an increase in gut permeability, and 
tartrazine is contained in a variety of alcoholic beverages, the food dye was administered in 
combination with ethanol to promote its absorption. Tartrazine alone, but not in combination 
with ethanol caused inflammation in the liver and the gastrointestinal tract without evidence 
of cholestasis. However, these effects occurred without interaction of tartrazine, its gut-
derived metabolites and a contaminant with the mERs and were more likely associated with 
their inhibitory effects on sulfotransferase enzyme activities. Given the role of 
sulfotransferases in bile acid excretion, the initiating event leading to adverse hepatic effects 
through systemic exposure – but not oral exposure – is, therefore, likely to be due to an 
inhibition of bile acid sulfation and cholestasis. Considering that tartrazine was administered 
at doses in excess (6.6-fold) of the current ADI, the absence of any cholestatic effects after 
oral exposure, even on a background of chronic high levels of exposure to alcohol, are 
unlikely to be of toxicological relevance in respect of its use as a food additive. Since human 
dopamine sulfotransferase were inhibited by tartrazine at lower concentrations (6.7 µM) 
(Bamforth et al., 1993) compared to murine sulfotransferase (>100 µM), however, there may 
be a greater potential for tartrazine to disrupt bile acid metabolism in humans. Combined with 
the fact that tartrazine is an activator of the hERα, humans may be more sensitive to 
tartrazine-mediated adverse hepatic effects compared to mice.  
The chronic cholestatic liver disease PBC is believed to be triggered in genetically pre-
disposed individuals through exposure to an environmental chemical(s)/toxin(s) or infectious 
agent(s). High incidences of PBC have been reported to occur around toxic waste sites (Ala et 
al., 2006). Given the ability of oestrogens to cause cholestasis, it was hypothesised that the 
environment around a waste tip site contains a variety of xenoestrogens. Several waste site 
soil extracts activated the hERα in a reporter gene assay in MCF-7 cells. Similarly, waste site 
soil samples activated all three mERs (mERα, mERβv1 and mERβv2) in the initially 
developed mouse-based reporter gene assay. Soil extracts prepared from soil samples 
collected from three separate control sites not in proximity to waste sites failed to activate or 
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had generally low oestrogenic activity in both the human- and mouse-based in vitro assays. 
For the first time, data in this thesis, therefore, demonstrate that xenoestrogens can be 
extracted from and detected in soil samples. Soil samples collected in close proximity to a 
waste site contained higher levels of detectable xenoestrogens compared to soil extracts 
prepared from soil samples collected at control sites not expected to be contaminated with 
chemicals. 
Waste site soil extract-mediated activation of the hERα, mERα and mERβv1 was inhibited by 
the ER antagonist ICI182,780. Although retaining its sensitivity to antagonism by ICI182,780 
when activated by E2 or EE, the ER antagonist failed to inhibit waste site soil extract-
dependent activation of the mERβv2. Assuming that xenoestrogens interact with the ligand 
binding domain of mERβv2 in a similar manner to natural oestrogens, this finding suggests 
that the dissociation rate of xenoestrogens is significantly reduced compared to E2. 
Alternatively, xenoestrogens may activate the mERβv2 via a different mechanism such as 
interacting and binding to the receptor through an alternative binding site which could prevent 
ICI182,780-mediated antagonism. This finding suggests that soil-based xenoestrogens may 
have ‘super-activating’ characteristics with an ERβ variant. Considering that clustal sequence 
alignments have shown that all hERβ protein variants share a higher degree of sequence 
homology in their ligand binding domain with the mERβv2 rather than the mERβv1, the 
hERβ is more likely to respond to xenoestrogens similarly to the mERβv2 protein.  Although 
ERβ expression in BECs under normal conditions is low and its functional role therefore 
likely to be negligible, ERβ expression is markedly up-regulated in a disease setting (Alvaro 
et al., 2006b). ERβ is generally known to antagonise the proliferative effects of ERα and 
Marzioni et al. (2012) reported that an ERβ-selective agonist induced apoptosis in 
cholangiocarcinoma (Marzioni et al., 2012). Since ERα mediates the proliferative response of 
BECs, and BEC proliferation is an important hepatic response counter-acting the loss of bile 
ducts, activation of the ERβ may therefore contribute to cholestatic disease progression. Thus, 
it is tempting to propose that the role xenoestrogens may play in the development of PBC is 
via an inhibition of bile duct proliferation and/or promotion of vanishing bile duct syndrome 
through a sustained activation of ERβ in cholangiocytes. Based on the calculated amount of 
soil an individual needs to be exposed to (1-50 kg of contaminated soil, see Section 5.5), 
however, it seems unlikely that an ERβ-targeting EDC alone could be the trigger for a disease 
such as PBC. If exposure to xenoestrogens is involved in PBC disease progression, it is more 
likely as a component of a xenobiotic insult, such as PDC-E2 targeting xenobiotics, that 
triggers PBC.  
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Overall, work in this thesis demonstrates that if significant exposure to environmental 
xenoestrogens occurs, they can have adverse hepatic effects and may be part of a trigger 
process in cholestatic liver diseases. Moreover, work presented in this thesis offers a 
foundation for future research and provides important information which may help to 
elucidate potential triggers in cholestatic liver diseases such as PBC. In this context, future 
work could be aimed at identifying the chemical nature of the compound(s) present in waste 
site soil extracts in order to find their source and prevent contamination. Provided that enough 
resources are available, it would further be interesting to examine the effects that chronic 
exposure to waste site soil extracts may have in vivo in mice and to determine the mechanism 
behind waste site soil extract-mediated hepatic adverse effects (i.e. inhibition of SULTs or 
ERα-dependent inhibition of bile acid transporters in hepatocytes).  
Although it is undoubtedly clear that the development of new medicines and materials for 
modern products has significantly contributed to improvements of everyday lives, continued 
production, use and release of novel chemicals into the environment necessitates continued 
research and strict monitoring to prevent environment contamination and to reduce the risk for 
development of endocrine disrupters-mediated diseases in wildlife and humans.  
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Appendix A.  
Alignment of mouse ERα (mERa) mRNA sequence with sequencing results of the mERα 
insert cloned into the destination vector pcDNA3.1 (Cloned mERa). The clustal alignment 
software (http://www.ebi.ac.uk/Tools/msa/clustalo/) was used. *, identical amino acid 
between sequences. 
CLUSTAL O(1.2.1) multiple sequence alignment  
 
Cloned mERa   ATGACCATGACCCTTCACACCAAAGCCTCGGGAATGGCCTTGCTGCACCAGATCCAAGGG 
mERa mRNA     ATGACCATGACCCTTCACACCAAAGCCTCGGGAATGGCCTTGCTGCACCAGATCCAAGGG 
              ************************************************************ 
 
Cloned mERa   AACGAGCTGGAGCCCCTCAACCGCCCGCAGCTCAAGATGCCCATGGAGAGGGCCCTGGGC 
mERa mRNA     AACGAGCTGGAGCCCCTCAACCGCCCGCAGCTCAAGATGCCCATGGAGAGGGCCCTGGGC 
              ************************************************************ 
 
Cloned mERa   GAGGTATACGTGGACAACAGCAAGCCCACTGTGTTCAACTACCCCGAGGGCGCCGCCTAC 
mERa mRNA     GAGGTATACGTGGACAACAGCAAGCCCACTGTGTTCAACTACCCCGAGGGCGCCGCCTAC 
              ************************************************************ 
 
Cloned mERa   GAGTTCAACGCCGCCGCCGCCGCCGCCGCCGCCGCCTCGGCGCCGGTCTACGGCCAGTCG 
mERa mRNA     GAGTTCAACGCCGCCGCCGCCGCCGCCGCCGCCGCCTCGGCGCCGGTCTACGGCCAGTCG 
              ************************************************************ 
 
Cloned mERa   GGCATCGCCTACGGCCCCGGGTCGGAGGCGGCCGCCTTCAGTGCCAACAGCCTGGGGGCT 
mERa mRNA     GGCATCGCCTACGGCCCCGGGTCGGAGGCGGCCGCCTTCAGTGCCAACAGCCTGGGGGCT 
              ************************************************************ 
 
Cloned mERa   TTCCCCCAGCTCAACAGCGTGTCGCCTAGCCCGCTGATGCTGCTGCACCCGCCGCCGCAG 
mERa mRNA     TTCCCCCAGCTCAACAGCGTGTCGCCTAGCCCGCTGATGCTGCTGCACCCGCCGCCGCAG 
              ************************************************************ 
 
Cloned mERa   CTGTCTCCTTTCCTGCACCCGCACGGCCAGCAGGTGCCCTACTACCTGGAGAACGAGCCC 
mERa mRNA     CTGTCTCCTTTCCTGCACCCGCACGGCCAGCAGGTGCCCTACTACCTGGAGAACGAGCCC 
              ************************************************************ 
 
Cloned mERa   AGCGCCTACGCCGTGCGCGACACCGGCCCTCCCGCCTTCTACAGGTCTAATTCTGACAAT 
mERa mRNA     AGCGCCTACGCCGTGCGCGACACCGGCCCTCCCGCCTTCTACAGGTCTAATTCTGACAAT 
              ************************************************************ 
 
Cloned mERa   CGACGCCAGAATGGCCGAGAGAGACTGTCCAGCAGTAACGAGAAAGGAAACATGATCATG 
mERa mRNA     CGACGCCAGAATGGCCGAGAGAGACTGTCCAGCAGTAACGAGAAAGGAAACATGATCATG 
              ************************************************************ 
 
Cloned mERa   GAGTCTGCCAAGGAGACTCGCTACTGTGCCGTGTGCAATGACTATGCCTCTGGCTACCAT 
mERa mRNA     GAGTCTGCCAAGGAGACTCGCTACTGTGCCGTGTGCAATGACTATGCCTCTGGCTACCAT 
              ************************************************************ 
 
Cloned mERa   TATGGGGTCTGGTCCTGCGAAGGCTGCAAGGCTTTCTTTAAGAGAAGCATTCAAGGACAC 
mERa mRNA     TATGGGGTCTGGTCCTGCGAAGGCTGCAAGGCTTTCTTTAAGAGAAGCATTCAAGGACAC 
              ************************************************************ 
 
Cloned mERa   AATGACTACATGTGTCCAGCTACAAACCAATGCACCATTGACAAGAACCGGAGGAAGAGT 
mERa mRNA     AATGACTACATGTGTCCAGCTACAAACCAATGCACCATTGACAAGAACCGGAGGAAGAGT 
              ************************************************************ 
 
Cloned mERa   TGCCAGGCCTGTCGGCTGCGCAAGTGTTACGAAGTGGGCATGATGAAAGGCGGCATACGG 
mERa mRNA     TGCCAGGCCTGTCGGCTGCGCAAGTGTTACGAAGTGGGCATGATGAAAGGCGGCATACGG 
              ************************************************************ 
 
Cloned mERa   AAAGACCGCCGAGGAGGGAGAATGTTGAAGCACAAGCGTCAGAGAGATGACTTGGAAGGC 
mERa mRNA     AAAGACCGCCGAGGAGGGAGAATGTTGAAGCACAAGCGTCAGAGAGATGACTTGGAAGGC 
              ************************************************************ 
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Cloned mERa   CGAAATGAAATGGGTGCTTCAGGAGACATGAGGGCTGCCAACCTTTGGCCAAGCCCTCTT 
mERa mRNA     CGAAATGAAATGGGTGCTTCAGGAGACATGAGGGCTGCCAACCTTTGGCCAAGCCCTCTT 
              ************************************************************ 
 
Cloned mERa   GTGATTAAGCACACTAAGAAGAATAGCCCTGCCTTGTCCTTGACAGCTGACCAGATGGTC 
mERa mRNA     GTGATTAAGCACACTAAGAAGAATAGCCCTGCCTTGTCCTTGACAGCTGACCAGATGGTC 
              ************************************************************ 
 
Cloned mERa   AGTGCCTTGTTGGATGCTGAACCGCCCATGATCTATTCTGAATATGATCCTTCTAGACCC 
mERa mRNA     AGTGCCTTGTTGGATGCTGAACCGCCCATGATCTATTCTGAATATGATCCTTCTAGACCC 
              ************************************************************ 
 
Cloned mERa   TTCAGTGAAGCCTCAATGATGGGCTTATTGACCAACCTAGCAGATAGGGAGCTGGTTCAT 
mERa mRNA     TTCAGTGAAGCCTCAATGATGGGCTTATTGACCAACCTAGCAGATAGGGAGCTGGTTCAT 
              ************************************************************ 
 
Cloned mERa   ATGATCAACTGGGCAAAGAGAGTGCCAGGCTTTGGGGACTTGAATCTCCATGATCAGGTC 
mERa mRNA     ATGATCAACTGGGCAAAGAGAGTGCCAGGCTTTGGGGACTTGAATCTCCATGATCAGGTC 
              ************************************************************ 
 
Cloned mERa   CACCTTCTCGAGTGTGCCTGGCTGGAGATTCTGATGATTGGTCTCGTCTGGCGCTCCATG 
mERa mRNA     CACCTTCTCGAGTGTGCCTGGCTGGAGATTCTGATGATTGGTCTCGTCTGGCGCTCCATG 
              ************************************************************ 
 
Cloned mERa   GAACACCCGGGGAAGCTCCTGTTTGCTCCTAACTTGCTCCTGGACAGGAATCAAGGTAAA 
mERa mRNA     GAACACCCGGGGAAGCTCCTGTTTGCTCCTAACTTGCTCCTGGACAGGAATCAAGGTAAA 
              ************************************************************ 
 
Cloned mERa   TGTGTGGAAGGCATGGTGGAGATCTTTGACATGTTGCTGGCTACGTCAAGTCGGTTCCGC 
mERa mRNA     TGTGTGGAAGGCATGGTGGAGATCTTTGACATGTTGCTGGCTACGTCAAGTCGGTTCCGC 
              ************************************************************ 
 
Cloned mERa   ATGATGAACCTGCAGGGAGAAGAGTTTGTGTGCCTCAAATCCATCATTTTGCTTAATTCC 
mERa mRNA     ATGATGAACCTGCAGGGAGAAGAGTTTGTGTGCCTCAAATCCATCATTTTGCTTAATTCC 
              ************************************************************ 
 
Cloned mERa   GGAGTGTACACGTTTCTGTCCAGCACCTTGAAGTCTCTGGAAGAGAAGGACCACATCCAC 
mERa mRNA     GGAGTGTACACGTTTCTGTCCAGCACCTTGAAGTCTCTGGAAGAGAAGGACCACATCCAC 
              ************************************************************ 
 
Cloned mERa   CGTGTCCTGGACAAGATCACAGACACTTTGATCCACCTGATGGCCAAAGCTGGCCTGACT 
mERa mRNA     CGTGTCCTGGACAAGATCACAGACACTTTGATCCACCTGATGGCCAAAGCTGGCCTGACT 
              ************************************************************ 
 
Cloned mERa   CTGCAGCAGCAGCATCGCCGCCTAGCTCAGCTCCTTCTCATTCTTTCCCATATCCGGCAC 
mERa mRNA     CTGCAGCAGCAGCATCGCCGCCTAGCTCAGCTCCTTCTCATTCTTTCCCATATCCGGCAC 
              ************************************************************ 
 
Cloned mERa   ATGAGTAACAAAGGCATGGAGCATCTCTACAACATGAAATGCAAGAACGTTGTGCCCCTC 
mERa mRNA     ATGAGTAACAAAGGCATGGAGCATCTCTACAACATGAAATGCAAGAACGTTGTGCCCCTC 
              ************************************************************ 
 
Cloned mERa   TATGACCTGCTCCTGGAGATGTTGGATGCCCACCGCCTTCATGCCCCAGCCAGTCGCATG 
mERa mRNA     TATGACCTGCTCCTGGAGATGTTGGATGCCCACCGCCTTCATGCCCCAGCCAGTCGCATG 
              ************************************************************ 
 
Cloned mERa   GGAGTGCCCCCAGAGGAGCCCAGCCAGACCCAGCTGGCCACCACCAGCTCCACTTCAGCA 
mERa mRNA     GGAGTGCCCCCAGAGGAGCCCAGCCAGACCCAGCTGGCCACCACCAGCTCCACTTCAGCA 
              ************************************************************ 
 
Cloned mERa   CATTCCTTACAAACCTACTACATACCCCCGGAAGCAGAGGGCTTCCCCAACACGATCTGA 
mERa mRNA     CATTCCTTACAAACCTACTACATACCCCCGGAAGCAGAGGGCTTCCCCAACACGATCTGA 
              ************************************************************ 
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Appendix B.  
Alignment of mouse ERβ variant 1 (mERbv1) mRNA sequence with sequencing results 
of the mERβv1 insert cloned into the destination vector pcDNA3.1 (Cloned mERbv1). 
The clustal alignment software (http://www.ebi.ac.uk/Tools/msa/clustalo/) was used. *, 
identical amino acid between sequences. 
CLUSTAL O(1.2.1) multiple sequence alignment  
 
mERbv1 mRNA     ------------------------------------------------------------ 
Cloned mERbv1   ATACTCAAGCTATGCATCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAG 
                                                                             
mERbv1 mRNA     ----------------CCGTGAGTCTCTGAGAGCATCATGTCCATCTGTGCCTCTTCTCA 
Cloned mERbv1   TGTGCTGGAATTCAGGCCGTGAATTCCAGAGAGCATCATGTCCATCTGTGCCTCTTCTCA 
                                ******.*  *:******************************** 
 
mERbv1 mRNA     CAAGGATTTTTCTCAGCTGAGACCTACGCAAGACATGGAGATCAAAAACTCACCATCAAG 
Cloned mERbv1   CAAGGATTTTTCTCAGCTGAGACCTACGCAAGACATGGAGATCAAAAACTCACCATCAAG 
                ************************************************************ 
 
mERbv1 mRNA     CCTTACTTCCCCTGCTTCTTATAACTGTAGCCAGTCCATCCTACCCTTGGAGCATGGTCC 
Cloned mERbv1   CCTTACTTCCCCTGCTTCTTATAACTGTAGCCAGTCCATCCTACCCTTGGAGCATGGTCC 
                ************************************************************ 
 
mERbv1 mRNA     CATCTATATCCCTTCCTCCTATGTAGAGAGCCGTCACGAATACTCAGCCATGACATTCTA 
Cloned mERbv1   CATCTATATCCCTTCCTCCTATGTAGAGAGCCGTCACGAATACTCAGCCATGACATTCTA 
                ************************************************************ 
 
mERbv1 mRNA     CAGTCCTGCTGTGATGAACTACAGTGTTCCCAGCAGCACCGGTAACCTGGAAGGTGGGCC 
Cloned mERbv1   CAGTCCTGCTGTGATGAACTACAGTGTTCCCAGCAGCACCGGTAACCTGGAAGGTGGGCC 
                ************************************************************ 
 
mERbv1 mRNA     TGTTCGCCAGACTGCAAGCCCAAATGTGCTATGGCCAACTTCTGGACACCTCTCTCCTTT 
Cloned mERbv1   TGTTCGCCAGACTGCAAGCCCAAATGTGCTATGGCCAACTTCTGGACACCTCTCTCCTTT 
                ************************************************************ 
 
mERbv1 mRNA     AGCCACCCACTGCCAATCATCGCTTCTCTATGCAGAACCTCAAAAGAGTCCTTGGTGTGA 
Cloned mERbv1   AGCCACCCACTGCCAATCATCGCTTCTCTATGCAGAACCTCAAAAGAGTCCTTGGTGTGA 
                ************************************************************ 
 
mERbv1 mRNA     AGCAAGATCACTAGAACACACCTTGCCTGTAAACAGAGAGACCCTGAAGAGGAAGCTTGG 
Cloned mERbv1   AGCAAGATCACTAGAACACACCTTGCCTGTAAACAGAGAGACCCTGAAGAGGAAGCTTGG 
                ************************************************************ 
 
mERbv1 mRNA     CGGGAGCGGTTGTGCCAGCCCTGTTACTAGTCCAAGCGCCAAGAGGGATGCTCACTTCTG 
Cloned mERbv1   CGGGAGCGGTTGTGCCAGCCCTGTTACTAGTCCAAGCGCCAAGAGGGATGCTCACTTCTG 
                ************************************************************ 
 
mERbv1 mRNA     CGCCGTCTGCAGTGATTATGCATCTGGGTATCATTACGGTGTCTGGTCCTGTGAAGGATG 
Cloned mERbv1   CGCCGTCTGCAGTGATTATGCATCTGGGTATCATTACGGTGTCTGGTCCTGTGAAGGATG 
                ************************************************************ 
 
mERbv1 mRNA     TAAGGCCTTTTTTAAAAGAAGCATTCAAGGACATAATGACTATATCTGTCCAGCCACGAA 
Cloned mERbv1   TAAGGCCTTTTTTAAAAGAAGCATTCAAGGACATAATGACTATATCTGTCCAGCCACGAA 
                ************************************************************ 
 
mERbv1 mRNA     TCAGTGTACCATAGACAAGAACCGGCGTAAAAGCTGCCAGGCCTGCCGACTTCGCAAGTG 
Cloned mERbv1   TCAGTGTACCATAGACAAGAACCGGCGTAAAAGCTGCCAGGCCTGCCGACTTCGCAAGTG 
                ************************************************************ 
 
mERbv1 mRNA     TTACGAAGTAGGAATGGTCAAGTGTGGATCCAGGAGAGAAAGGTGTGGGTACCGAATAGT 
Cloned mERbv1   TTACGAAGTAGGAATGGTCAAGTGTGGATCCAGGAGAGAAAGGTGTGGGTACCGAATAGT 
                ************************************************************ 
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mERbv1 mRNA     ACGAAGACAGAGAAGTGCCAGCGAGCAGGTGCATTGCCTGAACAAAGCCAAGAGAACCAG 
Cloned mERbv1   ACGAAGACAGAGAAGTGCCAGCGAGCA-GTGCATTGCCTGAACAAAGCCAAGAGAACCAG 
                *************************** ******************************** 
 
 
mERbv1 mRNA     TGGGCACACACCCCGGGTGAAGGAGCTACTGCTGAACTCTCTGAGTCCCGAGCAGCTGGT 
Cloned mERbv1   TGGGCACACACCCCGGGTGAAGGAGCTACTGCTGAACTCTCTGAGTCCCGAGCAGCTGGT 
                ************************************************************ 
 
mERbv1 mRNA     GCTCACCCTGCTGGAAGCTGAGCCACCCCAATGTGCTAGTGAGCCGTCCCAGCATGCCCTT 
Cloned mERbv1   GCTCACCCTGCTGGAAGCTGAGCCACCCCAATGTGCTAGTGAGCCGTCCCAGCATGCCCTT 
                ************************************************************* 
 
mERbv1 mRNA     CACCGAGGCCTCCATGATGATGTCCCTCACGAAGCTGGCTGACAAGGAACTGGTGCACAT 
Cloned mERbv1   CACCGAGGCCTCCATGATGATGTCCCTCACGAAGCTGGCTGACAAGGAACTGGTGCACAT 
                ************************************************************ 
 
mERbv1 mRNA     GATTGGCTGGGCCAAGAAAATCCCTGGCTTTGTGGAGCTCAGCCTGTTGGACCAAGTCCG 
Cloned mERbv1   GATTGGCTGGGCCAAGAAAATCCCTGGCTTTGTGGAGCTCAGCCTGTTGGACCAAGTCCG 
                ************************************************************ 
 
mERbv1 mRNA     CCTCTTGGAAAGCTGCTGGATGGAGGTGCTGATGGTGGGGCTGATGTGGCGCTCCATCGA 
Cloned mERbv1   CCTCTTGGAAAGCTGCTGGATGGAGGTGCTGATGGTGGGGCTGATGTGGCGCTCCATCGA 
                ************************************************************ 
 
mERbv1 mRNA     CCACCCCGGCAAGCTCATCTTTGCTCCAGACCTCGTTCTGGACAGGTCCTCAGAAGACCC 
Cloned mERbv1   CCACCCCGGCAAGCTCATCTTTGCTCCAGACCTCGTTCTGGACAGGTCCTCAGAAGACCC 
                ************************************************************ 
 
mERbv1 mRNA     TCACTGGCACGTTGCGCAGACGAAGAGTGCTGTCCCAAGGGATGAGGGGAAGTGCGTGGA 
Cloned mERbv1   TCACTGGCACGTTGCGCAGACGAAGAGTGCTGTCCCAAGGGATGAGGGGAAGTGCGTGGA 
                ************************************************************ 
 
mERbv1 mRNA     AGGGATTCTGGAAATCTTTGACATGCTCCTGGCGACGACGGCACGGTTCCGTGAGTTAAA 
Cloned mERbv1   AGGGATTCTGGAAATCTTTGACATGCTCCTGGCGACGACGGCACGGTTCCGTGAGTTAAA 
                ************************************************************ 
 
mERbv1 mRNA     ACTGCAGCACAAAGAATATCTGTGTGTGAAGGCCATGATTCTCCTCAACTCCAGTATGTA 
Cloned mERbv1   ACTGCAGCACAAAGAATATCTGTGTGTGAAGGCCATGATTCTCCTCAACTCCAGTATGTA 
                ************************************************************ 
 
mERbv1 mRNA     CCCCTTGGCTACCGCAAGCCAGGAAGCAGAGAGTAGCCGGAAGCTGACACACCTATTGAA 
Cloned mERbv1   CCCCTTGGCTACCGCAAGCCAGGAAGCAGAGAGTAGCCGGAAGCTGACACACCTATTGAA 
                ************************************************************ 
 
mERbv1 mRNA     CGCAGTGACAGATGCCCTGGTCTGGGTGATTTCGAAGAGTGGAATCTCTTCCCAGCAGCA 
Cloned mERbv1   CGCAGTGACAGATGCCCTGGTCTGGGTGATTTCGAAGAGTGGAATCTCTTCCCAGCAGCA 
                ************************************************************ 
 
mERbv1 mRNA     GTCAGTCCGTCTGGCCAACCTCCTGATGCTTCTTTCTCATGTCAGGCACATCAGTAACAA 
Cloned mERbv1   GTCAGTCCGTCTGGCCAACCTCCTGATGCTTCTTTCTCATGTCAGGCACATCAGTAACAA 
                ************************************************************ 
 
mERbv1 mRNA     GGGCATGGAACATCTGCTCAGCATGAAGTGCAAAAATGTGGTCCCGGTGTACGACCTGCT 
Cloned mERbv1   GGGCATGGAACATCTGCTCAGCATGAAGTGCAAAAATGTGGTCCCGGTGTACGACCTGCT 
                ************************************************************ 
 
mERbv1 mRNA     GCTGGAGATGCTGAATGCTCACACGCTTCGAGGGTACAAGTCCTCAATCTCGGGGTCTGA 
Cloned mERbv1   GCTGGAGATGCTGAATGCTCACACGCTTCGAGGGTACAAGTCCTCAATCTCGGGGTCTGA 
                ************************************************************ 
 
mERbv1 mRNA     GTGCTGCTCGACAGAGGACAGTAAGAGCAAAGAGGGCTCCCAGAACCTCCAGTCACAGTG 
Cloned mERbv1   GTGCTGCTCGACAGAGGACAGTAAGAGCAAAGAGGGCTCCCAGAACCTCCAGTCACAGTG 
                ************************************************************ 
 
mERbv1 mRNA     ACGGCCAGGCTGGAGGCGGA 
Cloned mERbv1   ACGGCCAGGCTGGAGGCGGA 
                ******************** 
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Appendix C.  
Alignment of mouse ERβ variant 2 (mERbv2) mRNA sequence with sequencing results 
of the mERβv1 insert cloned into into the destination vector pcDNA3.1 (Cloned 
mERbv2). The clustal alignment software (http://www.ebi.ac.uk/Tools/msa/clustalo/) was 
used. *, identical amino acid between sequences. 
 
CLUSTAL O(1.2.2) multiple sequence alignment 
 
 
mERbv2_mRNA        CCCGTGAGTCTCTGAGAGCATCATGTCCATCTGTGCCTCTTCTCACAAGGATTTTTCTCA 
Cloned_mERbv2      ---CAGAATTCCTGAGAGCATCATGTCCATCTGTGCCTCTTCTCACAAGGATTTTTCTCA 
                        ** *  ************************************************* 
 
mERbv2_mRNA        GCTGAGACCTACGCAAGACATGGAGATCAAAAACTCACCATCAAGCCTTACTTCCCCTGC 
Cloned_mERbv2      GCTGAGACCTACGCAAGACATGGAGATCAAAAACTCACCATCAAGCCTTACTTCCCCTGC 
                   ************************************************************ 
 
mERbv2_mRNA        TTCTTATAACTGTAGCCAGTCCATCCTACCCTTGGAGCATGGTCCCATCTATATCCCTTC 
Cloned_mERbv2      TTCTTATAACTGTAGCCAGTCCATCCTACCCTTGGAGCATGGTCCCATCTATATCCCTTC 
                   ************************************************************ 
 
mERbv2_mRNA        CTCCTATGTAGAGAGCCGTCACGAATACTCAGCCATGACATTCTACAGTCCTGCTGTGAT 
Cloned_mERbv2      CTCCTATGTAGAGAGCCGTCACGAATACTCAGCCATGACATTCTACAGTCCTGCTGTGAT 
                   ************************************************************ 
 
mERbv2_mRNA        GAACTACAGTGTTCCCAGCAGCACCGGTAACCTGGAAGGTGGGCCTGTTCGCCAGACTGC 
Cloned_mERbv2      GAACTACAGTGTTCCCAGCAGCACCGGTAACCTGGAAGGTGGGCCTGTTCGCCAGACTGC 
                   ************************************************************ 
 
mERbv2_mRNA        AAGCCCAAATGTGCTATGGCCAACTTCTGGACACCTCTCTCCTTTAGCCACCCACTGCCA 
Cloned_mERbv2      AAGCCCAAATGTGCTATGGCCAACTTCTGGACACCTCTCTCCTTTAGCCACCCACTGCCA 
                   ************************************************************ 
 
mERbv2_mRNA        ATCATCGCTTCTCTATGCAGAACCTCAAAAGAGTCCTTGGTGTGAAGCAAGATCACTAGA 
Cloned_mERbv2      ATCATCGCTTCTCTATGCAGAACCTCAAAAGAGTCCTTGGTGTGAAGCAAGATCACTAGA 
                   ************************************************************ 
 
mERbv2_mRNA        ACACACCTTGCCTGTAAACAGAGAGACCCTGAAGAGGAAGCTTGGCGGGAGCGGTTGTGC 
Cloned_mERbv2      ACACACCTTGCCTGTAAACAGAGAGACCCTGAAGAGGAAGCTTGGCGGGAGCGGTTGTGC 
                   ************************************************************ 
 
mERbv2_mRNA        CAGCCCTGTTACTAGTCCAAGCGCCAAGAGGGATGCTCACTTCTGCGCCGTCTGCAGTGA 
Cloned_mERbv2      CAGCCCTGTTACTAGTCCAAGCGCCAAGAGGGATGCTCACTTCTGCGCCGTCTGCAGTGA 
                   ************************************************************ 
 
mERbv2_mRNA        TTATGCATCTGGGTATCATTACGGTGTCTGGTCCTGTGAAGGATGTAAGGCCTTTTTTAA 
Cloned_mERbv2      TTATGCATCTGGGTATCATTACGGTGTCTGGTCCTGTGAAGGATGTAAGGCCTTTTTTAA 
                   ************************************************************ 
 
mERbv2_mRNA        AAGAAGCATTCAAGGACATAATGACTATATCTGTCCAGCCACGAATCAGTGTACCATAGA 
Cloned_mERbv2      AAGAAGCATTCAAGGACATAATGACTATATCTGTCCAGCCACGAATCAGTGTACCATAGA 
                   ************************************************************ 
 
mERbv2_mRNA        CAAGAACCGGCGTAAAAGCTGCCAGGCCTGCCGACTTCGCAAGTGTTACGAAGTAGGAAT 
Cloned_mERbv2      CAAGAACCGGCGTAAAAGCTGCCAGGCCTGCCGACTTCGCAAGTGTTACGAAGTAGGAAT 
                   ************************************************************ 
 
mERbv2_mRNA        GGTCAAGTGTGGATCCAGGAGAGAAAGGTGTGGGTACCGAATAGTACGAAGACAGAGAAG 
Cloned_mERbv2      GGTCAAGTGTGGATCCAGGAGAGAAAGGTGTGGGTACCGAATAGTACGAAGACAGAGAAG 
                   ************************************************************ 
 
mERbv2_mRNA        TGCCAGCGAGCAGGTGCATTGCCTGAACAAAGCCAAGAGAACCAGTGGGCACACACCCCG 
Cloned_mERbv2      TGCCAGCGAGCAGGTGCATTGCCTGAACAAAGCCAAGAGAACCAGTGGGCACACACCCCG 
                   ************************************************************ 
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mERbv2_mRNA        GGTGAAGGAGCTACTGCTGAACTCTCTGAGTCCCGAGCAGCTGGTGCTCACCCTGCTGGA 
Cloned_mERbv2      GGTGAAGGAGCTACTGCTGAACTCTCTGAGTCCCGAGCAGCTGGTGCTCACCCTGCTGGA 
                   ************************************************************ 
 
mERbv2_mRNA        AGCTGAGCCACCCAATGTGCTAGTGAGCCGTCCCAGCATGCCCTTCACCGAGGCCTCCAT 
Cloned_mERbv2      AGCTGAGCCACCCAATGTGCTAGTGAGCCGTCCCAGCATGCCCTTCACCGAGGCCTCCAT 
                   ************************************************************ 
 
mERbv2_mRNA        GATGATGTCCCTCACGAAGCTGGCTGACAAGGAACTGGTGCACATGATTGGCTGGGCCAA 
Cloned_mERbv2      GATGATGTCCCTCACGAAGCTGGCTGACAAGGAACTGGTGCACATGATTGGCTGGGCCAA 
                   ************************************************************ 
 
mERbv2_mRNA        GAAAATCCCTGGCTTTGTGGAGCTCAGCCTGTTGGACCAAGTCCGCCTCTTGGAAAGCTG 
Cloned_mERbv2      GAAAATCCCTGGCTTTGTGGAGCTCAGCCTGTTGGACCAAGTCCGCCTCTTGGAAAGCTG 
                   ************************************************************ 
 
mERbv2_mRNA        CTGGATGGAGGTGCTGATGGTGGGGCTGATGTGGCGCTCCATCGACCACCCCGGCAAGCT 
Cloned_mERbv2      CTGGATGGAGGTGCTGATGGTGGGGCTGATGTGGCGCTCCATCGACCACCCCGGCAAGCT 
                   ************************************************************ 
 
mERbv2_mRNA        CATCTTTGCTCCAGACCTCGTTCTGGACAGGGATGAGGGGAAGTGCGTGGAAGGGATTCT 
Cloned_mERbv2      CATCTTTGCTCCAGACCTCGTTCTGGACAGGGATGAGGGGAAGTGCGTGGAAGGGATTCT 
                   ************************************************************ 
 
mERbv2_mRNA        GGAAATCTTTGACATGCTCCTGGCGACGACGGCACGGTTCCGTGAGTTAAAACTGCAGCA 
Cloned_mERbv2      GGAAATCTTTGACATGCTCCTGGCGACGACGGCACGGTTCCGTGAGTTAAAACTGCAGCA 
                   ************************************************************ 
 
mERbv2_mRNA        CAAAGAATATCTGTGTGTGAAGGCCATGATTCTCCTCAACTCCAGTATGTACCCCTTGGC 
Cloned_mERbv2      CAAAGAATATCTGTGTGTGAAGGCCATGATTCTCCTCAACTCCAGTATGTACCCCTTGGC 
                   ************************************************************ 
 
mERbv2_mRNA        TACCGCAAGCCAGGAAGCAGAGAGTAGCCGGAAGCTGACACACCTATTGAACGCAGTGAC 
Cloned_mERbv2      TACCGCAAGCCAGGAAGCAGAGAGTAGCCGGAAGCTGACACACCTATTGAACGCAGTGAC 
                   ************************************************************ 
 
mERbv2_mRNA        AGATGCCCTGGTCTGGGTGATTTCGAAGAGTGGAATCTCTTCCCAGCAGCAGTCAGTCCG 
Cloned_mERbv2      AGATGCCCTGGTCTGGGTGATTTCGAAGAGTGGAATCTCTTCCCAGCAGCAGTCAGTCCG 
                   ************************************************************ 
 
mERbv2_mRNA        TCTGGCCAACCTCCTGATGCTTCTTTCTCATGTCAGGCACATCAGTAACAAGGGCATGGA 
Cloned_mERbv2      TCTGGCCAACCTCCTGATGCTTCTTTCTCATGTCAGGCACATCAGTAACAAGGGCATGGA 
                   ************************************************************ 
 
mERbv2_mRNA        ACATCTGCTCAGCATGAAGTGCAAAAATGTGGTCCCGGTGTACGACCTGCTGCTGGAGAT 
Cloned_mERbv2      ACATCTGCTCAGCATGAAGTGCAAAAATGTGGTCCCGGTGTACGACCTGCTGCTGGAGAT 
                   ************************************************************ 
 
mERbv2_mRNA        GCTGAATGCTCACACGCTTCGAGGGTACAAGTCCTCAATCTCGGGGTCTGAGTGCTGCTC 
Cloned_mERbv2      GCTGAATGCTCACACGCTTCGAGGGTACAAGTCCTCAATCTCGGGGTCTGAGTGCTGCTC 
                   ************************************************************ 
 
mERbv2_mRNA        GACAGAGGACAGTAAGAGCAAAGAGGGCTCCCAGAACCTCCAGTCACAGTGACGG 
Cloned_mERbv2      GACAGAGGACAGTAAGAGCAAAGAGGGCTCCCAGAACCTCCAGTCACAGTGACGG 
                   ******************************************************* 
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Appendix D.  
Alignment of mouse ERβ variant 1 (ERb_v1) and variant 2 (ERb_v2) amino acid 
sequences with 5 hERβ amino acid sequences using clustal alignment software 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). *, identical amino acid in all sequences. Unique 
ERβ variant 1 domain is shown in red. 
CLUSTAL O(1.2.2) multiple sequence alignment 
 
 
mERb_v1      MSICASSHKDFSQLRPTQDMEIKNSPSSLTSPASYNCSQSILPLEHGPIYIPSSYVESRH 
mERb_v2      MSICASSHKDFSQLRPTQDMEIKNSPSSLTSPASYNCSQSILPLEHGPIYIPSSYVESRH 
hERb_v1      -------------------MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHH 
hERb_v5      -------------------MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHH 
hERb_v3      -------------------MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHH 
hERb_v2      -------------------MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHH 
hERb_v6      -------------------MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHH 
                                * ******** ** ************** ******** * * 
 
mERb_v1      EYSAMTFYSPAVMNYSVPSSTGNLEGGPVRQTASPNVLWPTSGHLSPLATHCQSSLLYAE 
mERb_v2      EYSAMTFYSPAVMNYSVPSSTGNLEGGPVRQTASPNVLWPTSGHLSPLATHCQSSLLYAE 
hERb_v1      EYPAMTFYSPAVMNYSIPSNVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAE 
hERb_v5      EYPAMTFYSPAVMNYSIPSNVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAE 
hERb_v3      EYPAMTFYSPAVMNYSIPSNVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAE 
hERb_v2      EYPAMTFYSPAVMNYSIPSNVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAE 
hERb_v6      EYPAMTFYSPAVMNYSIPSNVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAE 
             ** ************* **   ****** *** ******** ******  * * * **** 
 
mERb_v1      PQKSPWCEARSLEHTLPVNRETLKRKLGGSGCASPVTSPSAKRDAHFCAVCSDYASGYHY 
mERb_v2      PQKSPWCEARSLEHTLPVNRETLKRKLGGSGCASPVTSPSAKRDAHFCAVCSDYASGYHY 
hERb_v1      PQKSPWCEARSLEHTLPVNRETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHY 
hERb_v5      PQKSPWCEARSLEHTLPVNRETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHY 
hERb_v3      PQKSPWCEARSLEHTLPVNRETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHY 
hERb_v2      PQKSPWCEARSLEHTLPVNRETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHY 
hERb_v6      PQKSPWCEARSLEHTLPVNRETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHY 
             **************************  *  ****** *  ******************* 
 
mERb_v1      GVWSCEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRR 
mERb_v2      GVWSCEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRR 
hERb_v1      GVWSCEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRR 
hERb_v5      GVWSCEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRR 
hERb_v3      GVWSCEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRR 
hERb_v2      GVWSCEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRR 
hERb_v6      GVWSCEGCKAFFKRSIQGHNDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRR 
             ************************************************************ 
 
mERb_v1      ERCGYRIVRRQRSASEQVHCLNKAKRTSGHTPRVKELLLNSLSPEQLVLTLLEAEPPNVL 
mERb_v2      ERCGYRIVRRQRSASEQVHCLNKAKRTSGHTPRVKELLLNSLSPEQLVLTLLEAEPPNVL 
hERb_v1      ERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVL 
hERb_v5      ERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVL 
hERb_v3      ERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVL 
hERb_v2      ERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVL 
hERb_v6      ERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVL 
             ****** ******* ** **  ****  ** *** ****  **************** ** 
 
mERb_v1      VSRPSMPFTEASMMMSLTKLADKELVHMIGWAKKIPGFVELSLLDQVRLLESCWMEVLMV 
mERb_v2      VSRPSMPFTEASMMMSLTKLADKELVHMIGWAKKIPGFVELSLLDQVRLLESCWMEVLMV 
hERb_v1      ISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESCWMEVLMM 
hERb_v5      ISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESCWMEVLMM 
hERb_v3      ISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESCWMEVLMM 
hERb_v2      ISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESCWMEVLMM 
hERb_v6      ISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGMYPLVTATQDADSSRKLAHLLNA 
              **** *********************** *******   *    *           *   
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mERb_v1      GLMWRSIDHPGKLIFAPDLVLDRSSEDPHWHVAQTKSAVPRDEGKCVEGILEIFDMLLAT 
mERb_v2      GLMWRSIDHPGKLI-----------------FAPDLVLDRDEGKCV-EGILEIFDMLLAT 
hERb_v1      GLMWRSIDHPGKLI-----------------FAPDLVLDRDEGKCV-EGILEIFDMLLAT 
hERb_v5      GLMWRSIDHPGKLI-----------------FAPDLVLDRDEGKCV-EGILEIFDMLLAT 
hERb_v3      GLMWRSIDHPGKLI-----------------FAPDLVLDRDEGKCV-EGILEIFDMLLAT 
hERb_v2      GLMWRSIDHPGKLI-----------------FAPDLVLDRDEGKC-VEGILEIFDMLLAT 
hERb_v6      V------TDALVWV-----------------IAKSGISSQQQSMRLANLLMLLSHVRHAS 
                                             *                         *  
 
mERb_v1      TARFRELKLQHKEYLCVKAMILLNSSMYPLATASQEAESSRKLTHLLNAVTDALVWVISK 
mERb_v2      TARFRELKLQHKEYLCVKAMILLNSSMYPLATASQEAESSRKLTHLLNAVTDALVWVISK 
hERb_v1      TSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDADSSRKLAHLLNAVTDALVWVIAK 
hERb_v5      TSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDADSSRKLAHLLNAVTDALVWVIAK 
hERb_v3      TSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDADSSRKLAHLLNAVTDALVWVIAK 
hERb_v2      TSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDADSSRKLAHLLNAVTDALVWVIAK 
hERb_v6      NKGMEH----LLNMKCKNVVP-----VYDLLLEMLNAHVLRG---CKSSIT--------- 
                            *           * *      *   *         *          
 
mERb_v1      SGISSQQQSVRLANLLMLLSHVRHISNKGMEHLLSMKCKNVVPVYDLLLEMLNAHTLRGY 
mERb_v2      SGISSQQQSVRLANLLMLLSHVRHISNKGMEHLLSMKCKNVVPVYDLLLEMLNAHTLRGY 
hERb_v1      SGISSQQQSMRLANLLMLLSHVRHASNKGMEHLLNMKCKNVVPVYDLLLEMLNAHVLRGC 
hERb_v5      SGISSQQQSMRLANLLMLLSHVRHARSCVYK----------------------------- 
hERb_v3      SGISSQQQSMRLANLLMLLSHVRHARWGEKQFIHLKLS---------------------- 
hERb_v2      SGISSQQQSMRLANLLMLLSHVRHARAEKASQTLTSFG------MKMETLLPEATMEQ-- 
hERb_v6      -GS-----ECSPAED-----------------SKSKEG------SQNPQSQ--------- 
              *          *                                                
 
mERb_v1      KSSISGSECCSTEDSKSKEGSQNLQSQ 
mERb_v2      KSSISGSECCSTEDSKSKEGSQNLQSQ 
hERb_v1      KSSITGSECSPAEDSKSKEGSQNPQSQ 
hERb_v5      --------------------------- 
hERb_v3      --------------------------- 
hERb_v2      --------------------------- 
hERb_v6      --------------------------- 
 
